Relevance of MUC1 mucin in gastric carcinogenesis by Maria Natália Rios Vieira da Costa
 Relevance of MUC1 mucin in gastric 
carcinogenesis  
 
 
Relevância da mucina MUC1 na carcinogénese 
gástrica 
 
 
 
 
 
 
 
 
 
 
 
Maria Natália Rios Vieira da Costa 
Porto, 2012 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Artigo 48º, § 3º - A Faculdade não responde pelas doutrinas expendidas na 
Dissertação (Regulamento da Faculdade de Medicina do Porto-Decreto-lei nº 
19337, 29 de Janeiro de 1931). 
 
Orientação do Doutor Filipe dos Santos-Silva 
 Professor Afiliado da Faculdade de Medicina da Universidade do Porto. 
 
Co-orientação do Doutor Michael Anthony Hollingsworth 
Eppley Institute for Research in Cancer and Allied Diseases 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                     Dissertação de candidatura ao grau de doutor 
                                                                     apresentada  à  Faculdade  de   Medicina   da  
                                  Universidade do Porto. 
 
 
 
Júri das provas de Doutoramento 
 
Presidente – Doutor José Agostinho Marques Lopes, 
          Director da Faculdade de Medicina da Universidade do Porto  
                     (por delegação reitoral) 
 
     Vogais – Doutora Sandra Jane Gendler 
     Professora Afiliada da Mayo Clinic, USA 
 
                    Doutora Sara Katarina Lindén 
     Professora Associada da University of Gothenburg, Sweden  
 
                    Doutor Manuel Alberto Coimbra Sobrinho Simões 
     Professor Catedrático da Faculdade de Medicina da Universidade do Porto 
 
                    Doutor João António Pinto de Sousa 
    Professor Associado Convidado da Faculdade de Medicina da Universidade      
                    do Porto 
 
                    Doutora Maria João dos Reis Conceição Martins de Almeida Ribeiro 
     Professora Auxiliar da Faculdade de Medicina da Universidade do Porto  
 
                    Doutor Luís Filipe dos Santos Silva 
     Professor Afiliado da Faculdade de Medicina da Universidade do Porto 
Ao abrigo do Art. 8º do Decreto-Lei nº 388/70 fazem parte integrante desta 
Dissertação os seguintes trabalhos já publicados: 
 
 
Natália R Costa, Nuno Mendes, Nuno T Marcos, Celso A Reis, Thomas Caffrey, 
Michael A Hollingsworth, Filipe Santos-Silva. “Relevance of MUC1 mucin variable 
number of tandem repeats polymorphism in H pylori adhesion to gastric epithelial 
cells”. World Journal of Gastroenterology 2008 14(9): 1411-1414. 
 
 
Natália R Costa, Andreia Sousa, Cristina Teixeira, Joana Castro, Nuno Guimarães, 
Filipe ,Santos-Silva. “Oncogenic Signaling in Gastric Carcinoma, Gastric Carcinoma - 
Molecular Aspects and Current Advances”. InTech 2011, ISBN: 978-953-307-412-2, 
Available from: http://www.intechopen.com/articles/show/title/oncogenic-signaling-in-
gastric-carcinoma. 
 
Natália R Costa, Paula Paulo, Thomas Caffrey, Michael A. Hollingsworth, Filipe 
Santos-Silva. “Impact of MUC1 Mucin Downregulation in the Phenotypic 
Characteristics of MKN45 Gastric Carcinoma Cell Line”. PLoS One 2011; 
6(11):e26970. Epub 2011 Nov 2.  
 
E em publicação: 
Natália R. Costa, Andreia Sousa, Cristina Teixeira, Thomas Caffrey , Michael A. 
Hollingsworth  and Filipe Santos-Silva. “MUC1 mucin conditions MAPK signaling 
pathway on MKN45 gastric carcinoma cells”. 
 
 
Em cumprimento com o disposto no referido Decreto-Lei declara que participou 
activamente na recolha e estudo do material incluído em todos os trabalhos. 
Esta dissertação inclui também resultados de trabalhos ainda não publicados. 
  
 
 
 
 
 
 
 
 
 
 
 
Financiamento 
 
Bolsa Individual de Doutoramento com a referência SFRH / BD / 36961 / 2007 da 
Fundação para a Ciência e a Tecnologia (FCT) 
 
 
 
 
                                                          
       
 
 i 
 
Agradecimentos 
 
Acknowledgments 
 
 Desejo aqui expressar a minha profunda gratidão a todos aqueles que me 
apoiaram ao longo da execução deste trabalho. De uma forma especial quero agradecer: 
 
Ao Doutor Luís Filipe Santos Silva, pela oportunidade de desenvolver um 
trabalho tão único e interessante, e também pela confiança e compreensão que depositou 
em mim ao longo de todo o meu percurso científico; 
 
Ao Professor Manuel Sobrinho-Simões, Director do IPATIMUP, a possibilidade 
de aprender e desenvolver o meu trabalho numa Instituição de um nível científico tão 
elevado;  
 
To Dr. Anthony Hollingsworth and Tom Caffrey for making me feel so welcome 
and for all the help and good ideas offered during my stays in Omaha; 
 
Agradeço a todos os meus amigos e colegas de grupo, com uma especial atenção à 
Natércia, Paula, Ana Maria, Joana, Nuno, Rita e Andreia por todos os bons e maus 
momentos que partilhámos e me permitiram crescer e encarar o dia-a-dia de uma forma 
diferente; 
 
Agradeço ao meu Pai e Irmã por sempre acreditarem em mim, pelas palavras de 
conforto nos momentos mais difíceis e pela partilha de alegria nos bons momentos. Um 
obrigada do tamanho do mundo ao meu Irmão, pela companhia, compreensão e apoio 
incondicionais nas decisões (nem sempre as mais fáceis nem convencionais) que fui 
fazendo ao longo da vida; 
 
Agradeço de uma forma muito especial à minha Mãe que, apesar de ausente, me 
preenche constantemente o coração de amor, força, coragem e perseverança. Pelo 
exemplo de Mulher excepcional que foi…por sempre ter sido e continuar a ser, em 
todos os momentos, o meu colo e referência de vida. 
 ii 
 
 
Em memória da minha Mãe 
 
“Who can say for certain? Maybe you're still here 
I feel you all around me, your memories so clear 
Deep in the stillness, I can hear you speak 
You're still an inspiration, can it be? 
That you are my forever Love! 
And you are watching over me from up above 
Fly me up to where you are, beyond the distant star 
I wish upon tonight to see you smile 
If only for awhile, to know you're there 
A breath away's not far to where you are 
Are you gently sleeping, here inside my dream? 
And isn't faith believing? All power can't be seen 
As my heart holds you, just one beat away 
I cherish all you gave me everyday 
'Cause you are my forever Love! 
Watching me from up above 
And I believe that angels breathe 
And that Love will live on and never leave 
Fly me up to where you are, beyond the distant star 
I wish upon tonight to see you smile 
If only for awhile, to know you're there 
A breath away's not far to where you are 
I know you're there, a breath away's not far 
To where you are!” 
 
 
O Teu Amor é eterno 
Brilhante como o luar 
Cada momento é um sonho 
Na esperança de te abraçar 
 ix 
 
Table of Contents 
 
 Abstract                                                                                                    x 
 
 Sumário                                                                                                   xi 
 
 Abbreviations                                                                                         xii 
 
 Introduction…………………………………………………………   17 
 
 1. Gastric Cancer …………………………………………...   19 
 
1.1. Gastric cancer epidemiology                                          19 
 
1.2. Gastric carcinogenesis                                                    20 
 
1.3. Deregulation of signaling pathways in gastric     
carcinogenesis                                                                  21 
                                                           
 
 2. Helicobacter pylori ………………………………..............   22 
 
                                                       
 3. Gastric Mucins …………………………………………...   25 
 
 
 4. Relevance of MUC1 in carcinogenesis…………………..   26 
 
 
 5. MUC1 in oncogenic signaling pathways…………….......   29 
 
5.1. MUC1 – cancer biomarker vs therapy target                  30 
 
 Aims………………………………………………………………….   33 
 
 Materials and Methods……………………………………………..   37 
 
 Results………………………………………………………………..   51 
 
 Discussion…………………………………………………………....   79 
 
 Summary and Conclusions…………………………………………   95 
 
 References…………………………………………………………....   99 
 
 Papers………………………………………………………………   119 
 x 
 
Abstract 
 
Gastric cancer is the third most frequent cause of cancer death worldwide. 
Reduced knowledge about gastric carcinogenesis model contributes for this high 
mortality. Gastric carcinogenesis is assumed to result from the interplay of genetic and 
environmental factors at the mucosa level, determined in great extent by mucus layer 
mucins. MUC1 is a major component of the stomach mucus layer that modulates 
interactions between the epithelium and external factors and its loss of polarity, 
overexpression, abnormal glycosylation and phosphorylation have been reported in 
gastric cancer and several other tumor types, suggesting a relevant role in cell 
transformation. MUC1 polymorphisms have been associated with susceptibility for 
gastric cancer development. Among environmental factors, Helicobacter pylori 
infection is known to be the most relevant event for gastric cancer development. This 
bacterium binds to MUC1 Variable Number of Tandem Repeats region, among other 
ligands, and exerts its effects on cells due the virulence factors it carries, ultimately 
leading to gastric cancer.  
Recent studies have shown that MUC1 can function as a cytokine receptor-like 
molecule and that its cytoplasmic domain participates in intracellular signaling 
pathways that lead to cellular growth control. This domain contains several residues that 
can be phosphorylated and also binding sites for molecules well known to participate in 
cell signaling cascades. Up to now there are no data about the relevance of MUC1-
cytoplasmic domain phosphorylation status or MUC1-mediated signaling pathways in 
the pathophysiology of gastric cancer cells. This project will a) evaluate the impact of 
MUC1 Variable Number of Tandem Repeats length in Helicobacter pylori bacterium 
adhesion, b) evaluate the impact of MUC1 on gene expression, phenotype and 
tumorigenicity, c) identify MUC1-mediated oncogenic signaling pathways, d) evaluate 
MUC1 impact in the expression and phosphorylation of gastric oncogenesis-related 
proteins and e) evaluate the impact of Helicobacter pylori binding in MUC1-mediated 
oncogenic signaling pathways in gastric carcinoma cells.  
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Sumário 
 
 O cancro gástrico é a terceira causa mais frequente de morte por cancro no 
mundo. O conhecimento reduzido do modelo de carcinogénese gástrica contribui para 
esta mortalidade elevada. A carcinogénese gástrica é assumida como sendo o resultado 
da interacção de factores genéticos e ambientais ao nível da mucosa gástrica, 
determinado em grande parte pela sua composição. A mucina MUC1 é um dos 
principais componentes da camada de muco que reveste o estômago e modula 
interacções entre o epitélio e a mucosa gástrica. A sua perda de polaridade, sobre-
expressão e glicosilação anormais têm sido reportados com frequência em cancro 
gástrico e outros tipos de cancro, sugerindo um papel relevante na transformação 
celular. Entre os factores ambientais, a infecção pela bactéria Helicobacter pylori é o 
factor mais relevante para o desenvolvimento de cancro gástrico. Esta bactéria liga-se à 
região com um número variável de Tandem Repeats de MUC1, entre outros ligandos, e 
exerce os seus efeitos nas células devido aos seus factores de virulência, que levam ao 
cancro gástrico. 
 Estudos recentes demonstraram que a mucina MUC1 pode funcionar como uma 
molécula do tipo receptor de citocinas e que o seu domínio citoplasmático participa em 
vias intracelulares de sinalização que controlam o crescimento celular. Este domínio 
contém diversos resíduos que podem ser fosforilados e também locais de ligação a 
moléculas que participam em cascatas de sinalização celular. Até à data, não existem 
dados acerca da relevância do estado de fosforilação de do domínio citoplasmático de 
MUC1 ou da sua participação em cascatas de sinalização na patofisiologia de células de 
carcinoma gástrico. Este projecto vai a) avaliar o impacto do comprimento do Número 
Variável de Tandem Repeats Tandem na adesão da bactéria Helicobacter pylori, b) 
avaliar o impacto da expressão de MUC1 na expressão de genes, fenótipo e 
tumorigenicidade, c) identificar vias de sinalização oncogénicas mediadas por MUC1, 
d) avaliar o impacto de MUC1 na expressão e fosforilação de proteínas relacionadas 
com a oncogénese gástrica e d) avaliar o impacto da ligação de Helicobacter pylori em 
vias de sinalização oncogénicas mediadas por MUC1 em células de carcinoma gástrico. 
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Introduction 
 
1. Gastric cancer 
 
1.1. Gastric cancer epidemiology 
 
Gastric cancer (GC) is one of the most common and life-threatening cancers 
worldwide [1] and nowadays the third cause of cancer-related deaths all over the world 
and the fifth in Portugal [2] (Figure 1). Although its incidence has been impressively 
falling in some world areas, there are still approximately 700,000 patients dying each 
year from GC [3].  The poor prognosis of this disease with a 5-year survival rate of 20% 
[4] reflects the reduced understanding of its etiological factors and pathogenesis, 
absence of specific symptoms and consequent late diagnosis and lack of effective 
treatments. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 > Incidence and mortality estimates of the most common cancers in both sexes in the 
whole world (left) and in Portugal (right). ASR-age-standardized rate. [Adapted from 
GLOBOCAN 2008 [2]]. 
 
 Although GC has been considered as a chemosensitive tumor for many years, 
no significant progress in its management has resulted within the last two decades. 
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Therefore, the identification of GC susceptibility markers, new tumorigenic markers and 
therapeutic targets assumes a significant priority, which will allow an early diagnosis 
and also the increase of survival and life quality of GC patients.  
 
1.2. Gastric carcinogenesis 
 
Gastric adenocarcinomas represent more than 95% of gastric neoplasms and are 
divided in two major types: diffuse and intestinal, with differences in morphologic, 
clinical and epidemiologic characteristics. In the intestinal type, there is preservation of 
the glandular structure and cell polarity, whereas in the diffuse type these characteristics 
are lost [5]. The intestinal type is more common and is associated with a sequence of 
pre-neoplastic lesions [6], triggered by Helicobacter pylori (H. pylori) infection. In fact,  
it is known that more than 80% of GC cases can be attributed to H. pylori chronic 
infection [7] and eradication of this bacterium in early stages of GC significantly 
decreases the incidence of this disease [8]. The symptoms of early stages of GC are 
often clinically silent, with patients frequently presenting advanced stage disease at the 
time of diagnosis. 
The diffuse type carcinoma is characterized by a poorly differentiated and 
infiltrative pattern [9]. There are some few cases of GC with mixed histology, and H. 
pylori was also shown to be associated with diffuse type GC  [10]. However, chronic 
inflammation is not a prerequisite for development of diffuse-type GC cancer, 
suggesting that different mechanisms are responsible for the ability of H. pylori to 
induce gastric malignancies.  
Oncogenic transformation is a multistep process that arises from a complex 
interplay between genetic and environmental factors at the gastric mucosa level [6]. The 
gastric microenvironment is a crucial factor, determined to a large extent by the mucin 
and carbohydrate composition of the gastric mucus layer [11], which directly influences 
the impact of external factors on gastric mucosa. Several individual genetic 
polymorphisms have been shown to be related with susceptibility to  GC development, 
such as polymorphisms in the gastric mucins Mucin 1 (MUC1) [12,13], Mucin 5AC 
(MUC5AC) [14] and Mucin 6 (MUC6) [15], Inflammation related proteins interleukin 1 
(IL-1), Interleukin 8 (IL-8),  Interleukin 10 (IL-10) (for review see [16]), Tumor 
necrosis factor alpha (TNF-α) [17] and pattern recognition systems such as Toll-like 
receptor 4 (TLR4) [18], among others.  
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As for environmental factors, H. pylori is known to be the most important risk  
factor for the development of GC, as referred before, but other factors, such as high salt 
intake [19] , low vegetables and fruits consumption [20] and tobacco smoking [21] have 
also been associated with the development of this disease. GC is now known to be a 
result of a multiple and complex deregulation of several potentially oncogenic cell 
signaling cascades [22], either due to external stimuli or internal cellular factors, or 
most probably  both. 
 
1.3. Deregulation of signaling pathways in gastric carcinogenesis 
 
One of the outcomes of the alteration of environmental factors and host genetic 
factors at the gastric mucosa level is the deregulation of the normal working of cell 
signaling cascades. There are several cell signaling pathways found to be deregulated in 
GC (for review see [23]). One of the most important is the Mitogen-activated Protein 
Kinase (MAPK) signaling pathway. This pathway is activated either by extracellular or 
intracellular ligands and regulates several processes, such as cell proliferation, 
differentiation and death. The extracellular signal-regulated kinase (ERK) MAPK 
pathway consists on a series of kinases (abbreviation of 'Rat sarcoma' (RAS), Rapidly 
accelerated fibrosarcoma (RAF), MAP kinase kinase (MEK), ERK) that are activated 
by phosphorylation and has often been found to be deregulated in several carcinomas, 
leading to cell’s oncogenic properties (for review see [24]). RAS family members were 
found to be deregulated in GC [25,26]. RAS/MAPK activation was found to be 
associated with cell proliferation in GCs [27]. ERK1/2, the final effectors of this 
cascade, were also found to be activated in GC [28] and in H. pylori-related cancers 
[29,30]. 
The Epidermal growth factor receptor (EGFR) is a member of the Human 
epidermal growth factor receptor (HER) family and works as a cell surface receptor of 
extracellular ligands. Its activation initiates a series of intracellular signals, including the 
activation of the ERK-MAPK signaling pathway. This molecule modulates processes of 
cell proliferation, migration, adhesion and proliferation and it is known to provide 
tumor cell with growth and survival advantages (for review see [31]). EGFR expression 
was found to be deregulated in GC, and correlated  with disease prognosis [32] and 
presence of lymph node metastasis [33]. Several other pathways apart from the MAPK 
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pathway have been found to be often deregulated in GC, such as Hybrid of Int and Wg 
in Drosophila (Wnt)/β-catenin pathway, Sonic-Hedgehog pathway, Notch pathway, 
Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2)  pathway, Nuclear factor kappa-
light-chain-enhancer of activated B cells (NFK-B) pathway, Transforming growth factor 
beta (TGF-β) pathway, Bone morphogenetic proteins (BMPs) pathway (for review see 
[23]). 
Oncogenic signaling pathways in GC have been recently chosen as elective 
targets for innovative therapeutic approaches. Inhibition of the EGFR molecule via 
monoclonal antibodies (i.e. cetuximab [34]) or tyrosine kinase inhibitors (i.e. gefitinib 
[35]), and inhibition of HER2 by trastuzumab monoclonal antibody [36] in combination 
with chemotherapy showed to date the most meaningful clinically survival 
improvement in patients with advanced GC that overexpress these receptors [37]. Also, 
the use of geldanamycin, an inhibitor of Heat shock protein 90 (HSP90) (a molecular 
chaperone increased in GC [38]), has been proven to reduce the activation of several 
potentially oncogenic signaling pathways [39]. 
 
2. Helicobacter pylori 
 
The Gram-negative microaerophilic bacterium H. pylori is involved in the 
pathogenesis of several gastrointestinal diseases, ultimately leading to GC [6,40]. 
According to the Centers for Disease Control and Prevention (CDC), approximately 
two-thirds of the world's population carries this bacterium, with percentages of infection 
higher in developing countries than in developed ones. In Portugal, it is estimated that 
more than 80% of the adult population (15-70 years old) is infected by this bacterium 
[41]. The infection is generally acquired during childhood and can persist during the 
lifetime of the individual, if untreated [42]. The high prevalence of this bacterium is in 
part due to the inability of the host immune system to fight the infection [43]. Most 
infected individuals don’t develop any H. pylori-associated diseases, and only a very 
small percentage develops GC. The majority of H.pylori is present in the mucus layer of 
gastric mucosa, but some bacteria can be attached to gastric epithelial cells [44], 
providing a crucial step for the maintenance, spreading and severity of the infection. 
Adhesion of this bacterium to the mucosal surface helps the bacteria to be protected 
from the continuous mucus washing of the mucosal surface. Upon cell binding, H. 
pylori induces important morphological alterations [45] and also alterations in the 
In
tr
o
d
u
ct
io
n
 
 23 
 
glycosylation patterns of gastric cells [46]. It also activates several signaling pathways 
and proteins, such as MAPK pathway, NFK-B pathway, activator protein 1 (AP-1) 
pathway, Wnt/β-catenin pathway, Phosphoinositide 3 kinase (PI3K) pathway and Signal 
transducer and activator of transcription 3 (STAT3) pathway (for review see [47]), 
Mammalian orthologue of the yeast Hog1p MAP kinase (p38), ERK1/2 and Progranulin 
(PGRN) [48], β-catenin, p120 catenin, and Peroxisome proliferator-activated receptor 
delta (PPARδ) [49] and TNF-α [50] proteins, among others. Other studies have shown 
that adherence of this bacterium induces cell proliferation and apoptosis during the early 
phase of chronic inflammation of the gastric mucosa [51] . 
The susceptibility of developing GC upon H. pylori infection is not only 
dependent on host genetic characteristics but also on the different genotypes of bacterial 
virulence genes [52]. There are mainly three bacterial proteins that are crucial for the 
development of GC, which are: blood group antigen binding adhesin (BabA) [53], 
protein encoded by the cytotoxin- associated gene A (CagA) [54] and vacuolating 
cytotoxin A (VacA) [55]. 
BabA mediates bacterial adhesion to antigens present on the cell surface, 
whereas CagA and VacA are associated with deregulation of basic functions and 
signaling pathways and cell vacuolation, respectively. H. pylori has been shown to 
induce the nuclear accumulation and activation of β-catenin [56,57] and EGFR [58], 
therefore deregulating important cell signaling cascades. 
Host genetic characteristics that influence the development of GC upon H.pylori 
infection include MUC1 Variable Number of Tandem Repeats (VNTR) variability. It 
has been previously shown that individuals homozygous for short VNTR domains have 
an increased risk for the development of pre-cancerous gastric lesions [12,13].   
The mucin MUC1 has been recently identified as an H. pylori binding target 
[59,60]. However, it has been shown to limit H. pylori colonization [61,62,63]. Mice 
deficient in Muc1 were shown to be more susceptible to infection by H. pylori [63]. 
Furthermore, there is evidence that H. pylori blocks the expression of MUC1 on cell 
membranes and therefore a decrease in MUC1 synthesis might be a host defensive 
response against stomach colonization [64,65]. Extracellular MUC1 VNTR domain is 
highly glycosylated and under normal conditions presents Lewis b (Le
b
) carbohydrate 
structures that are involved in the strong binding of H. pylori  to gastric cells through its 
adhesin   BabA  [66].  Under   conditions   of    inflammation, synthesis    of    sialylated  
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carbohydrate structures such as sialyl-Lewis x (sialyl -Le
x
) occurs in the gastric mucosa, 
including in the VNTR region of MUC1. Another bacterial adhesin, SabA, binds to 
these antigens, promoting a weaker but closer adhesion of H. pylori to gastric epithelial 
cells [67] (Figure 2).  This weaker binding allows the bacteria a constant 
attachment/detachment, enabling an efficient escape from the immune system effectors.  
The relevance of MUC1 VNTR variability for H. pylori adhesion to gastric cells 
and possible consequent infection remains to be clarified.  
 
                       
 
Figure 2 > H. pylori binding to Le
b
 and Sialyl-Le
x
 antigens in gastric cells secreted and 
membrane-associated mucins, through its adhesins BabA and SabA, respectively. In the first 
steps of infection, the BabA adhesin binds Le
b
 antigens present in healthy epithelia. After 
infection and inflammation, the expression of Sialyl-Le
x
 antigens allows the bacteria to bind 
closer to the cells. 
 
The eradication of H.pylori has been proved as effective in the prevention of GC 
[68]. The best strategy to prevent co-morbitidies associated with H. pylori infection is 
the development of a prophylactic vaccine, since bacterial eradication strategies with 
antibiotics are becoming inefficient [69]. Another possible and in theory ideal strategy 
would be to stop the deregulation of signaling pathways triggered by bacterial infection, 
but this approach would need a deep and detailed knowledge about such pathways and 
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the development of peptides/molecules to prevent them from being deregulated, without 
interfering with their normal action. 
 
3. Gastric mucins 
 
Independently of the genetic predisposition for the development of GC, 
interaction of the gastric mucosa with the external environment is essential for the 
initiation of the neoplastic process. Therefore, understanding the biological mechanisms 
that occur at the interface between the epithelium and external environment is crucial to 
establish a carcinogenesis model and to develop new therapeutic strategies. The 
glycoproteins (mucins) present in the mucus layer that covers the gastric epithelium are 
an efficient barrier and thus constitute elective targets to study the gastric oncogenesis 
model.  
The mucus layer lining the stomach is comprised of secreted and membrane-
associated mucins which canonical function is to provide protection to vulnerable 
epithelia. Secreted mucins act mainly by lubricating and protecting the epithelia, 
constituting a barrier against microorganisms and chemical aggressions [70]. 
Membrane-associated mucins also share these features, with the addition of also 
participating in cell signaling cascades, immune responses, cell adhesion and  
differentiation and renewal of the epithelium [71]. 
Mucins are large, heavily O-glycosylated glycoproteins ubiquitously expressed 
in the surface of all epithelial cell. Mucins genes contain TR motifs that code for 
regions with a high amount of serine, threonine and proline aminoacids. The serine and 
threonine residues can be extensively O-glycosylated, and are responsible for most of 
the mucins molecular weight. The length and number of the TR region varies between 
mucins and also between individuals – VNTR polymorphism.  
The   gastric   mucus   of   a   normal   stomach   is   composed   of  two  secreted  
mucins, MUC5AC and MUC6, and one membrane-associated mucin, MUC1, that is 
also the most highly expressed gastric mucin [72,73,74] (Figure 3).     
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Figure 3 > Representation of the normal gastric mucus layer, composed of secreted (MUC5AC 
and MUC6) and membrane-associated (MUC1) mucins. These mucins form a cohesive net that 
protects the epithelial cells surface. 
 
MUC1, MUC5AC  and  MUC6   polymorphisms   have   been   associated   with 
individual susceptibility to GC development [12,13,14,15]. During the development of 
intestinal type GC, there is a de novo expression of the intestinal Mucin 2 (MUC2) and 
it is also common to exist alterations in the expression of MUC1, MUC5AC and MUC6 
[75].  In the diffuse GC, there is also a common significant alteration of the expression 
of all these mucins [76,77].  
 
4. Relevance of MUC1 in carcinogenesis 
 
Abnormal expression and/or glycosylation of mucins, namely MUC1, have been 
described in several cancer models, suggesting their involvement in cancer development 
[75,78,79,80,81]. MUC1 was the first mucin to be identified and encodes a 
transmembrane glycoprotein with structural features similar to receptors of cytokines 
and growth factors (Figure 4).  
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Figure 4 > Schematic representation of MUC1, including an N-terminal domain with a VNTR 
region, a SEA domain and a C-terminal domain with a transmembrane (TM) region and a 
cytoplasmic domain (CD). 
 
 MUC1 is an heterodimer composed of two distinct subunits, formed by  
autocatalytic cleavage of the Sea urchin sperm protein-enterokinase-agrin (SEA) 
domain and bound by non-covalent forces [82]. The N-terminal subunit (MUC1-N) can 
protrude 200 nm to 500 nm from the cell surface [83] and therefore is the first barrier 
encountered by microorganisms / other cells. MUC1 extracellular domain can be 
released from the epithelial surface, thereby acting as a releasable decoy [61]. This 
domain includes the VNTR region, ranging from 20 to 120 TR of 20 aminoacids - 
“short” or “large” alleles) [84],  that are  extensively modified by O-linked glycans 
[85,86] . Glycosylation of this extracellular domain, together with the variability of its 
length, can provide tumor cells an enormous range of potential interactions with other 
ligands and/or receptors at the cell surface [70], namely with Intercellular Adhesion 
Molecule 1 (ICAM-1) [87] and galectin-3 [88] , mediating processes of cell adhesion 
[88], motility and migration [89,90], metastasis [91] and cell-cell aggregation [92]. 
Another study has shown that Pseudomonas aeruginosa or its flagellin protein can serve 
as activators of MUC1-mediated signaling by binding MUC1 extracellular domain and 
promoting activation of the MAPK pathway [93]. MUC1 abnormal expression, 
glycosylation and loss of apical expression have been observed in several cancer cells 
[75,78,94] (Figure 5). 
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Figure 5 > MUC1 expression, glycosylation and membrane localization in normal and cancer 
cells. 
 
Furthermore, it has been shown that in H.pylori infected individuals, the highly 
glycosylated extracellular domain of MUC1 is shed from the gastric surface [59], 
suggesting that this bacterium interferes with many processes mediated by the MUC1 
extracellular domain. 
MUC1 C-terminal sub-unit (MUC1-C) encompasses an extracellular, a 
transmembrane region and a cytoplasmic domain. MUC1-C extracellular domain 
interacts with the molecule galectin-3, forming complexes with EGFR [95]. MUC1-CD 
contains seven highly conserved tyrosines and several serine/threonine phosphorylation 
sites [96] and interacts with several molecules involved in intracellular signaling 
pathways such as β-catenin, Cellular sarcoma (Schmidt-Ruppin A-2) protein (c-Src), 
Growth factor receptor-bound protein 2/Son of sevenless (Grb2/Sos), tumor protein 53 
(p53), Glycogen synthase kinase 3 beta (GSK-3β), EGFR and protein kinase C delta 
(PKC-δ) [97], Tyrosine-protein kinase Lyn (Lyn) [98] , Lymphocyte-specific protein 
tyrosine kinase (Lck) and Zeta-chain-associated protein kinase 70 (Zap 70) [99], 
Estrogen receptor alpha (ER-α) [100] and NFK-B [101].  
 
 
 
In
tr
o
d
u
ct
io
n
 
 29 
 
5. MUC1 in oncogenic signaling pathways 
 
MUC1 is predicted  to function as an “oncogene”, whereby overexpression 
correlates with tumor formation, tumor progression and poor survival of cancer patients 
[102].  Although both MUC1 extracellular domain and MUC1-CD were shown to be 
essential for tumor formation [103], much of the ability of MUC1 to foster 
tumorigenesis and tumor progression likely originates from the interaction of its 
cytoplasmic domain with proteins involved in oncogenic signaling.   
Zrihan–Licht et al were the first to demonstrate that MUC1-CD could be 
tyrosine phosphorylated and that it contains a putative binding motif for the signaling 
molecule Grb2 in human breast cancer cells [104]. Studies with MCF-7 breast 
carcinoma cells have also shown that MUC1/Grb2 complex associates with the protein 
Sos and with Ras at the cell membrane, which further supports a role for MUC1 in 
intracellular signaling [105]. Meerzaman et al demonstrated, using a Cluster of 
differentiation 8 (CD8)/MUC1 chimeric receptor, that tyrosine phosphorylation of 
MUC1-CD led to the activation of the RAS-RAF-MEK-ERK2 MAPK pathway [106]. 
In vitro and in vivo approaches have shown that MUC1-CD could be phosphorylated by 
c-Src tyrosine kinase and PKC-δ, increasing the binding to β-catenin, while its 
phosphorylation by GSK3β kinase decreased the binding to β-catenin [107,108,109]. 
Direct binding of MUC1 with β-catenin and -catenin (proteins involved in cell 
adhesion with E-cadherin and in transcriptional complexes) demonstrates a connection 
between MUC1 and signaling networks between the cell membrane and the nuclear 
compartment [108,109,110]. 
MUC1 physically associates with all four EGFR family receptors in a MUC1 
transgenic mouse model and this interaction increases ERK1/2 activation [111]. MUC1 
overexpression is not only associated with its accumulation in the cytoplasm, but also in 
the cell nucleus [112] Chromatin immunoprecipitation and reciprocal 
coimmunoprecipitation assays have shown that at the nucleus compartment MUC1-CD 
associates with β-catenin, -catenin, p53 and ER-, supporting the hypothesis that 
MUC1 contributes to transcriptional regulation, as been also shown for other molecules 
[101,113,114,115,116,117,118,119,120]. 
 Currently, data about potential docking sites for Grb2/Sos, AP-2, p53, ER-α and 
β-catenin  and  phosphorylation  sites   to  GSK-3β, c-Src, EGFR, Lyn, Lck, PKC-δ  and  
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Zap70 provide significant evidence to support MUC1-CD involvement in signal 
transduction [94,105,107,108,110,111,120,121].  MUC1 has been also shown to interact 
with other molecules such as Abelson murine leukemia viral oncogene homolog 1 (c-
Abl) [122], Ataxia telangiectasia mutated (ATM) [123] and Calcium-modulating 
cyclophilin ligand (CAML) [124]. 
MUC1-CD overexpression has been shown to activate β-catenin [117],  NFK-B 
[101], STAT1/STAT3 [125,126], Protein Kinase B (also known as Akt) and ERK 
[127,128] signaling. Although a role for MUC1-CD as a scaffolding protein has not yet 
been clearly established, its interaction with these proteins that represent several 
different signaling cascades suggests a role for MUC1-CD as an integrator of signaling 
networks with oncogenic potential and therefore a promising target for the development 
of new therapeutic strategies against GC (reviewed in [129]). 
Most studies examining MUC1 signaling activity have focused on breast cancer 
cells, where MUC1 is overexpressed, aberrantly glycosylated, and constitutively 
phosphorylated. Up to now there is little information about MUC1 participation in 
signaling pathways of GC cells, which reinforces the relevance of a comprehensive 
study of the MUC1-receptor model in these cells. It has been found that ERK1/2 
molecules, the final effectors of the MAPK signaling pathway, were deregulated in  
H.pylori-related GCs [29]. It is known that MUC1 overexpression is correlated with the 
progression and prognosis of GCs [76,130] and therefore this molecule is likely to play 
a relevant role in oncogenic signaling pathways of GC cells.  
 
5.1. MUC1 – cancer biomarker vs therapy target  
 
 Since MUC1 has been shown to play an important role in the tumorigenesis of 
several tumor types, there is a major drive to explore its potential either as a cancer 
biomarker as well as a therapy target. Circulating MUC1-N, result of cleavage by the 
action of proteases [131] has been used as a prognostic and predictive cancer biomarker, 
mainly in breast carcinoma [132]. However, recent studies have shown that the 
significance of circulating MUC1 is not that relevant, since its levels greatly vary in 
healthy individuals. Furthermore, although very sensitive, these biomarkers will be 
influenced by individual polymorphisms, multiple epitopes or glycosylation differences. 
It is thought that MUC1-C terminus will be a better prognostic and predictive marker in 
carcinomas that overexpress MUC1 [133]. 
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Immunotherapy against this molecule has been explored for the treatment of 
several cancers. However, there has been a general failure in MUC1 immunotherapy 
treatments to overcome the pre-clinical phases, which can be explained by several 
factors. MUC1 immunogen used for many of these studies is the TR domain, which 
glycosylation varies significantly between normal and cancer cells and even between 
cells of the same tumor. The TR contains a repeating unit of 20 aminoacids and 
therefore is only capable of generating a weak immune response [134]. Furthermore, the 
TR region is known to interact with several other extracellular molecules and this 
interaction may reduce the efficacy of the immunological surveillance. Strategies have 
been developed in order to overcome this problem [135], opening exciting paths for 
MUC1 immunotherapy. 
Recently, MUC1 peptides and small molecule inhibitors have been proven to be 
effective in inhibiting cancer progression, both in vitro and in vivo [136,137,138]. 
However, all MUC1-based therapies that are under development are still relatively 
recent and not yet fully tested or even proven to be efficient. Therapies that were 
successful in mice have not progressed to clinic [139] and therefore it is urgent to 
develop new and more efficient therapies. 
Considering that existing chemo and radiotherapies have been proven not to be 
effective in GC treatment, the detailed characterization of MUC1 impact in gastric 
carcinogenesis assumes a significant relevance for the development of future MUC1-
based therapies. 
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General Aims 
 
With this project, we plan to evaluate the relevance of MUC1 in gastric 
carcinogenesis, namely its impact in H.pylori adhesion and its participation in 
oncogenic signaling pathways. 
 
Specific Aims 
 
1. Evaluation  of  the impact MUC1  VNTR length in H.pylori adhesion to 
GC cells. Paper I.  
 
In  the  first  part  of  the  work,  we  tested  the  hypothesis  that  MUC1  VNTR  
polymorphism affects the adhesion of H. pylori  to GC cells and thus plays an important 
role in the colonization of gastric mucosa. We used H. pylori strains with different 
pathogenicities (pathogenic strain HP26695 and non-pathogenic strain HPTx30a), co-
cultured with two different GC-derived cell lines GP202 and MKN45, and GP202 
clones expressing recombinant MUC1 with different VNTR lengths. Adhesion was 
evaluated by an ELISA-based adhesion assay [140], that was optimized in our 
laboratory. 
 
2. Evaluation   of   MUC1   impact   on   gene   expression,  phenotype   and 
tumorigenicity of GC cells. Paper II. 
 
In the second part of the work, we tested the hypothesis that MUC1 is a relevant 
molecule for GC biology. We used retrovirus-mediated transfection of short-hairpin 
RNAs (shRNA) to induce a stable downregulation of MUC1 in the GC-derived cell 
lines MKN45 and GP202. Four MUC1 downregulated clones (MKN45-C1 and 
MKN45-C2, GP202-C1 and GP202-C2) and two scrambled controls (MKN45-SC and 
GP202-SC) were successfully isolated and expanded. The impact of MUC1 
downregulation on global gene expression in the GC cells MKN45 and GP202 was 
evaluated by microarray analysis. The effects of MUC1 downregulation in MKN45 and 
GP202 cells phenotype were studied in vitro with respect to cell proliferation, apoptosis, 
migration, invasion and cell-cell aggregation. In vivo assays were also performed in 
mice with the MKN45 GC cell line, in order to study the tumorigenicity of cells with 
and without MUC1 downregulation. 
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3. Identification   of   MUC1-mediated   oncogenic   signaling  pathways   in 
GC cells. Paper III. 
 
In the third part of the work, we have identified MUC1 signaling partners in 
MKN45 GC cells. We used immunoprecipitations and Proximity Ligation Assays 
(PLAs) to identify interactions between MUC1-CD and oncogenic signaling molecules. 
The interactions of MUC1-CD with oncogenic signaling partners were also studied in 
GC and normal gastric tissue samples, in order to evaluate their relevance for gastric 
carcinogenesis. 
 
4. Evaluation  of  MUC1  impact  in  the expression and phosphorylation of 
gastric oncogenesis-related proteins in GC cells. Paper III. 
 
In the fourth part of the work, we evaluated the impact of MUC1 
downregulation in the MKN45 GC cell line on gastric oncogenesis-related proteins 
expression and phosphorylation by immunoblots, RT-PCR and Kinexus phospho-
antibody screening.  
 
5. Evaluation  of   the  impact   of   H. pylori  binding   in   MUC1-mediated 
oncogenic signaling pathways in GC cells.  
 
In the fifth part of the work, we tested the hypothesis that H. pylori triggers 
MUC1-dependent oncogenic signaling pathways in GC cells. We evaluated the 
phosphorylation of ERK1/2, using co-cultures of H. pylori pathogenic strain HP26695 
and MKN45 GC cells.  
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Materials and Methods 
 
Cell culture 
 
We have used two GC cell lines: GP202, previously established in our laboratory [141] 
from a signet ring cell GC that constitutively expresses MUC1 and MKN45, derived 
from a poorly differentiated adenocarcinoma, Japan Health Sciences Foundation [142], 
both derived from diffuse type GCs. MKN45 and GP202 cell lines were grown in 
Roswell Park Memorial Institute (RPMI) 1640 containing Glutamax
TM
I and 25 mM 
Hydroxy ethyl piperazine ethane sulfonic acid (HEPES), supplemented with 10% FBS 
and 50 μg/ml gentamicin. The GC intestinal-type cell line AGS was obtained from 
ATCC (CRL-1739) and grown under the same conditions described. 
GP202 clones expressing recombinant MUC1 with different VNTR lengths
 
were 
previously established by stable transfection with an eukaryotic expression vector pHb-
APr1-neo containing subcloned epitope-tagged MUC1 (FLAG-MUC1) complementary 
DNAs (cDNAs) with different number of TR units (0, 3, 9 and 42 repeats, respectively 
GP202- ΔTR, GP202- 3TR, GP202- 9TR and GP202- 42TR) [85]. GP202-Neo was 
obtained by transfection with the empty vector. Recombinant MUC1 transfectants were 
cultured at 37ºC in a humidified 5% carbon dioxide (CO2) incubator and maintained in 
RPMI 1640 medium (with Glutamax and 25 mmol/L Hepes) supplemented with 10% 
foetal bovine serum (FBS) and 50 µg/mL gentamicin. 
The packaging cell line PhoenixGP [143] was maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) containing Glutamax
TM
I, 4,500 mg/l D-Glucose and 
Sodium Pyruvate, supplemented with 10% FBS and 1% (v/v) penicillin/streptomycin. 
 Stable MUC1 downregulated clones were grown in standard growth medium 
supplemented with 5µg/ml puromycin. After evaluation of MUC1 levels at different 
time points in culture, all the assays were performed considering the time of cell culture 
in which the downregulation was higher, at 96 h of cell culture for MKN45 and 48 h for 
GP202 cells. Cells were grown at 37ºC with 5% CO2 in humidified atmosphere. 
Cell culture reagents were obtained from Invitrogen. 
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H. pylori strains 
 
 Two H. pylori strains were used in this study: the pathogenic strain HP26695 
(vacA s1/m1, cag pathogenicity island (PAI)+, American Type Culture Collection 
(ATCC) 700392) and the non-pathogenic strain HPTx30a (vacA s2/m2, cag PAI-, 
ATCC 51932). Bacteria were grown on Trypticase soy agar with 5% sheep blood 
(BioMérieux) at 37ºC in microaerobic conditions.  
 
Clinical Samples 
 
Normal gastric tissues were obtained from the University of Nebraska Medical 
Center’s Tissue Bank through the Rapid Autopsy Pancreatic program in compliance 
with IRB 091-01. To ensure minimal degradation of tissue, organs are harvested within 
three hours post mortem and the specimens placed in formalin for immediate fixation. 
Sections were cut from paraffin blocks into 4 micron thick sections and mounted on 
charged slides. For GC tissue samples, we have used paraffin embebbed slides from the 
antrum part of the stomach treated in a similar way as the normal samples and obtained 
from the Medical Faculty of Porto from gastric biopsies.  
 
Co-cultures and Enzyme-linked immunosorbent assay (ELISA) assays 
 
Quantitative evaluation of H. pylori adhesion to gastric cells was performed by ELISA, 
as previously described [140], with some modifications. Briefly, cells were cultured in 
96 well plates and allowed to form confluent monolayers. Cells were washed and H. 
pylori suspension was added in a 200:1 Multiplicity of infection (MOI) and incubated 
for 60 min. Cells were washed and fixed at 4ºC with 8% paraformaldehyde (PF) for 60 
min. Endogenous peroxidase was inactivated by addition of 1% Hydrogen peroxide 
(H2O2) in methanol. After washing with PBS solution, anti-H. pylori monoclonal 
antibody MAB922 (Chemicon) was added overnight (O.N.), at 4ºC, followed by the 
addition of peroxidase-conjugated goat anti-mouse immunoglobulins (Santa Cruz 
Biotechnology) for 30 min,  RT. Tetramethylbenzidine (TMB) (Sigma) was added and 
reaction stopped with 1M Hydrochloric Acid (HCl). Plates were read in a 680 ELISA 
microplate reader (Bio-Rad) at 450 nm. Optical density (O.D.) values were used as the 
index of the number of H. pylori adhering to cells. Two sets of triplicates were made for 
each assay. Statistical analysis was performed using the Mann-Whitney test - StatView 
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Software version 5.0 (SAS Institute, Cary, NC). A P value of less than 0.05 was 
accepted as statistically significant. 
 
Co-cultures with MKN45 GC cell line and HP26695 bacteria 
 
 MKN45-SC cells were cultured until subconfluency in 24-well plates. HP26695 
bacteria were added to each plate in a MOI of 100:1 and incubation was performed for 1 
h or 6 h. Washes were performed with Tris-buffered saline (TBS) to remove non 
adherent bacteria. Protein extraction was performed in the remaining plates, as will be 
hereafter described for the Kinexus assays. 
 
MUC1 downregulation strategy 
 
 MUC1 downregulated cells were produced using a retroviral expression system 
with short hairpin Ribonucleic acid (RNA)s. Briefly, a 21-nucleotide sequence of the 
MUC1 gene, with no homology to other Deoxyribo nucleic acid (DNA) sequences 
detected in a BLAST search, was chosen according to standard Ribonucleic acid 
interference (RNAi) rules [144]. The scrambled control was designed and tested for 
homology in a BLAST search as well. Sense and antisense oligos (Proligo) were ligated 
and inserted in the pSUPER.retro.puro vector (Oligoengine). The oligos used were the 
following: MUC1 Exon 2 (sense: GATCCCCACCTCCAGTTTAATTCCTC 
TTCAAGAGAGAGGAATTAAACTGGAGGTTTTTTA; antisense: AGCTTAAAAA 
ACCTCCAGTTTAATTCCTCTCTCTTGAAGAGGAATTAAACTGGAGGTGGG;the 
MUC1-cDNA target region is underlined) and scrambled control (sense: 
GATCCCCATCACCTTCGTACTCCTTATTCAAGAGATAAGGAGTACGAAGGTG
ATTTTTTA, antisense: AGCTTAAAAAATCACCTTCGTACTCCTTATCTCTTGAA 
TAAGGAGTACGAAGGTGATGGG; the “unpaired”-cDNA target region is 
underlined). The MUC1 specific target or the scrambled control constructs were 
transfected into PhoenixGP packaging cell line by calcium-phosphate mediated 
transfection and transfected cells were selected using puromycin. Stable transfectants 
were seeded in a 6-well plate (1x10
6
cells/well) and incubated for 24 h at 32ºC. The 
media containing the virus was collected, filtered through a 0.45 µm filter to remove 
remnant cells, and used to infect MKN45 and GP202 cells, during 24 h at 37ºC. The 
viral supernatant was then replaced by the standard growth medium and cells were 
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incubated 48 h at 37ºC. Efficiently transduced cells were selected and grown in standard 
media supplemented with puromycin. Two independent MUC1 downregulated clones 
(C1 and C2) were isolated and expanded for three times, using cloning rings.  
 
Immunofluorescence and antibodies 
 
 MKN45 and GP202 cells in culture were harvested, seeded in 12-well slides 
(Cell Line) and air-dried O.N. at RT. Cells were then fixed in ice cold acetone for 5 
min, washed twice with PBS and blocked with normal rabbit serum (DAKO) diluted 1:5 
in 10% bovine serum albumin (BSA) for 30 min. Serum was then replaced by the 
MUC1 monoclonal antibody HMFG1 (NovoCastra) diluted 1:50 in 5% BSA, and 
incubated O.N. at 4ºC. After three washes with PBS, cells were incubated with a rabbit 
anti-mouse Fluorescein isothiocyanate (FITC) labeled antibody (DAKO) diluted 1:70 in 
5% BSA for 30 min in the dark at RT. Cells were washed 3 times with PBS and 
mounted in vectashield (Vectorlabs). Images were acquired in a Leica DMIRE2 
fluorescence microscope. Results are representative of three independent experiments.  
 
Confocal Microscopy 
 
MKN45-SC and MKN45-C2 cells were grown until confluency in round slides, 
washed with PBS and fixed with 4% PF/120mM sucrose for 15 min. 0.1M glycine was 
added after fixative removal for 15 min. Cells were washed with PBS 1% BSA twice 
and permeabilized with 0.15% Triton-X100/1%BSA in PBS for 15 min. After washing 
with PBS 1% BSA, the primary antibodies were added in PBS 1% BSA : MUC1-CT2 
1:300 (ThermoScientific) and calreticulin 1:50 (Cell Signaling) and incubated O.N. at 
4ºC. After washing with PBS, the secondary antibodies were added (Alexa Dylight-488 
anti-hamster 1:500 and donkey anti-rabbit-649 1:500) for 1 h at RT. After PBS washing, 
nuclei were stained with DAPI (1:10,000 in PBS for 2 min), cells were washed again 
with PBS and mounted in Vectashield. Images were acquired in a Zeiss Confocal 
Microscope LSM410. 
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Protein extraction, Western blot and Immunoprecipitations 
 
 MKN45 and GP202 cells were cultured in 60-mm dishes to 80-90%-confluence. 
After washing twice with PBS, lysis buffer (10 mM Tris hydroxylmethyl amino 
methane (Tris) pH 7.4, 150 mM Sodium chloride (NaCl), 0.1% (p/v) Sodium dodecyl 
sulfate (SDS), 1 mM Phenylmethylsulfonyl fluoride (PMSF), 1% (v/v) Triton X-100) 
was added and cells were scraped. Lysates were incubated on ice for 15 min and 
centrifuged for 30 min at 4ºC to collect the supernatants. Protein content was assessed 
by the bicinchoninic acid method (Pierce), as described in the manufacturer’s 
instruction manual. Protein extracts  were analysed by a 4-10% Sodium dodecyl sulfate 
– polyacrylamide gel electrophoresis (SDS-PAGE) (Invitrogen), transferred to 
Polyvinylidene fluoride (PVDF) membranes (Amersham Biosciences), blocked with 5% 
nonfat dry milk in PBS containing 0.01% Tween 20 and blotted O.N. at 4ºC with anti 
MUC1-CT2 monoclonal antibody 1:300 (ThermoScientific), anti-β-actin polyclonal 
antibody 1:5,000 (Sigma), anti ERK1/2 1:1,000 (Cell Signaling), anti-EGFR 1:200 
(Santacruz Biotec.),  anti-B-RAF 1:200 (Santacruz Biotec.) and anti-Grb2 1:200 
(Santacruz Biotec.) in 5% non-fat milk in PBS-0.1% Tween 20 (Sigma). Membranes 
were washed 3 times with PBS-0.1% Tween 20 and the primary antibodies were 
revealed using goat anti-mouse/rabbit/hamster peroxidase-conjugated antibodies 
(1:2,000, DAKO) in 5% non-fat milk in PBS-0.1% Tween 20, followed by ECL 
detection kit (BioRad).  
For co-culture experiments (MKN45 cells and HP26695 bacteria), 20 µg of 
protein extracts were obtained as will be hereafter described for Kinexus assays and 
using TBS instead of PBS buffer and were analyzed using phospho-ERK1/2 antibody 
1:1,000 (Cell Signaling). When β-actin values were not similar among samples, films 
were scanned in GS-800 Calibrated Densitometer (BioRad) and optical density of each 
specific P-ERK1/2 band was analysed using the Quantity One software (BioRad) and 
normalized to the β-actin density. Results are representative of three independent 
experiments.  
For immunoprecipitations, 750 µg of protein lysate were incubated for 3 h at 4ºC 
with anti-MUC1-CT2 1:300 (ThermoScientific) and normal armenian hamster IgG 
(EBioscience), previously precipitated with Protein G Sepharose (Sigma) for 1 h at 4ºC. 
After washing with non-denaturing lysis buffer, the immunoprecipitates and lysates 
M
a
te
r
ia
l 
a
n
d
 M
et
h
o
d
s 
  
 
M
a
te
r
ia
l 
a
n
d
 M
et
h
o
d
s 
were separated in 12% Tris-Glycine Gels (Invitrogen). The rest of the immunoblot 
procedure was performed as mentioned before. 
 
RNA extraction and Real-Time PCR 
 
 Total RNA was isolated from MKN45 and GP202 cells in culture using 
TriReagent
TM
 (Sigma), according to the manufacturer’s instructions. 5 μg of RNA were 
primed with random hexamers (Invitrogen) and reverse transcribed with Superscript II 
(Invitrogen) in a final volume of 20 μl. 2 μl of a 1:10 dilution of cDNA were amplified 
with 300 nM of each primer and SYBRGreen (Applyed BioSystems) in a final volume 
of 20μl, using the fluorescence reader ABI Prism 7000. Each sample was run in 
triplicate. The primers used were the following: MUC1 (sense: 
CTCCTTTCTTCCTGCTGCTG, antisense: CTGGAGAGTACGCTGCTGGT); 18S 
(sense:       CGCCGCTAGAGGTGAAATTC,     antisense:   CATTCTTGGCAAATGC 
TTTCG); TBP (sense: GCACAGGAGCCAAGAGTGAA, antisense: TCACAGC 
TCCCCACCATATT), EGFR (sense: GAGCGACTGCCTGGTCTGCC, antisense: 
CACGCAGGTGGCACCAAAGC), ERK2 (sense: GACACAACACCTCAGCAAT 
GACCA, antisense:  GGCTTGAGGTCACGGTGCAGA) and BRAF (sense: TTAGT 
GAGCCAGGTAATGAGGCA; antisense: ATCAATTTGGGCAACGAGACCGA)   
and their specificity was confirmed using the software BLASTn on-line and by melt 
curve analysis. For each sample, the level of 18S/TBP RNA was measured and used for 
normalization of target genes abundance. Relative Messenger RNA (mRNA) levels 
were then calculated using the comparative Ct method [145]. Data are expressed as a 
ratio of the results obtained with each clone and the scrambled control, from three 
independent experiments. Statistical analysis was performed using the Mann-Whitney 
test - StatView Software version 5.0 (SAS Institute, Cary, NC). 
 
Gene expression analysis 
 
The expression of 12,135 genes in MKN45 and GP202-MUC1 downregulated 
clones and the respective scrambled control was evaluated following the same protocol 
as in [146]. Briefly, following RNA extraction (as described previously), cDNA was 
obtained by reverse transcription, during which labeled nucleotides were incorporated: 
MKN45-C1, MKN45-C2, GP202-C1 and GP202-C2 cDNAs were labeled with Cy3 
 
 
45 
 
(green emission) and MKN45-SC and GP202-SC controls with Cy5 (red emission). 
After hybridization, the mixture was hybridized with the array O.N. and then the array 
was digitalized with the ScanArray4000 (Perkin-Elmer) system and fluorescence 
analysed by the QuantArray software package (Perkin-Elmer).   
 Normalization and background subtraction were performed and ratios 
downregulated clones /SC control and SC control/downregulated clones were calculated 
using Microsoft Excel software. Gene expression with a ratio higher than 2 was 
considered statistically significant. 
All data are MIAME compliant and the raw from the microarray experiments 
were uploaded onto the Gene Expression Omnibus Database      
http://www.ncbi.nlm.nih.gov/geo (Geo accession numbers: GSM717858 and 
GSM717859). 
Methyl thiazol tetrazolium (MTT) proliferation assay 
 
MKN45 and GP202 cells were plated in triplicate in 96-well plates at 5,000 cells 
per well and incubated at normal conditions. At each time point, the medium was 
removed and cells incubated with 20 µl of MTT solution (5mg/ml, Sigma) for 3 h at 
normal conditions. MTT was removed and 200µl of Dimethyl sulfoxide (DMSO) were 
added to each well to dissolve formazan. Finally, formazan O.D. was measured using a 
microplate reader at a wavelength of 540nm. The relative growth was defined as the 
following formula: Relative Growth = (A540nm at Tn / A540nm at T024h). Data are 
expressed as a ratio of the results obtained with each clone and the scrambled control, 
from three independent experiments. Statistical analysis was performed using the Mann-
Whitney test - StatView Software version 5.0 (SAS Institute, Cary, NC). 
 
TUNEL assay  
 
Post-confluent MKN45 and GP202 cells were harvested and fixed with 4% PF 
in PBS for 15 min. Fixated cells were seeded in 12-well slides (Cell Line) and air-dried 
O.N. at RT. Following washing with PBS, cells were permeabilized with ice-cold 
freshly-made PBSTrCit solution (PBS + 0.1%TritonX + 0.1% Sodium Citrate) for 2 
min on ice. Cells were washed again twice, and incubated with TUNEL reaction mix 
(enzyme solution, label solution and dilution buffer, 1:9:10, In Situ Death Detection Kit, 
Fluorescein, Roche) for 1 h at 37ºC. Two additional washing steps were performed and 
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slides were mounted in Vectashield with Diamidino phenylindole (DAPI) (Vectorlabs). 
Results were analysed under a Leica DMIRE2 fluorescence microscope and data are 
expressed as a ratio of the results obtained with each clone and the scrambled control, 
from three independent experiments. Statistical analysis was performed using the Mann-
Whitney test - StatView Software version 5.0 (SAS Institute, Cary, NC). 
 
Migration assay 
 
MKN45 and GP202 cells were cultured in 60-mm dishes until full confluency. 
The epithelial cells monolayer was then washed with PBS and wounded with a 10µl 
micropipette tip. Non-adherent cells were removed by washing twice with PBS. Images 
of cells at the edge of the wound were acquired automatically at 20x magnification in a 
Leica DMIRE2 fluorescence microscope with a Leica DFC Twain camera for 144 
frames at 10 min intervals (with a total time corresponding to 24 h) controlled by Leica 
FW4000 software. Frames from 0, 6, 12, 18 and 24 h were used to quantify the 
percentage of migration: a grid of 50x30 squares was used to fulfill the wound space 
and the percentage of migration was calculated by the number of squares occupied by 
cells at each time point. Data are expressed as a ratio of the results obtained with each 
clone and the scrambled control, from three independent experiments. Statistical 
analysis was performed using the Mann-Whitney test - StatView Software version 5.0 
(SAS Institute, Cary, NC). 
 
Matrigel invasion assay  
 
Cell invasion was studied by using BD Biocoat™ Matrigel™ invasion chambers 
with 8-μm size pores (BD Biosciences), according to the manufacturer’s instructions. 
MKN45 and GP202 cells in culture were harvested and seeded in duplicate at 250,000 
cells per insert (sized for 24-well plates) in 1% FBS containing medium, and 20% FBS 
containing medium was added to the bottom of the growth well, as an attractant. Cells 
were allowed to invade for 22 h (37ºC, 5% CO2 atmosphere). The non-invading cells 
were then swabbed from the top of the inserts and the invading cells on the lower 
surface were fixed with 100% methanol and stained with DAPI for 15 min in the dark. 
The membranes were removed and cells were counted under a Leica DMIRE2 
fluorescence microscope. Data are expressed as a ratio of the results obtained with each 
 
 
47 
 
clone and the scrambled control, from three independent experiments. Statistical 
analysis was performed using the Mann-Whitney test - StatView Software version 5.0 
(SAS Institute, Cary, NC). 
 
Cell-cell Aggregation assay 
 
MKN45 and GP202 cells in culture were harvested and seeded in duplicate at 
250,000
 
cells per well in 24-well plates. Plates were placed at 37ºC with constant 
stirring (150rpm) for 1 and 2 h. Cells were fixed with 100 μl of 25% glutaraldehyde at 
time zero and at the end of the incubation. Aggregates were photographed under a light 
microscope and isolated cells were counted (cells in duplicates were counted as isolated 
cells). The aggregation index was defined taking into account the number of isolated 
cells at Tn and number of isolated cells at T0. Data are expressed as a ratio of the results 
obtained with each clone and the scrambled control, from three independent 
experiments. Statistical analysis was performed using the Mann-Whitney test - 
StatView Software version 5.0 (SAS Institute, Cary, NC). 
 
In Vivo mice assays  
 
Six-week-old female N:NIH(s)II:nu/nu nude mice were obtained previously 
from the Medical School, University of Cape Town in 1991 and then reproduced, 
maintained and housed at IPATIMUP Animal House at the Medical Faculty of the 
University of Porto, in a pathogen-free environment under controlled conditions of light 
and humidity. Males and females, aged 6-8 weeks, were used for in vivo experiments. 
Animal experiments were carried out in accordance with the Guidelines for the Care 
and Use of Laboratory Animals, directive 86/609/EEC.  Mice were subcutaneously 
injected in the dorsal flanks using a 25-gauge needle with 1x10
5
 of MKN45-SC (2 male 
and 2 female mice) or MKN45-C2 cells (3 male and 3 female mice). Mice were 
weighed, and tumor width and length were measured with calipers every week. Mice 
were euthanized 21 days after cell injection, time when there was the need of 
euthanizing the first mouse. For statistical analysis, the Mann Whitney test - StatView 
Software version 5.0 (SAS Institute, Cary, NC) was used. A P value of less than 0.05 
was considered as statistically significant.  
 
M
a
te
r
ia
l 
a
n
d
 M
et
h
o
d
s 
  
 
M
a
te
r
ia
l 
a
n
d
 M
et
h
o
d
s 
Phospho-antibody screening (Kinexus) 
 
MKN45 and GP202 pre-confluent cells  were  lysed   by  the  addition  of   lysis buffer 
(20 mM Morpholino propane sulfonic acid (Mops), pH 7.0, 2 mM  Ethylene glycol 
tetraacetic acid (EGTA), 5 mM  Ethylene diamine tetraacetic acid (EDTA), 30 mM 
sodium fluoride, 60 mM  β-glycerophosphate, 10 mM  sodium  pyrophosphate, 2 mM  
sodium orthovanadate, 1 mM PMSF, 3 mM benzamidine, 5 μM pepstatin,10 μM 
leupeptin, and 0.5% Triton X-100; final pH 7.0). Cells sonication was performed twice 
for 15 s and the homogenate was subjected to ultracentrifugation for 30 min at 50,000 
rpm. 
Protein concentration was measured by the Bio-Rad assay and phospho-kinase 
screening was performed by Kinexus (Vancouver, BC; KPSS-10.1). 
 
Proximity Ligation Assays 
 
MUC1-CD antibody (MUC1-CT2, ThermoScientific) is produced in armenian 
hamster. Since there are no probes against hamster antibodies commercialized by O-link 
Biosciences, we have first labeled the antibody with a kit, the Duolink II Probemarker 
Plus (OLink Bioscience), according to the manufacturer’s instructions. 
MKN45-SC and MKN45-C2  clones were grown until subconfluency in round 
slides,  fixed with PF 4% 120mM sucrose and permeabilized with Triton-X  at RT and 
washed with PBS. We have followed the instructions of the kit DII anti-rabbit minus or 
the DII anti-mouse minus (both OLink Bioscience), followed by the detection kit DII 
Det. Reag.Orange (OLink Bioscience). Primary antibodies used were anti-MUC1-CT2 
1:300 (labelled in the previous step), anti-ERK1/2 1:100 (Cell Signaling), anti-EGFR 
1:50 (Santacruz Biotec.), anti-B-RAF 1:50 (Santacruz Biotec.), anti-Grb2 (1:50, 
Santacruz Biotec), anti CDK1/2 1:50 (Santacruz Biotec.), anti-B23 1:50 (Santacruz 
Biotec.), anti-E-cadherin 1:500 (BD Transduction Laboratories) and anti β-catenin 
1:100 (BD Transduction Laboratories).  Fluorescence spots were observed under a 
DMIRE2 fluorescence microscope and quantified using the Blobfinder software [147]. 
Negative controls (MKN45-SC (-)) correspond to the assay with the MUC1-CD labeled 
antibody only. The AGS cell line was also used to study the interaction between MUC1-
CD and ERK1/2, using the same conditions described before. 
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PLA assays were also performed in both normal and GC tissue slides, using the 
same conditions described, after deparaffinization and rehydratation with xylene and 
ethanol. Antigen retrieval was performed by the method of Sodium Citrate Buffer 
(10mM Sodium Citrate, 0.05% Tween 20, pH 6.0). A positive control of the PLA assay 
in tissues was used with a GC slide and the hybridoma supernatants PMH1 and TKH2, 
for MUC2 and sialyl-Tn, a well known interaction in this tissue. 
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Results  
  
1. Evaluation of the impact of MUC1 expression and variability (VNTR 
polymorphism) in H. pylori adhesion to GC cells. 
 
Evaluation of H. pylori adhesion shows that the pathogenic strain HP26695 
(positive for the virulence factors cagA and vacA) has significantly (P < 0.05) higher 
adhesion values for both GP202 and MKN45 cell lines (1.97±0.10 and 1.47±0.06) when 
compared with the non-pathogenic strain HPTx30a (negative for the virulence factors 
cagA and vacA) (1.40±0.15 and 0.85±0.15) (Figure 6).  
                
 
Figure 6 >  Adhesion of HP26695 and HPTx30a H. pylori strains to GP202 and MKN45GC 
cell lines.* P < 0.05 (Mann-Whitney test). 
 
Furthermore, GP202 cell line shows higher adhesion levels than MKN45 cell 
line for both bacterial strains (HP26695 strain 1.97 ± 0.10 vs 1.47 ± 0.06; HPTx30a 
strain 1.40 ± 0.15 and 0.85 ± 0.15) (Figure 6).   
This statistically significant association between pathogenicity and higher 
adhesion (strain HP26695 vs HPTx30a) is also observed for the GP202 MUC1 
recombinant clones  (GP202-Neo 1.1 ± 0.10 vs 0.72 ± 0.06; GP202-∆TR 1.32 ± 0.09 vs 
1.0 ± 0.10; GP202-3TR 1.45 ± 0.08 vs 1.18 ± 0.05; GP202-9TR 2.2 ± 0.12 vs 1.96 ± 
0.12; and GP202-42TR 2.3 ± 0.07 vs 1.89 ± 0.11) (Figure 7).  
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Figure 7 > Adhesion of HP26695 and HPTx30a H. pylori strains to GP202 transfectants 
GP202-Neo, GP202-ΔTR, GP202-3TR, GP202-9TR and GP202-42TR. * P < 0.05, compared to 
the control (GP202 Neo) and ** P < 0.05 (Mann-Whitney test). 
 
Adhesion of both H. pylori strains (HP26695 and HPTx30a) is significantly 
higher in all the GP202-MUC1 transfectants overexpressing MUC1 (GP202-∆TR 1.32 
± 0.09 and 1.0 ± 0.10; GP202-3TR 1.45 ± 0.08 and 1.18 ± 0.05; GP202-9TR 2.2 ± 0.12 
and 1.96 ± 0.12; GP202-42TR 2.3 ± 0.07 and 1.89 ± 0.11) when compared with the 
control, GP202-Neo (1.1 ± 0.10 and 0.72 ± 0.06) (Figure 7). There is also an 
association between the increased number of TR and increased adhesion, for both 
strains (Figure 7).  
 
2. Evaluation of MUC1 impact on gene expression, phenotype and 
tumorigenicity of GC cells. 
 
For the MKN45 GC cell line, we established by shRNA two independent MUC1 
downregulated clones, MKN45-C1 and MKN45-C2, and one scrambled control, 
MKN45-SC.  MUC1 downregulation was verified by immunofluorescence (Figure 
8A), confocal microscopy (Figure 8B), Western blot (Figure 8C) and Real-Time PCR 
(Figure 8D). 
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Figure 8 > MUC1 downregulation by shRNA in MKN45 GC cell line at 96 h in culture. 
(A) MUC1-VNTR detection in green by immunofluorescence with HMFG-1 antibody in 
MKN45-C1 and MKN45-C2 and MKN45-SC control; (B) MUC1-CD protein detection by 
confocal microscopy (MUC1-CD in green, the endoplasmic reticulum in red and the nuclei in 
blue); (C) MUC1-CD protein detection by western blot with MUC1-CT2 and β-actin antibodies 
of total protein extracts from MKN45-C1, MKN45-C2 and MKN45-SC control; (D) 
Quantification of MUC1 RNA in MKN45-C1, MKN45-C2 and MKN45-SC control  by Real-
Time PCR. MUC1 expression was corrected to the house-keeping gene 18S and normalized to 
the data obtained with the scrambled control. *P  < 0.01 (Mann-Whitney test). 
                       MKN45-SC                                          MKN45-C2                                            
D 
   MKN45-SC                        MKN45-C1                        MKN45-C2 
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B 
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For the GP202 GC cell line, two independent MUC1 downregulated clones, 
GP202-C1 and GP202-C2, and one scrambled control, GP202-SC were also established 
and downregulation verified by immunofluorescence (Figure 9A), Western blot 
(Figure 9B) and Real-Time PCR (Figure 9C). 
 
 
 
   
 
 
            
                                                    
Figure 9 > MUC1 downregulation by shRNA in GP202 GC cell line at 48 h in culture. 
(A) MUC1-VNTR detection in green by immunofluorescence with HMFG-1 antibody in 
GP202-C1 and GP202-C2 and GP202-SC control; (B) MUC1-CD protein detection by western 
blot with MUC1-CT2 and β-actin antibodies of total protein extracts from GP202-C1, GP2025-
C2 and GP202-SC control; (C) Quantification of MUC1 RNA in GP202-C1, GP202-C2 and 
GP202-SC control  by Real-Time PCR. MUC1 expression was corrected to the house-keeping 
gene 18S and normalized to the data obtained with the scrambled control. *P < 0.01 (Mann-
Whitney test). 
 
      GP202-SC                                 GP202-C1                                GP202-C2 
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There was a significant downregulation of MUC1 expression in MKN45-C1, 
MKN45-C2, GP202-C1 and GP202-C2 clones when compared to the respective 
MKN45-SC and GP202 controls. The expression of MUC1 at the protein level was 
detected with two different antibodies, one that binds the VNTR extracellular domain 
(HMFG-1, Figure 8A and 9A) and other that recognizes a 14-28 KDa sequence in 
MUC1-CD (MUC1-CT2, Figure 8C and 9B). Both showed a significant reduction of 
the amount of MUC1 protein in MUC1 downregulated  clones when compared to the 
scrambled controls. Real-Time PCR results indicate that the MUC1 downregulation was 
48% (MKN45-C1) and 38% (MKN45-C2) (Figure 8D) and 48% (GP202-C1) and 42% 
(GP202-C2) (Figure 9C). MUC1 RNA levels were evaluated at 48, 72 and 96h of cell 
culture and the highest downregulation has occurred at 96h for MKN45 cells and at 48h 
for GP202 cells (results not shown). All the further assays were performed with cells at 
these time points for each cell line. 
 
2.1.  Effects of MUC1 downregulation on MKN45 and GP202 cells global 
gene expression  
 
We evaluated the overall effects of downregulating MUC1 in the MKN45 and 
GP202 GC cell lines by performing a global analysis of gene expression by 
oligonucleotide microarrays (Tables 1 and 2, respectively). Only differences that were 
observed for both clones were considered and are shown. The results revealed that a 
number of genes that influence proliferation, migration, invasion and motility were 
differentially expressed in MKN45-C1 and MKN45-C2 clones and the MKN45-SC 
control. The most significant differences were found for TCN1, KLK6 and ADAM29 
genes (>10 fold upregulated between the MKN45-C1 and MKN45-C2 clones and the 
MKN45-SC control) and LGALS4, TSPAN8 and SHPS-1 (> 3.5 fold downregulated 
between the MKN45-C1 and MKN45-C2 clones and the MKN45-SC control). 
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Table 1. Oligonucleotide microarray results by comparison between MKN45-C1/MKN45-
C2 and MKN45-SC control cells, by order of magnitude. 
 
Genes upregulated > 2 fold in MKN45-C1 and 
MKN45-C2 downregulated clones 
Gene function 
Transcobalamin 1 (TCN1) 
Kallikrein-related peptidase 6 (KLK6) 
Desintegrin and metalloproteinase 29 (ADAM29) 
Keratoepithelin (TGFBI) 
MRP family of ATP transport member 2 (ABCC2) 
Amyloid beta precursor-like protein 2 (APLP2) 
Mitochondrial ATP synthase  (ATP5I) 
Sulfide dehydrogenase like protein (SQRDL) 
Sarcoglycan, epsilon (SGCE) 
Hypothetical protein (FLJ20323) 
Galectin 1 (LGALS1) 
Proline-histidine rich protein (PHLDA1) 
Trypsin 2 (PRSS2) 
Mesotrypsin (PRSS3) 
SP2 transcription factor (SP2) 
Ubiquitin-conjugating enzyme (UBE2L6) 
Vitellogenic-like carboxypeptidase (CPVL) 
Vitamin B12 transport to cells [148] 
 
Serine protease [149] 
 
Cell-cell and cell-matrix interactions [150] 
 
Anti adhesion cell molecule [151] 
 
Multi drug resistance molecule [152] 
 
Synaptic transmission [153] 
 
ATP synthesis [154] 
 
Involved in metabolic syndrome [155] 
 
Cell-matrix interactions [156] 
 
Unknown 
 
Cell-cell and cell-matrix interactions [157] 
 
Anti-apoptotic effect [158] 
 
Serine protease [159] 
 
Serine protease [160] 
 
Regulation of  chorionic gonadotropin hormone 
expression [161] 
 
Ubiquitinilation of proteins [162] 
 
Carboxypeptidase activity [163] 
Genes downregulated > 2 fold in MKN45-C1 and 
MKN45-C2 downregulated clones 
Gene function 
Galectin 4 (LGALS4) 
Tetraspanin 8 (TSPAN8) 
Tyrosine phosphatase SHP substrate (SHPS-1) 
Polymerase (DNA-directed), delta 4 (POLD4) 
H2B histone family, member J (HIST1H2BH) 
H2B histone family, member T (HIST1H2Bk) 
Carcinoembryonic molecule 5 (CEACAM5) 
Annexin IV (ANXA4) 
Intercellular adhesion molecule 4 (ICAM4) 
Polypeptide 39 (DDX39) 
Apolypoprotein B (APOBEC2) 
Clusterin (CLU) 
GDP-mannose 4,6-dehydratase (GMDS) 
Serine/threonine kinase 38 like (STK38L) 
CD55 (CD55)                                                                                             
Apolipoprotein 3C (APOBEC3C) 
Cell adhesion related-molecule (CDON) 
Villin-1 (VIL1) 
Cell-cell and cell-matrix interactions [164] 
 
Cell motility [165] 
 
Regulation Insuline growth factor1 [166] 
 
Polymerase activity [167] 
 
Nucleossome Structuration  
 
Nucleossome Structuration 
 
Cell adhesion [168] 
 
Cellular dissemination [169] 
 
Cell extravasation [170] 
 
 
RNA helicase [171] 
 
Citidine-deaminase activity [172] 
 
Apoptosis [173] 
 
Fucose synthesis [174] 
 
Serine/threonine kinase [175] 
 
Complement system activation [176] 
 
Citidine-deaminase activity [177] 
 
Cell-cell interaction and differentiation [178] 
 
Migration and actin organization [179] 
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In the case of GP202 cells, only three genes were differentially expressed 
between MUC1 downregulated clones and the control. There is no direct association 
between the genes with altered expression levels and migration, invasion and motility 
upon MUC1 downregulation, as found for MKN45 GC cell line. 
 
Table 2. Oligonucleotide microarray results by comparison between GP202-C1/GP202-C2 
and GP202-SC control cells, by order of magnitude. 
 
Genes downregulated > 2 fold in GP202-C1 and 
GP202-C2 downregulated clones 
Gene function 
Calcium P-protein (S100P) 
α-protein interferon- induced (ISG15) 
β-tubulin 2A (TUBB2A) 
Differentiation, Cell cycle progression [180] 
Ubiquitin-proteossome regulation [181] 
Cytoskeleton organization [182] 
 
 
 
2.2.  Effects of MUC1 downregulation on MKN45 and GP202 cells phenotype 
In the previous immunofluorescence assays (Figures 8A and 9A) it has been 
shown that MKN45-SC cells express a higher amount of MUC1 when compared to 
GP202-SC cells. Furthermore, downregulation levels differ between cell lines in terms 
of total MUC1 molecules present upon downregulation. Thus, it is expectable that 
MUC1 downregulation has different effects in these cells phenotypic characteristics. 
Levels of cell proliferation, apoptosis, aggregation, migration and invasion were 
measured for both GC cell lines. 
 
2.2.1. Cell proliferation 
 
MKN45-C1 and MKN45-C2 cells showed significantly increased proliferation 
rates (P < 0.01)  when  compared  to  the MKN45-SC control (2.29 and 2.48 vs 1), when  
evaluated by MTT assay (Figure 10A).  In the case of GP202 cells, the results were not 
consistent since one of the clones showed decreased proliferation and the other showed 
increased proliferation (P < 0.01, 0.30 and 2.14 vs 1) (Figure 10 B).  
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Figure 10 > Quantification of cell proliferation by MTT assay.  
(A) Quantification of metabolically active cells by MTT assay in MKN45-C1 and MKN45-C2 
clones and MKN45-SC control at 96h in culture and (B) quantification of metabolically active 
cells by MTT assay in GP202-C1 and GP202-C2 clones and GP202-SC control at 48h in 
culture. Data from 24 h were used to set time zero and results were normalized to the data 
obtained with the scrambled control.*P < 0.01 (Mann-Whitney test). 
 
2.2.2. Cell apoptosis 
 
MKN45-C1 and MKN45-C2 cells showed significantly increased levels of 
apoptosis (P < 0.01) when compared to the MKN45-SC control (3.32 and 2.41 vs 1), 
when evaluated by a TUNEL assay (Figure 11A).  In the case of GP202 cells, the 
apoptosis levels of GP202-C1 and GP202-C2 results were not significantly different 
when compared to the control, GP202-SC (1.28 and 1.62 vs 1) (Figure 11 B).                                      
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Figure 11 > Quantification of apoptotic cells by TUNEL assay.  
(A) Apoptosis of MKN45-C1 and MKN45-C2 clones and MKN45-SC control was evaluated at 
96h in culture by a TUNEL assay. Results were normalized to the data obtained with the 
scrambled control; (B) Apoptosis of GP202-C1 and GP202-C2 clones and GP202-SC control 
were also evaluated at 48h in culture. Results were normalized to the data obtained with the 
scrambled control. *P < 0.01 , NS- not significant  (Mann-Whitney test). 
 
2.2.3. Cell-cell aggregation 
 
MKN45-C1 and MKN45-C2 cells showed significantly decreased cell-cell 
aggregation levels (P < 0.01), when compared to the MKN45-SC control (0.34 and 0.49 
vs 1 at 1h; 0.52 and 0.64 vs 1 at 2h), when evaluated by a cell aggregation assay 
(Figures 12A1). In the case of GP202 cells, GP202-C1 and GP202-C2 cells showed 
significantly decreased cell-cell aggregation levels (P < 0.01), when compared to the 
GP202-SC control but only after 2 h of stirring (0.64 and 0.66 vs 1 at 2h) (Figure 
12B1). 
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Figure 12 > Quantification of cell-cell aggregation by a cell aggregation assay. 
(A1 and A2) Quantification of the cell-cell aggregation index in MKN45-C1, MKN45-C2, 
GP202-C1 and GP202-C2 clones and MKN45-SC and GP202-SC controls. The cell-cell 
aggregation index was assessed by scoring the number of isolated cells over time, and 
normalized to the data obtained with the scrambled control. *P < 0.01 , NS- not significant  
(Mann-Whitney test); (B1 and B2) Images of the aggregates formed after 1 and 2 h of constant 
stirring. First column shows isolated cells at time 0h (20x magnification) and second and third 
columns show aggregates formed after 1h and 2h of stirring (40x magnification), in MKN45-
C1,MKN45-C2, GP202-C1 and GP202-C2 clones and MKN45-SC and GP202-SC controls. 
B1 
B2 
R
es
u
lt
s 
  
 
2.2.4. Cell invasion and migration  
 
There were no significant differences in cell invasion of MKN45-C1 and 
MKN45-C2 clones when compared to the MKN45-SC control, when evaluated by 
invasion assays (results not shown). However, differences were observed concerning the 
GP202 cell line. GP202-C1 and GP202-C2 showed significantly increased invasion 
levels (P < 0.01) when compared to GP202-SC control (3.29 and 4.14 vs 1) (Figure 13).  
 
Figure 13 > Quantification of cell invasion by cell invasion assay.  
Quantification of the cell invasion in GP202-C1 and GP202-C2 clones and GP202-SC control. 
*P < 0.01 (Mann-Whitney test). 
 
 In terms of cell migration, GP202-C1 and GP202-C2 cells showed significantly 
increased migration levels (P < 0.01) when compared to GP202-SC control (2.61 and 
2.13 vs 1) (Figure 14A), whereas no significant differences were found for MKN45-C1 
and MKN45-C2 when compared to MKN45-SC control (1.23 and 0.66 vs 1) (Figure 
14B). 
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Figure 14 > Quantification of cell migration by wound-healing assay. 
(A) Quantification of the cell migration in GP202-C1 and GP202-C2 clones and GP202-SC 
control and (B) MKN45-C1 and MKN45-C2 clones and MKN45-SC control by a wound-
healing assay. *P < 0.01 , NS- not significant  (Mann-Whitney test). 
 
2.3. Effects of MUC1 downregulation in MKN45 GC cells tumorigenicity 
 
Our next step was to study the effects of MUC1 suppression in the tumorigenic 
potential of MKN45 GC cells in vivo. Mice injected with MKN45-C2 MUC1 
downregulated clones have shown smaller and slower-growing tumors when compared 
to mice injected with the MKN45-SC control cells (Figure 15). 
 
 
Figure 15 > Tumor growth curves. 1 x 10
5
 cells were subcutaneously injected in mice at day 0. 
The curves show tumor growth until day 21, the day on which all mice were sacrificed.* P < 
0.05 (Mann-Whitney test), when compared to the MKN45-SC control cell line. 
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3. Identification of MUC1-mediated oncogenic signaling pathways in GC cells. 
 
The phenotypic modifications observed in MUC1 downregulated clones were 
likely due in part to alterations in signal transduction pathways mediated by MUC1-CD, 
since overexpression of MUC1 has been shown to modulate gene expression through 
reprograming transcription of multiple genes [101,113,114,115,116,117,118,119]. 
 
3.1. Interaction between MUC1-CD and ERK1/2 signaling effectors in 
MKN45 GC cells - Immunoprecipitation assays 
 
We started by studying the molecule ERK1/2, a member of the MAPK signaling 
pathway often found to be deregulated in GC, as mentioned before. MUC1 was shown 
to interact with ERK1/2 in MKN45 control and downregulated cells, as shown by 
immunoprecipitation assays (Figure 16).  
                                 
 
Figure 16 > In the figure above, MKN45-SC, C1 and C2 lysates were immunoprecipitated 
(IPP) with anti-MUC1-CT2 and with an hamster control IgG and blotted with anti-ERK1/2 
antibody.  
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3.2. Interaction between MUC1-CD and MAPK signaling effectors - PLA 
assays 
 
Due to higher sensitivity of PLA technique, PLA assays were performed to 
confirm previously found MUC1-CD-ERK1/2 interaction and also in an attempt to find 
new ones. We have looked for molecules related to ERK1/2 proteins and MAPK 
signaling pathway (such as EGFR, B-RAF and Grb2). 
The interaction between MUC1-CD and ERK1/2 was confirmed (Figure 17) 
and we have also found interactions between MUC1-CD and EGFR, B-RAF and Grb2 
(Figures 18, 19 and 20). 
 
 
 
 
Figure 17 > In situ PLA assay. PLA assay was performed using MKN45-SC cells and the 
antibodies MUC1-CT2 and ERK1/2 (signal from interaction of both molecules is in red). 
MKN45-SC(-) – negative control. 
 
 
Figure 18 > In situ PLA assay. PLA assay was performed using MKN45-SC cells and the 
antibodies MUC1-CT2 and EGFR (signal from interaction of both molecules is in red). 
MKN45-SC(-) – negative control. 
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Figure 19 > In situ PLA assay. PLA assay was performed using MKN45-SC cells and the 
antibodies MUC1-CT2 and B-RAF (signal from interaction of both molecules is in red). 
MKN45-SC(-) – negative control. 
 
 
 
 
 
Figure 20 > In situ PLA assay. PLA assay was performed using MKN45-SC cells and the 
antibodies MUC1-CT2 and Grb2 (signal from interaction of both molecules is in red). MKN45-
SC(-) – negative control. 
 
An average of the number of interactions found between MUC1-CD and the 
studied MAPK signaling molecules was calculated with the Blobfinder Software 
(OLINK Biosciences) (Figure 21). 
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           MKN45-SC                                                   MKN45-SC(-) 
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Figure 21 > Average of number of interactions between MUC1-CD and MAPK signaling 
effectors in MKN45-SC GC cells, as found by PLA assays. 
 
3.3. Interaction between MUC1-CD and other possible MUC1 oncogenic 
signaling partners in MKN45 GC cell line - PLA assays 
 
 In an attempt to find new MUC1-CD interactions with oncogenic signaling 
partners in GC cells, we have studied the possible interaction between this molecule and 
cell cycle-related molecules such as B23 and CDK1/2, known to be involved in 
tumorigenic events. The interaction was found to exist for both molecules (Figures 22 
and 23).  
 
 
 
Figure 22 > In situ PLA assay. PLA assay was performed using MKN45-SC cells and the 
antibodies MUC1-CT2 and B23 (signal from interaction of both molecules is in red). MKN45-
SC(-) – negative control. 
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Figure 23 > In situ PLA assay. PLA assay was performed using MKN45-SC cells and the 
antibodies MUC1-CT2 and CDK1/2 (signal from interaction of both molecules is in red). 
MKN45-SC(-) – negative control. 
 
We further evaluated the possible interaction of MUC1-CD with E-cadherin and  
β-catenin, molecules known to be deregulated in most cases of cancer. The result was 
positive for both molecules (Figures 24 and 25).  
 
 
 
 
Figure 24 > In situ PLA assay. PLA assay was performed using MKN45-SC cells and the 
antibodies MUC1-CT2 and E-cadherin (signal from interaction of both molecules is in red). 
MKN45-SC(-) – negative control. 
 
 
 
 
                MKN45-SC                                                     MKN45-SC(-) 
             MKN45-SC                                                      MKN45-SC(-) 
R
es
u
lt
s 
 71 
 
 
 
 
Figure 25 > In situ PLA assay. PLA assay was performed using MKN45-SC cells and the 
antibodies MUC1-CT2 and β-catenin (signal from interaction of both molecules is in red). 
MKN45-SC(-) – negative control. 
 
An average of the number of interactions with MUC1-CD for all the MAPK not-
related studied molecules was calculated with the Blobfinder Software (OLINK 
Biosciences) (Figure 26). 
 
                  
 
Figure 26 > (A) Average of number of interactions of MUC1-CD with B23 and CDK1/2 and 
(B) E-cadherin and β-catenin molecules in MKN45-SC GC cells, as found by PLA assays. 
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3.4. Interaction between MUC1-CD and MAPK signaling effectors and other 
oncogenic signaling partners in normal and GC tissues – PLA assays 
 
In order to see if the interactions previously found with MUC1-CD and cell 
oncogenic molecules in MKN45 GC cells were cancer-specific or if they already exist 
in gastric normal cells, we have performed PLA assays in normal gastric tissue slides. 
No interactions were found between MUC1-CD and the signaling partners previously 
described for MKN45 GC cells (results not shown). GC tissue slides were also tested 
for interactions between the previously described signaling partners for MUC1-CD and 
no interactions were found (results not shown). 
 
4.  Evaluation of MUC1 impact in the expression and phosphorylation of gastric 
oncogenesis-related proteins in MKN45 GC cell line. 
 
    The expression levels of the MAPK related signaling molecules ERK1/2, EGFR, 
B-RAF and Grb2 were quantified by Western blot (Figure 27). 
                                     
 
Figure 27 > MKN45-SC, C1 and C2 whole lysates were blotted with anti-ERK1/2, anti-EGFR, 
anti-B-RAF,anti-Grb2 and anti-β-actin.   
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The relative levels of ERK1/2, EGFR and B-RAF vary between the silenced 
clones and the scrambled control, suggesting that MUC1 may regulate not only their    
phosphorylation     but   also    their transcription and/or stability.  
ERK2, EGFR and B-RAF mRNA levels were studied by Real-Time PCR 
(Figure 28) in MKN45 GC cells. We observed that ERK2 upregulation and BRAF 
downregulation at a protein level are likely to be regulated by MUC1 at a transcriptional 
level, whereas EGFR protein levels are most likely regulated by MUC1 through post-
transcriptional regulation mechanisms. 
 
 
Figure 28 > Relative quantification of ERK2, EGFR and B-RAF by Real-Time PCR in 
MKN45-SC, C1 and C2 clones. Values were adjusted to the expression of TBP gene. * P < 0.05 
(Mann-Whitney test), when compared to the MKN45-SC control. 
 
Phosphorylation profiling of MKN45-SC, MKN45-C1 and MKN45-C2 by 
Kinexus antibody screening have shown that phosphorylation of MKN45-C1 and 
MKN45-C2 clones is significantly altered when compared to the MKN45-SC control in 
several phosphorylation sites of cell cycle related proteins (Table 3).  
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Table 3. Percentage of the increase/decrease in phosphorylation levels of some important 
phosphorylation sites of cell cycle related proteins between each MUC1 downregulated 
clone (MKN45-C1 and MKN45-C2) and the control cells. 
 
                              Clones 
                                                                         
Proteins’ phospho-site 
 
MK45-SC 
 
MK45-C1 
 
MKN45-C2 
3-PDK1 [S244] --- --- --- 
B23 [S4] + + 116% +69% 
B23 [T199] + + 373% +255% 
BRCA1 [S1497] + -27% -19% 
CDK1/2 [T14+Y15] ---/+ ---/+87% ---/+264% 
CDK1/2 [T161+T160] +/+ +106%/+198 -41%/+195 
CDK1/2 [Y15] +/+ +80%/150% -25%/93% 
ERK1 [T202+Y204] + -73% -59% 
ERK2 [T185+Y187] + +59% +33% 
GSK3α [S21] + +5% +25% 
GSK3α [Y279] +/--- -53%/--- -39%/--- 
GSK3β [S9] --- --- --- 
GSK3 β [Y216] +/--- -39%/--- -27%/--- 
FRAP [S2448] --- --- --- 
MKK1 [S297] + -40% +51% 
MKK1 [S291] + +10% +132% 
MKK1 [T385] + +22% +128% 
MKK1/2 [S217/S221] + +1% +183% 
MKK2 [T394] --- --- --- 
p27 1B [T187] + -68% -35% 
p70 S6-α [T229] + +167% +28% 
p70 S6-α [T421+S424]] + +365% +270% 
p85 S6 Kinase 2 [T444+S447] --- --- --- 
PTEN [S380+T382+S385] --- --- --- 
Akt1 [S473] + -26% +9% 
Akt1 [T308] --- --- --- 
RAF1 [S259] --- --- --- 
Retinoblastoma protein [S612] --- --- --- 
Retinoblastoma protein [S780] + -21% -20% 
Retinoblastoma protein [S807] + +71% +8% 
Retinoblastoma protein 
[S807+S811] 
+ -4% +4% 
Retinoblastoma protein [T356] + -32% -47% 
Retinoblastoma protein [T821] --- --- --- 
Retinoblastoma protein [T826] + +208% +81% 
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Ribossomal S6 
Kinase1/2[S221/S227] 
+/---/---/--- -41%/---/---/--- +42%/---/---/--- 
Ribossomal S6 
Kinase1/2[S363/S369] 
+/---/---/--- +64%/---/---/--- -8%/---/---/--- 
Ribossomal S6 
Kinase1/2[S380/S386] 
+/+/---/--- +209%/-38%/---/--- +112%/-72%/---/--- 
Src [Y418] ---/--- ---/--- ---/--- 
Src [Y529] +/--- -30%/--- -34%/--- 
P53 [S392] + +11% -7% 
 
Different results that are shown for the same protein were obtained with different antibodies 
+ phosphorylation signal detected 
--- no phosphorylation was detected  
 
Among all these proteins, we have selected the proteins nucleophosmin (B23), 
CDK1/2 and ERK1/2 to highlight the differences found (Figure 29). 
 
 
 
Figure 29 > Relative phosphorylation levels of important phosphorylation sites of proteins 
B23, CDK1/2 and ERK1/2 in MKN45-SC, MKN45-C1 and MKN45-C2 cells.  
 
These three molecules were previously shown to interact physically with 
MUC1-CD, in the last step of this work.  
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5. Evaluation of the impact of H. pylori binding in MUC1-mediated oncogenic 
signaling pathways in MKN45 GC cell line. 
 
In the previous part of this work we observed that MUC1-CD interacts with 
several cell signaling molecules that are important for the modulation of diverse 
cascades with oncogenic potential. ERK1/2 molecules and the MAPK pathway are the 
main responders to external environmental stresses. ERK1/2 activation by 
phosphorylation has been previously reported in many cancers and we have shown that 
MUC1-CD may be a crucial regulator of these molecules expression and 
phosphorylation. Our next step was to check if the binding of H. pylori to MKN45-GC 
cells could induce ERK1/2 activation, by phosphorylation, result already shown for 
other GC cell lines, and if this activation is modulated by MUC1 (since this molecule is 
known to be a major target for bacterial binding). Co-cultures of the H. pylori 
pathogenic strain HP26695 with MKN45-SC and MKN45-C1 and MKN45-C2 clones 
were performed for 1 and 6h, and the levels of phosphorylated ERK1/2 were evaluated 
by Western blot (Figure 30).  
      
 
Figure 30 > Expression of phospho- ERK1/2  in MKN45-SC, MKN45-C1 and MKN45-C2 
cells upon infection with HP26695 pathogenic bacteria, for 1 or 6h. 
 
Levels of phospho-ERK1/2 expression were adjusted to the levels of β-actin 
expression, with the software Quantity One software (BioRad) (Figure 31).  
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Figure 31 > Relative quantification of ERK1/2 phosphorylation in MKN45-SC, C1 and C2 
cells upon infection with HP26695 pathogenic bacteria, for 1 or 6h. 
 
Incubation of cells with bacteria was therefore shown to induce ERK1/2 
phosphorylation, in a time-dependent manner, even in MUC1 downregulated clones 
MKN45-C1 and MKN45-C2. In MUC1 downregulated clones, the overall levels of 
phospho-ERK1/2 were significantly reduced when compared with the MKN45-SC 
control.  
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Discussion  
 
Evaluation of MUC1 impact on H.pylori adhesion to GC cells. 
 
Epidemiological studies and animal models have shown that H. pylori chronic 
infection is associated with several gastric pathologies, including gastric 
adenocarcinoma [6]. The different consequences of infection suggest that several factors 
from the host and the bacteria are involved in bacteria-host interactions, making the 
pathogenic potential dependent on the molecular context of the colonization of the 
gastric mucosa. To date, several factors involved in the H. pylori infection have been 
identified (e.g. bacterial adhesins, host mucins and pro-inflammatory cytokines). 
However, the complete mechanism of this infection remains to be clarified 
[183,184,185].  
Adhesion of H. pylori to gastric mucosa is a fundamental step for the epithelium 
colonization. Different adhesion mechanisms, commonly targeting carbohydrate 
structures present on gastric cells surface, have been identified [186],  with H. pylori 
ligands including, among others, blood group antigens Le
b
 and sialyl-Le
x
 on mucins and 
glycolipids [66,67,187].  
The best characterized H. pylori adhesin is BabA, which mediates a strong 
adhesion between the bacteria and Le
b
 blood group antigen expressed on the surface of 
epithelial cells [66,188]. This work showed that adhesion is a relevant feature of H. 
pylori pathogenicity potential, with significantly higher adhesion levels observed for the 
HP26695 (pathogenic strain) when compared to the HPTx30a (non-pathogenic strain) 
for both cell lines studied (GP202 and MKN45). Considering that both strains don’t 
express the adhesin BabA [189] , the observed differences cannot be explained through 
the BabA binding model, which suggests that other bacterial molecules are involved in 
the adhesion process.  
Another important observation is that there is a higher adhesion of HP26695 and 
HPTx30a strains to GP202 cell line when compared with MKN45 cell line, a fact that 
reflects different expression levels and availability of ligands at the cells surface. 
Previous characterization of mucins and carbohydrate expression on GP202 and 
MKN45 cell lines showed that Le
b
 has a significantly higher expression in GP202 cell 
line [190,191], still this difference might not be relevant since BabA is not present in 
both bacterial strains. GP202 has a higher expression of other carbohydrate antigens 
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a
 and Le
y
) [190,191]
 
when compared to MKN45, that might be involved in H. pylori 
binding interactions. Moreover, additional ligands/interactions that are not yet explored 
may also exist that can explain this difference in adhesion levels between cell lines. 
In order to study the influence of MUC1 VNTR variability in H. pylori binding, 
we used GP202, the cell line that showed higher bacterial adhesion, and we analysed 
bacterial binding to GP202 transfected clones expressing recombinant MUC1 with 
different number of MUC1 TR units. These clones overexpress similar levels of 
recombinant MUC1 [85].   We observed that MUC1 VNTR polymorphism influences 
the extent of H. pylori binding to gastric cells, with higher adhesion levels observed for 
clones with larger VNTR regions. This may be due to the fact that MUC1 with larger 
TR regions contains more potential glycan receptors, thus potentially providing more 
bacterial binding sites. Moreover, we have previously shown that differences in VNTR 
length lead to glycosylation changes in the MUC1 TR [85] , which may also contribute 
to the observed altered adhesion. Detailed evaluation of the results showed a small 
increase between the adhesion of GP202-Neo (control) and GP202-∆TR, that may be 
explained by the overexpression of MUC1 in recombinant clone GP202-∆TR [85] and 
by the potential presence of binding sites outside the VNTR region. No significant 
difference was observed between the adhesion of the bacteria to GP202-9TR and to 
GP202-42TR clones. We previously observed the overexpression of MUC1 
underglycosylated forms in GP202-42TR [85] ,which might explain why the adhesion 
levels are not proportional to VNTR size. 
Although we have found in vitro that TR alleles with more TR are able to carry 
more bacteria, it is known that individuals homozygous for short TR alleles have an 
increased risk  for the development of pre-cancerous gastric lesion [13]. We can 
speculate that this fact can be due to MUC1 shedding from the cell surface, previously 
observed for other gastric cell line, and inhibition of adhesion by steric hindrance [61]. 
MUC1 acts as a releasable decoy, after bacterial adherence (Figure 32). 
 
D
is
cu
ss
io
n
 
 
 
83 
 
       
 
Figure 32 > Model for H. pylori shedding from gastric mucosa.  
H.pylori adheres to the extracellular domain of MUC1. (A) If this region is longer, more 
bacteria will adhere. Upon shedding of MUC1, most of the bacteria are removed from the 
gastric mucus; (B) If this region is shorter, less bacteria will adhere but they are in closer contact 
with the gastric cells and therefore upon shedding of MUC1, some bacteria may remain attached 
to the surface of epithelial cells. Therefore, individuals with larger TR regions are less prone to 
have bacterial infection and further gastric diseases, as proposed before [13]. 
 
All these observations are important for understanding the bacterial and host 
molecular context of the colonization of gastric mucosa. Identification of a pathogenesis 
background, based upon host susceptibility traits like MUC1 VNTR polymorphism, will 
help to identify candidates more prone to bacterial colonization and patients more 
resilient to eradication strategies.  
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Evaluation of MUC1 impact on gene expression, phenotype and 
tumorigenicity of GC cells. 
 
MUC1 relevance for malignant phenotype has been previously described for 
several tumor models [146,192,193,194,195,196], still the impact of MUC1 in gastric 
tumor cells biology remains to be clarified. In this work, we used sh-RNA interference 
to downregulate MUC1 expression in GC cells, in order to evaluate the impact of this 
mucin on gene expression, phenotype characteristics and tumorigenicity of MKN45 and 
GP202 cells. For each cell line, we established two independent clones with stable 
MUC1 downregulation (C1 and C2) and one scrambled control (SC). Even though 
MUC1 downregulation is not complete, the results obtained are consistent at protein and 
RNA levels. MUC1 is known to be a vital molecule for epithelial cancer cells [197] and 
our downregulation experiment results suggest that complete silencing of MUC1 
expression may not be compatible with MKN45 and GP202 cells survival.  
MKN45 MUC1 downregulated clones showed a significantly different 
transcriptional profile (as shown by oligonucleotide microarray analysis) when 
compared with MKN45-SC control. We found significant alterations in the expression 
levels of several genes, mainly TCN1, KLK6, ADAM29, LGALS4, TSPAN8 and 
SHPS-1 between MKN45-C1 and C2 cells and the MKN45-SC control. Some of these 
molecules have functions not yet fully clarified yet others are known to be associated 
with cell proliferation and migration, including KLK6, LGALS4, SHPS-1 and TCN1 
[198,199,200,201,202,203], apoptosis, such as KLK6, LGALS4 and SHPS-1 
[204,205,206], invasion, including KLK6 and TSPAN8 [200,207] and motility, 
including LGALS4 [199]. These alterations are likely due to MUC1 downregulation, 
since MUC1 has been shown to directly conduct signals that alter the transcriptional 
program of tumor cells [101,113,114,115,116,117,118,119]. In the case of GP202 cell 
line, the impact of MUC1 downregulation in the transcriptional profile was not 
significant (only three genes were found to be altered: calcium P-protein, α-protein 
interferon- induced and β-tubulin 2A), fact that may reflect the different cellular context 
of MUC1 signaling partners in this cell line (e.g. transcription factors). 
MUC1 silencing by interference RNA has been previously performed for other 
cell lines [146,192,193,194,195,196], with different impact on cells phenotypic 
characteristics. MUC1 contributes to tumor progression of adenocarcinomas and 
therefore its downregulation was predicted to affect the malignant properties of cancer 
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cells, including proliferation, apoptosis, migration, invasion and cell-cell aggregation. 
Our next step was to evaluate the effects of MUC1 downregulation on cancer-related 
properties of MKN45 and GP202 GC cells. 
We found that proliferation was significantly increased in MUC1 downregulated 
clones MKN45-C1 and MKN45-C2 when compared to the control MKN45-SC. Similar 
studies with breast and pancreatic carcinoma cell lines have shown respectively similar 
[196] and opposite results [146,195,196]. In different tumor models, such as breast, oral 
and human embryonic kidney gastric carcinoma cells, MUC1 was shown to regulate 
cell proliferation by interacting with several proteins such as ER-α, EGFR and β-
catenin, respectively [100,192,208]. However, for GC cells, such interactions have not 
been investigated. KLK6 expression was increased in MKN45-C1 and MKN45-C2 
clones, whereas LGALS-4 expression was decreased and these differences may explain 
the observed differences in proliferation [198,199]. The mechanisms by which KLK6 
and LGALS4 expression is altered in MKN45-C1 and MKN45-C2 when compared to 
MKN45-SC control remains to be elucidated. Recent studies have shown that galectin-4 
functions as a tumor suppressor in colorectal cancers, by interacting with the Wnt 
signaling pathway [205]. Its knockdown results in increased cell proliferation. KLK6 
was shown to activate multiple signal transduction pathways in neurons in astrocytes, 
among which the activation of  MAPK signaling cascade [209]. Both these results are in 
agreement with ours and indicate two possible candidates that may be influencing cell 
proliferation. In the case of GP202 cells, the results were not consistent, since one of the 
clones showed decreased and the other clone showed increased proliferation levels, 
reflecting that the clones may have different molecular contexts. Furthermore, global 
gene expression hasn’t shown significant alterations in genes that regulate cell 
phenotypic characteristics, e.g., KLK6 and LGAL4.  
 Another important observation was that apoptosis was significantly increased in 
MKN45-C1 and MKN45-C2 clones when compared to the MKN45-SC control, 
demonstrating a MUC1 anti-apoptotic activity. MUC1 was previously shown to mediate 
a pro-apoptotic response in hamster ovary cells [210] and it was also attributed with 
anti-apoptotic functions in myeloma, breast and colorectal carcinoma cell lines 
[211,212,213].
 
However, little is known about the influence of MUC1 on cell apoptosis 
in GC cells. KLK6, LGALS4 and SHPS-1 are known to be involved in apoptosis events 
and therefore their different expression between MUC1 downregulated clones and the 
control may contribute to the differences observed. In the case of GP202 cells, the 
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differences found between apoptosis in MUC1 downregulated clones and the scrambled 
control were not significant. Global gene expression hasn’t shown significant 
differences in apoptosis-related genes. 
 Cell-cell aggregation was decreased in MKN45-C1 and MKN45-C2 clones 
when compared to the MKN45-SC control in both time-points, whereas in GP202-C1 
and GP202-C2 a decrease was found when compared to GP202-SC only at the 2-hours 
time point. Previous studies have shown that overexpression of different forms of 
MUC1 can lead to an increase or a decrease of cell-cell aggregation in a pancreatic 
carcinoma cell line [214], whereas others have shown that MUC1 downregulation 
induces an increase of cell-cell aggregation in an oral carcinoma cell line [192].  
Modulation of cell aggregation may be explained by the fact that MUC1 contributes to 
both adhesive [215,216] and anti-adhesive [217,218] properties of cells. One possible 
explanation is that decreased expression of MUC1 extracellular domain influences the 
binding potential of other molecules on the surface of different cells, such as ICAM-1 
[87,89,90] and galectin-3 [88,91,92]. 
No significant differences were found between MKN45-C1 and C2 clones and 
MKN45-SC control with respect to cell migration and invasion. This is in contrast to 
previous findings in which MUC1 was shown to influence cell migration in breast, 
cervical, renal and pancreatic carcinoma cell lines [90,193,194,219] and cell invasion in 
breast, lung, gastrointestinal, hepatic and pancreatic carcinoma cell lines 
[193,220,221,222]. However, in the case of GP202 cell line, invasion was found to be 
increased in MUC1 downregulated clones when compared to the control, whereas 
differences in terms of migration were not consistent between clones. Although global 
gene expression hasn’t shown significant differences in migration or invasion-related 
genes, other not analysed genes may be involved in the differences observed. 
The differences found between the two cell lines may be explained by their 
different expression of the levels of MUC1 molecule. MKN45 parental cell line 
expresses higher levels of MUC1 than G202 parental cell line and therefore this 
molecule must have a different relevance in each cell line. In terms of percentage of 
silencing, the levels are very similar for both cell lines, but its effects on MKN45 cell 
line phenotypic characteristics are clearly more pronounced that in GP202 cell line. 
Furthermore, each cell line has its different molecular context (e.g. MUC1 signaling 
partners). 
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  MUC1 overexpression has been associated with the neoplastic progression of 
several tumors, including the acquisition of invasive and metastatic properties. 
Phenotypic studies in cell models other than GC have suggested that MUC1 influences 
events such as proliferation, apoptosis, migration, invasion, adhesion and cell-cell 
aggregation. The work presented here shows for the first time that MUC1 expression 
influences proliferation, apoptosis and cell-cell aggregation of MKN45 GC cells.  In the 
case of GP202 cells, the results were not always consistent with the ones found for 
MKN45 cell line. These results are consistent with the view that MUC1 modulates 
different signaling pathways in a manner that is dependent on the expression and 
activity of other regulatory mechanisms and molecules, which are influenced by the 
cellular and biological context of the cell type that is overexpressing MUC1.  
Considering all the differences found between MKN45 and GP202 cell lines and 
between the different MUC1 downregulated clones, we can hypothesize that the 
molecular context where signaling through MUC1-CD occurs influences gene 
expression, which in turn affects the phenotypic properties of the MKN45 and GP202 
cell lines.  
 Considering the results obtained when studying the phenotypic effects of MUC1 
downregulation in malignant properties of GC cells, we decided to perform the 
following studies with the MKN45 GC cell line, the one that has shown the most 
significant differences.  
In vivo assays have shown that MKN45 cells with decreased amount of MUC1, 
MKN45-C2, form smaller and slowest-growing tumors than the control MKN45-SC 
cells. Even if MUC1 downregulated cells are more proliferative than the control, 
probably that fact is not enough to make them more tumorigenic. Aggregation of cells 
may be a fundamental step to form a cohesive mass, supportive of tumor growth, and 
MUC1 downregulated cells were shown to be less aggregative. Or, by another hand, the 
injected cells may change their behavior when in an in vivo context, and become less 
proliferative. Although some components of these mice’s immune system are missing, 
the B cells, dendritic cells and granulocytes are all relatively intact, and there is a 
compensatory increase in both natural killer (NK)-cell activity and tumoricidal 
macrophages in these mice [223]. Other mice strain should be used as a control in future 
work, to evaluate the impact of mice immunological background on the growth of 
MUC1 downregulated tumors. Further studies would need to be performed in mice with 
respect to invasion and other aspects concerning the tumor aggressiveness. However, 
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we might speculate so far that MUC1 downregulation decreases the aggressiveness of 
MKN45 GC cells and this molecule may be therefore be a good candidate for GC 
therapy. 
  
Identification of MUC1-mediated signaling pathways in GC cells.  
 
We have previously observed that alterations on gene expression, cell phenotype 
and tumorigenicity occur upon MUC1 downregulation. These alterations may be due, 
among other factors, to deregulation of cell signaling pathways. MUC1 is known to 
interfere with some of these pathways in different cancer models [96,111,224,225,226] 
and its absence may have altered the normal functioning of these cells signaling 
pathways. Our next step was therefore to explore possible signaling pathways and 
molecules that could be altered in MKN45 GC cells upon MUC1 downregulation and 
that could justify the differences observed. 
The MAPK signaling pathway has been one of the signaling pathways more 
often shown to be deregulated in several carcinomas, including GC [23]. 
The MAPK signaling pathway is composed of several cell signaling molecules. 
The initiator molecule is EGFR, a member of the growth factor family ErbB that works 
as a cell surface receptor of extracellular ligands. Ligand binding to EGFR extracellular 
domain leads to its activation, with subsequent homodimerization, leading to the 
phosphorylation of its intracellular tyrosine kinase domain. This will initiate a series of 
phosphorylations and intracellular signals that will ultimately activate the central 
MAPK signaling pathway (Figure 33). 
 
Figure 33 > MAPK signaling pathway. 
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EGFR molecule modulates processes of cell proliferation, migration, adhesion 
and proliferation and it is known to provide tumor cells with growth and survival 
advantages [31]. EGFR expression was found to be deregulated in several types of 
cancers, including GC. High EGFR levels in GC were found have been associated with 
the disease prognosis [32] and presence of lymph node metastasis [74]. EGFR 
overexpression is thought to be the main mechanism for its activation [227]. 
Grb2 is an important molecule that integrates the stimulatory signals of the 
MAPK signaling pathway [228]. This molecule has been previously shown to interact 
with MUC1 in breast carcinoma [105]. 
B-RAF is another member of the MAPK signaling pathway often overexpressed 
in GCs, promoting tumorigenesis and angiogenesis [229]. MUC1 was previously shown 
to activate the RAS-mediated signaling pathway in non-tumorigenic and tumorigenic 
mammary cell lines [230]. 
ERK1/2 molecules are the final effectors of the MAPK signaling cascade and  
have been shown to be activated by MUC1 in some cancer models [96,111,226], 
overexpressed and activated in the majority of GC cases and correlate with tumor 
progression and invasion [28]. These molecules were also found to be activated in 
H.pylori related cancers [29,30]. These events were found for GC cell lines, but when 
examining human GC biopsies, a decrease in the activation of ERK1/2 was found [231]. 
One possible explanation for this fact is that gastric cells start expressing molecules that 
attenuate ERK-mediated signaling upon its activation, or on the other hand, the cells act 
by activating negative feedback mechanisms. Stimulation of EGFR in cancer cells has 
been previously shown to activate the ERK signaling pathway [232]. 
Our results support an extensive involvement of MUC1-CD with MAPK 
signaling pathway. MUC1-CD was shown to interact with ERK1/2 in MKN45-SC 
control and downregulated cells, MKN45-C1 and MKN45-C2, as shown by 
immunoprecipitation assays.  The interaction between MUC1-CD and ERK1/2 was later 
confirmed by proximity ligation assays. This technique also allowed us to show 
interactions between MUC1-CD and other MAPK signaling effectors such as EGFR, 
Grb2 and B-RAF. 
Apart from MAPK signaling cascade, several other pathways have been shown 
to be deregulated in GC [23], as well as the abnormal expression of several molecules 
[233]. 
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One example of a molecule found to be deregulated in GC is nucleophosmin 
(B23) [234]. B23 is a nucleolar protein with several cellular functions, including 
ribosome assembly, intracellular trafficking, DNA polymerase activity, and centrosome 
duplication [235]. Other well known example are Cyclin dependent kinases 1 and 2 
(CDK1/2) [236,237,238]. CDK1/2 proteins are involved in several cell processes, 
mainly in regulating the cell cycle [239]. Both these molecules were found to interact 
with MUC1-CD in MKN45 GC cells. So far, there are no known interactions between 
these molecules and MUC1-CD in any other carcinoma cell type. 
 We have further decided to study the possible interaction of MUC1 with E-
cadherin and β-catenin, since these are two of the most studied molecules that are 
involved in the development of most tumor types, including GC. 
 E-cadherin is expressed in all epithelial cell types and mediates cell-cell 
adhesion and also the maintenance of the normal epithelium architecture [240]. Loss of 
expression of this molecule has been found in GCs, relating with tumor 
dedifferentiation, invasiveness, metastasis and prognosis [241,242]. It has been shown 
in colorectal carcinomas that MUC1 expression was negatively correlated to E-cadherin 
expression [243], but to the best of our knowledge, there are no known interactions 
between MUC1-CD and E-cadherin in any carcinoma cell line. 
β-catenin is a molecule also expressed in epithelial cells that is important in 
mediating the E-cadherin related cell adhesion and also by participating in Wnt 
signaling pathways, that has been found to be frequently deregulated in GCs 
[244,245,246]. Aberrant β-catenin activation has been found in several cancers [247] 
and by H. pylori in GCs [56]. Loss of this molecule has been found in metastatic GC 
[248]. Recent studies have shown that MUC1 overexpression can modulate the 
intracellular distribution of β-catenin, as well as its participation in signaling pathways 
[117,221,249,250]. These facts suggest that the interaction of MUC1-CD with β-catenin 
in GC cells has an important role in tumor progression. Interaction of β-catenin and 
MUC1 has been found in H.pylori induced GC [225], breast cancer [110], airway 
epithelial cells [251], among others. 
Both E-cadherin and β-catenin molecules were found to interact with MUC1-CD 
in MKN45-SC GC cells. These are the first results that clearly show an interaction 
between MUC1-CD and these molecules in GC cells.  
Although further studies need to be performed to better clarify the meaning and 
importance of these interactions, they seem to suggest that somehow MUC1-CD may 
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influence the role of all the referred molecules in GC cells, leading to the differences in 
gene expression, phenotypic characteristics and tumorigenicity that were found. 
Therefore, this mucin may play a crucial role in regulating mechanisms that mediate cell 
tumorigenesis and it is valuable to develop strategies to limit and control the 
development of GC. 
In order to see if these interactions were restricted to MKN45 cell line, derived 
from a diffuse GC, we have tested the possible interaction between MUC1-CD and 
ERK1/2 in AGS GC cells, derived from an intestinal-type GC and the result was 
positive (results not shown). Therefore we may affirm that this interaction is not 
restricted to gastric cell lines derived from a diffuse carcinoma type. 
In the next step we checked if the interactions found to exist between MUC1-CD 
and ERK1/2, EGFR, B-RAF, Grb2, B23, CDK1/2, E-cadherin and β-catenin were also 
occurring in normal gastric cells. In order to do so, we performed PLA assays in normal 
gastric tissue samples. However, no interaction was detected between all the mentioned 
molecules and MUC1-CD in the samples studied. A similar result was obtained when 
testing GC tissue slides.  
Tissue samples and cancer cell lines have several important differences. One of 
these differences is that GC cell lines grow with high proliferation rates, while in 
normal and carcinoma tissue samples, the proliferative pool is restricted to a few set of 
cells. This reason can explain the fact that the results obtained by PLA assays regarding 
MUC1-CD interaction with cell signaling molecules are different between MKN45-SC 
cells and normal and GC tissue samples. 
Summarizing, this is the first report that shows MUC1-CD interaction with 
ERK1/2, EGFR, B-RAF, Grb2, B23, CDK1/2, E-cadherin and β-catenin in MKN45 GC 
cell line, and with ERK1/2 in AGS GC cell line. 
 
Evaluation of MUC1 impact in the expression and phosphorylation of GC-
related proteins.  
 
We have shown in the previous step that MUC1-CD physically interacts with 
several cell signaling molecules, including some that are critical effectors of the MAPK 
signaling pathway (such as EGFR, B-RAF, Grb2 and ERK1/2).  
Our next step was to evaluate the impact of MUC1 on the expression and 
phosphorylation of these MAPK signaling cascade members. We have observed by 
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Western blot analysis that ERK2 expression is increased, whereas ERK1 expression is 
decreased upon MUC1 downregulation, suggesting that MUC1 may regulate the 
transcription and/or stability of these molecules. These two molecules were shown to 
have opposite effects, since ERK1 is thought to attenuate ERK2 effects [252] and 
therefore these results are in accordance. EGFR and B-RAF were also shown to be 
affected by MUC1 downregulation, whereas Grb2 levels don’t seem to be altered upon 
MUC1 downregulation.  
We can speculate that MUC1-CD is exerting a negative feedback regulation of 
the MAPK signaling pathway in MKN45 GC cells. Since MUC1 downregulation 
increases the levels of ERK2 (the crucial molecule when concerning ERK1/2 signaling), 
this fact may by negative feedback mechanisms decrease the levels of EGFR/B-RAF 
that are available.  
Our next step was to perform Real Time PCR assays, to evaluate the mRNA 
level of ERK2, EGFR and B-RAF. The results suggested that ERK2 and B-RAF gene 
expression is regulated by MUC1 at a transcriptional level whereas differences observed 
for EGFR protein levels are probably due to MUC1-mediated post-transcriptional 
regulation mechanisms.  
Until now, there are no references about MUC1 transcriptional regulation of 
expression for both ERK2 and B-RAF molecules. However, promotion of transcription 
of other genes by MUC1 has been previously reported 
[101,113,114,115,116,117,118,119,253]. It is therefore possible that MUC1-CD is 
interacting with the promoters of both ERK2 and B-RAF genes, regulating their 
transcription. 
MUC1 was already shown to protect EGFR from degradation [254] and the 
same may be occurring in MKN45-SC cells. Previous results in oral carcinoma cells 
have shown that MUC1 suppression leads to a decrease of both EGFR mRNA and 
protein levels [192]. No binding of MUC1-CD was found for any region proximal of 
EGFR promoter (results not shown), result in accordance with our idea that EGFR 
levels are being regulated post-transcriptionally. 
 We know that several vital cell processes are regulated by consequent 
phosphorylation/dephosphorylation  of  proteins. This  process will  lead  to  consequent  
activation/deactivation of these proteins, according to the cells needs. Therefore, our 
next step was to see if MUC1 downregulation was interfering with the phosphorylation 
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of activation-related phosphorylation sites of several proteins involved in the cell cycle 
and therefore in possible oncogenic events.  
The most significative results obtained by the antibody screening by Kinexus 
have shown that phosphorylation of MKN45-C1 and MKN45-C2 downregulated clones 
is significantly increased when compared to the MKN45-SC control in proteins: B23, 
CDK1/2 and ERK2, which have been all also found to physically interact with MUC1-
CD. Phosphorylation of the studied specific phosphorylation sites is known to lead to an 
activation of the proteins B23, CDK1/2 and ERK1/2 [235,239,255,256,257,258]. These 
molecules, as previously referred, are involved in a multitude of signaling pathways 
(e.g. cell proliferation/differentiation) with oncogenic potential and therefore these 
results are in accordance with previously observed phenotype alterations in MUC1 
downregulated clones, which show increased proliferation rates. These results are in 
contrast with previous found ones in mouse mammary gland, airway cells and 
embryonic cells have shown that MUC1 activation by phosphorylation [93,226] and 
also its higher expression [111] are related to an increase of ERK1/2 activity. 
The differences in phosphorylation observed are rather due to physical 
interactions between MUC1-CD and these molecules, since MUC1 is not known to 
possess any kinase activity. It’s also possible that MUC1-CD is interacting with kinases 
or phosphatases that phosphorylate/dephosphorylate B23, CDK1/2 and ERK1/2 and that 
this interaction is altering the phosphorylation of these proteins. MUC1 can be 
promoting the activity of cell kinases or, by another hand, be inhibiting the activity of 
cell phosphatases, a group of enzymes also found ubiquitously, which are responsible 
for the dephosphorylation of various proteins. 
It is important to highlight that expression and activation are two different 
topics, and although they are usually related (higher expression is associated with higher 
activation), there is not any established correlation between both. We have shown that 
in MUC1 downregulated clones there is an increase of the expression of ERK2 and 
decrease of ERK1. ERK2 molecules are more phosphorylated also and therefore more 
activated. The opposite occurs for ERK1. The higher proliferation observed in MUC1 
downregulated clones may be due to these molecules. The decreased expression 
observed for EGFR and B-RAF would suggest lower proliferation rates, but  this fact  is  
most probably overcomed by ERK2 increased levels and phosphorylation. Furthermore, 
the activation status of both EGFR and B-RAF were not studied and it is possible that, 
although less expressed, they can have a higher activation status.  
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Evaluation of the impact of H. pylori binding in MUC1-mediated oncogenic 
signaling pathways in GC cells. 
 
H.pylori infection was previously shown to activate ERK1/2 molecules in GC 
cells [30,259,260,261,262,263]. This was observed for different multiplicities of 
infection, infection periods and for different pathogenicities of bacterial strains [259]. 
The results obtained in our co-culture assays are in accordance with these published 
data. Therefore, this bacterium is able to interfere with signaling pathways in which 
ERK1/2 molecules participate and therefore contribute to gastric carcinogenesis in 
MKN45 GC cells. One possible explanation is that, by binding MUC1 extracellular 
domains, this bacterium may promote the binding of MUC1-CD to ERK1/2 and 
consequent activation of these molecules (by facilitating other interactions, since it is 
known that MUC1-CD doesn’t possess any kinase activity). The mechanism underlying 
this fact remains unclear, but one of two things can be occurring: the bacteria may 
somehow modify MUC1-CD’s affinity for cytoplasmic ERK1/2 or by another hand it 
may originate the cleavage of MUC1-CD from the cell membrane, and this molecule 
will be more available to interact with both cytoplasmic and nuclear ERK1/2, 
facilitating its activation. 
Furthermore, ERK1/2 phosphorylation seems to be MUC1 expression-
dependent, since MUC1 downregulated cells express a considerably lower amount of 
phospho-ERK1/2 when compared to the control cells. 
An interesting observation can be made at this time point of the work. ERK1/2 
total phosphorylation levels are decreased in MUC1 downregulated clones when 
compared to the control cells. Kinexus results exhibit an increase of the phosphorylation 
of ERK2 and a decrease of ERK1 phosphorylation in MUC1 downregulated clones 
when compared to the control cells. One possible explanation for this fact is that the 
same cells were used at completely different confluences in the two different assays. In 
the  co-culture  assays, the  cells  were  almost  in  a  confluent state, whereas in kinexus  
assays  they were  at  an  approximate  60%  confluency. This   means  that   cells   were  
at completely different proliferation states, with the confluent cells being at an almost 
quiescent state, and the cells with 60% confluency at high proliferative levels. Thus, 
ERK1/2 expression and activation are very likely to be regulated differently according 
to the proliferative status of the cells.  
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Summary and conclusions 
 
GC is a worldwide major health problem, mostly due to the reduced knowledge 
of its etiological factors and pathogenesis model. This cancer is also resistant to most 
cancer therapies with no significant progress made during the last decades. Therefore it 
is critical to find new therapeutic targets to overcome resistance mechanisms. The main 
objective of this work was to better understand the biology of MUC1, previously 
described as frequently altered in GC, in the pathogenesis model. 
 
The research work performed allowed us to: 
 
- Establish an association between MUC1 VNTR polymorphism and H.pylori 
adhesion to GC cells.  
 
- Demonstrate that MUC1 downregulation in MKN45 and GP202 GC cell lines 
conditions global gene expression and tumor phenotypic characteristics. 
 
- Demonstrate that MUC1 downregulation in MKN45 GC cells affects their 
tumorigenicity in vivo. 
 
- Identify molecules that directly interact with MUC1-CD in MKN45 GC cells 
and that may therefore be MUC1 oncogenic signaling partners, contributing for 
GC development. Data suggests that MUC1 acts as an integrator of signaling 
pathways (MAPK signaling pathway,e.g.) with oncogenic potential. 
 
- Identify signaling molecules (ERK1/2, EGFR, B-RAF) whose expression is 
significantly altered by MUC1 downregulation in MKN45 GC cells. 
 
- Identify molecules (ERK1/2, B23 and CDK1/2) whose phosphorylation is 
significantly altered by MUC1 downregulation in MKN45 GC cells. 
 
- Show that  H.pylori activates, by phosphorylation, the molecules ERK1/2 in 
MKN45 GC cells. 
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The molecular complexity of MUC1, mostly associated with the variability of its VNTR 
domain and with the diversity of the sugar chains that are coupled to it, has been an 
obstacle to understand its relevance to the tumorigenic potential of the cancer cells. 
MUC1 overexpression and aberrant glycosylation have been associated with the 
neoplastic progression of several tumors, namely to the acquisition of invasive and 
metastatic properties [94,264,265]. Phenotypic studies in different cell models have 
suggested MUC1 involvement in proliferation [192,266,267], adhesion [214,267], 
invasion [221,268], aggregation [192] and migration [90]. Considering the association 
of MUC1 overexpression with all these biological processes, it makes sense that MUC1 
involvement in the signaling pathways that lead to the acquisition of these 
characteristics will be dependent on the expression and activity of multiple regulatory 
mechanisms, characteristics of a specific cellular context. We reinforced the idea that 
MUC1 signaling will depend on the cell context, that determines the amount of MUC1 
and also the availability of its ligands.  
The results found in this research work reinforce the importance of MUC1 in the 
tumorigenic behavior of GC cells, and therefore its importance as a new elective target 
for innovative therapeutic approaches.   
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Abstract
AIM: To evaluate the influence of MUC1 mucin variable 
number of tandem repeats (VNTR) variability on H pylori 
adhesion to gastric cells. 
METHODS: Enzyme linked immunosorbent assay 
(ELISA)-based adhesion assays were performed to 
measure the adhesion of different H pylori  strains 
(HP26695 and HPTx30a) to gastric carcinoma cell lines 
(GP202 and MKN45) and GP202 clones expressing 
recombinant MUC1 with different VNTR lengths.
RESULTS: Evaluation of adhesion results shows that 
H pylori  pathogenic strain HP26695 has a significantly 
higher (P  < 0.05) adhesion to all the cell lines and clones 
tested, when compared to the non-pathogenic strain 
HPTx30a. Bacteria showed a significantly higher (P < 0.05) 
adhesion to the GP202 cell line, when compared to the 
MKN45 cell line. Furthermore, both strains showed a 
significantly higher (P  < 0.05) adhesion to GP202 clones 
with larger MUC1 VNTR domains.
CONCLUSION: This work shows that MUC1 mucin 
variability conditions H pylori  binding to gastric cells. The 
extent of bacterial adhesion depends on the size of the 
MUC1 VNTR domain. The adhesion is further dependent 
on bacterial pathogenicity and the gastric cell line. MUC1 
mucin variability may contribute to determine H pylori 
colonization of the gastric mucosa.
© 2008 WJG. All rights reserved.
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INTRODUCTION
The Gram negative bacterium H pylori is involved in the 
pathogenesis of  several gastrointestinal diseases, ultimately 
leading to gastric carcinoma[1,2]. In the gastric mucosa, the 
majority of  the bacteria is found within the mucus layer, but 
can be also attached to gastric epithelial cells[3], a crucial step 
for the maintenance, spreading and severity of  the infection. 
This attachment is mediated by the interaction of  bacterial 
molecules, such as adhesins and LPS[4], with gastric cell 
surface ligands such as glycolipids and glycoproteins. MUC1 
is a membrane glycoprotein that protects epithelial surfaces 
and has been recently identified as an H pylori binding 
target[5,6]. Extracellular MUC1 variable number of  tandem 
repeats (VNTR) domain is highly glycosylated[7], presenting 
carbohydrate structures (e.g. Lewis b carbohydrate antigen) 
involved in the binding of  H pylori through its adhesins 
BabA and SabA[8,9]. Furthermore this repetitive region 
shows extensive allelic variation ranging from 25-125 repeat 
units[12]. The relevance of  MUC1 VNTR variability for 
H pylori adhesion to gastric cells remains to be clarified.
In this work we tested the hypothesis that MUC1 VNTR 
polymorphism affects the H pylori adhesion to gastric 
cells and thus plays an important role in the colonization 
www.wjgnet.com
of  gastric mucosa. We used H pylori strains with different 
pathogenicity (strain HP26695 and strain HPTx30a) co-
cultured with gastric cell lines GP202 and MKN45, and 
GP202 clones expressing recombinant MUC1 with different 
VNTR lengths. Adhesion was evaluated by an enzyme 
linked immunosorbent assay (ELISA)-based adhesion assay.
The results showed that MUC1 VNTR polymorphism 
influences the binding of  H pylori to gastric cells. 
Furthermore, higher adhesion was observed in co-cultures 
with the pathogenic strain (HP26695) when compared 
to the non-pathogenic strain (HPTx30a) and GP202 cell 
line when compared to the MKN45 cell line. This work 
contributes to the understanding of  the interplay between 
host and bacterial factors in H pylori infection pathogenesis.
MATERIALS AND METHODS
Cell lines
We used two gastric carcinoma cell lines: GP202, 
previously established in our laboratory[13] from a signet 
ring cell gastric carcinoma that constitutively expresses 
MUC1 and MKN45 (Japan Health Sciences Foundation).
GP202 clones expressing recombinant MUC1 with 
different VNTR lengths[14] were previously established by 
stable transfection with an eukaryotic expression vector 
pHb-APr1-neo containing subcloned epitope-tagged 
MUC1 (FLAG-MUC1) cDNAs with different number of  
TR units (0, 3, 9 and 42 repeats, respectively GP202-dTR, 
GP202-3TR, GP202-9TR and GP202-42TR)[15]. GP202-
Neo was obtained by transfection with empty vector. 
The parental cell lines and transfectants were cultured 
in 150 cm2 flasks at 37℃ in a humidified 5% CO2 
incubator and maintained in RPMI 1640 medium (with 
Glutamax and 25 mmol/L Hepes) supplemented with 
10% fetal bovine serum and 50 µg/mL gentamicin. Media 
was changed every 3 d to 4 d, and the cells were passaged 
when they reached 80% to 90% confluence using 0.05% 
trypsin-0.53 mmol/L ethylenediamine tetra-acetic acid in 
Hank’s balanced salt solution. Cell culture reagents were 
obtained from Invitrogen (Carslbad, CA, USA). 
H pylori strains
Two H pylori strains were used in this study: the pathogenic 
strain HP26695 (vacA s1/m1, cag PAI+, ATCC 700392) 
and the non-pathogenic strain HPTx30a (vacA s2/m2, cag 
PAI-, ATCC 51932). Bacteria were grown on Trypticase 
soy agar with 5% sheep blood (BioMérieux) at 37℃ in mi-
croaerobic conditions. 
ELISA assay 
Quantitative evaluation of  H pylori adhesion to gastric cells 
was performed by ELISA, as previously described[16], with 
some modifications. Briefly, cells were cultured in 96 well 
plates and allowed to form confluent monolayers. Cells 
were washed and H pylori suspension was added in a 200:1 
bacteria to cell ratio (MOI) and incubated for 60 min. Cells 
were washed and fixed at 4℃ with 8% paraformaldehyde 
for 60 min. Endogenous peroxidase was inactivated 
by addition of  1% H2O2 in methanol. After washing 
with PBS, anti-H pylori monoclonal antibody MAB922 
(Chemicon, USA) was added overnight, 4℃, followed 
by addition of  peroxidase-conjugated goat anti-mouse 
immunoglobulins (Santa Cruz Biotechnology) 30 min, RT. 
Tetramethylbenzidine (TMB) (Sigma, USA) was added and 
reaction stopped with 1 mol/L HCl. Plates were read in a 
680 ELISA microplate reader (Bio-Rad, USA) at 450 nm. 
OD values were used as the index of  the number of  H pylori 
adhering to cells[16]. Two sets of  triplicates were made for 
each assay. 
Statistical analysis
Statistical analysis was performed using the Mann-Whitney 
test, StatView Software version 5.0 (SAS Institute). A 
P value of  less than 0.05 was accepted as statistically 
significant.
RESULTS
Evaluation of  H pylori adhesion shows that pathogenic 
strain HP26695 has significantly (P < 0.05) higher adhesion 
values for both GP202 and MKN45 cell lines (1.97 ± 
0.10 and 1.47 ± 0.06) when compared with the non-
pathogenic strain HPTx30a (1.40 ± 0.15 and 0.85 ± 0.15; 
Figure 1). This statistically significant association between 
pathogenicity and higher adhesion (strain HP26695 
vs HPTx30a) is also observed for the GP202 MUC1 
recombinant clones (GP202-Neo 1.1 ± 0.10 vs 0.72 ± 0.06; 
GP202-dTR 1.32 ± 0.09 vs 1.0 ± 0.10; GP202-3TR 1.45 ± 
0.08 vs 1.18 ± 0.05; GP202-9TR 2.2 ± 0.12 vs 1.96 ± 0.12; 
and GP202-42TR 2.3 ± 0.07 vs 1.89 ± 0.11; Figure 2). 
Furthermore, GP202 cell line shows higher adhesion levels 
than MKN45 cell line for both bacteria strains (HP26695 
strain 1.97 ± 0.10 vs 1.47 ± 0.06; HPTx30a strain 1.40 ± 
0.15 and 0.85 ± 0.15; Figure 1). 
Adhesion of  both H pylori strains (HP26695 and 
HPTx30a) is significantly higher in all the GP202-MUC1 
transfectants over-expressing MUC1 (GP202-dTR 1.32 
± 0.09 and 1.0 ± 0.10; GP202-3TR 1.45 ± 0.08 and 1.18 
± 0.05; GP202-9TR 2.2 ± 0.12 and 1.96 ± 0.12; GP202-
42TR 2.3 ± 0.07 and 1.89 ± 0.11) when compared with the 
control, GP202 Neo (1.1 ± 0.10 and 0.72 ± 0.06, Figure 2). 
There is also an association between the increased number 
of  Tandem Repeats (GP202-9TR and GP202-42TR) and 
the increased adhesion, for both strains (Figure 2). 
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Figure 1  Adhesion of HP26695 and HPTx30a H pylori strains to GP202 and 
MKN45 gastric cell lines. aP < 0.05.
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DISCUSSION
Epidemiological studies and animal models have shown 
that H pylori chronic infection is associated with several 
gastric pathologies, ranging from asymptomatic gastritis 
to gastric adenocarcinoma and MALT lymphoma[1,2]. 
The different consequences of  the infection suggest that 
several factors from the host and the bacteria are involved 
in the bacteria-host interactions, being the pathogenic 
potential dependent upon the molecular context of  the 
colonization of  gastric mucosa. To date several factors 
involved in the H pylori infection have already been 
identified (e.g. bacterial adhesins, host mucins and pro-
inflammatory cytokines) however the complete mechanism 
remains to be clarified[17-19]. 
Adhesion of  H pylori to gastric mucosa is a fundamental 
step for epithelium colonization. Different adhesion 
mechanisms, commonly targeting carbohydrate structures 
present on gastric cells surface, have been identified[4] with 
H pylori ligands including, among others, blood group 
antigens on mucins and glycolipids[8-11,20-26]. 
The best-characterized H pylori adhesin is BabA, that 
mediates a strong adhesion between the bacteria and Leb 
blood group antigen expressed on the surface of  epithelial 
cells[8,27]. This work showed that adhesion is a relevant 
feature of  H pylori pathogenicity potential, with significantly 
higher adhesion levels observed for the HP26695 
(pathogenic strain) when compared to the HPTx30a (non-
pathogenic strain) in both cell lines. Considering that 
both strains don’t express BabA adhesin[28], the observed 
differences can not be explained through the BabA binding 
model, what suggests that other bacterial molecules are 
involved in the adhesion process. 
Another important observation is that there is a 
higher adhesion of  HP26695 and HPTx30a strains to 
GP202 cell line when compared with MKN45 cell line. 
This reflects different expression levels and availability 
of  ligands at the cells surface. Previous characterization 
of  mucins and carbohydrate expression on GP202 and 
MKN45 cell lines showed that Leb has a significantly 
higher expression in GP202 cell line[29]. Still, this difference 
might not be relevant since BabA is not present in both 
bacterial strains[28]. In addition, the MUC1 expression is 
identical for both cell lines[29] and therefore can not be held 
responsible for the observed differences. GP202 has a 
higher expression of  other carbohydrate antigens (Lea and 
Ley)[29,30] compared to MKN45, that might be involved in 
H pylori binding interactions. Moreover, additional ligands/
interactions that are not yet explored may also exist that 
can explain this difference in adhesion levels between cell 
lines.
In order to study the influence of  MUC1 VNTR 
variability in H pylori binding, we used GP202, the cell line 
that showed higher bacteria adhesion and we analyzed 
GP202 transfected clones expressing recombinant 
MUC1 with a different number of  repeats. These clones 
overexpress similar levels of  recombinant MUC1[14]. We 
observed that MUC1 VNTR polymorphism has influence 
in the extent of  H pylori binding to gastric cells, with the 
higher adhesion levels observed in clones with larger 
VNTR regions. This may be due to the fact that MUC1 
with larger Tandem Repeat regions contains more potential 
glycan receptors, thus potentially providing more bacterial 
binding sites. Moreover, we have previously shown that 
differences in VNTR length lead to glycosylation changes 
in the MUC1 Tandem Repeat[14], which may also contribute 
to the altered adhesion observed. Detailed evaluation of  
the results showed a small increase between the adhesion 
of  GP202-NEO (control) and GP202-dTR that may be 
explained by the overexpression of  MUC1 in recombinant 
clone GP202-dTR[14] and by the potential presence of  
O-glycosylated binding sites outside the VNTR region. No 
significant difference was observed between the adhesion 
of  the bacteria to GP202-9TR and to GP202-42TR clones. 
We have previously observed the overexpression of  MUC1 
underglycosylated forms in GP202-42TR[14], which might 
explain why the adhesion levels are not proportional to 
VNTR size.
All these observations are important for understanding 
the bacterial and host molecular context of  the colonization 
of  gastric mucosa. Identification of  a pathogenesis 
background, based upon host susceptibility traits like MUC1 
VNTR polymorphism, will help to identify candidates more 
prone to bacterial colonization and patients more resilient to 
eradication strategies. 
Ad
he
re
nc
e 
of
 H
 p
yl
or
i 
to
 c
el
ls
 (
O
D
 4
50
) 2.5
2.0
1.5
1.0
0.5
0.0
26695
Tx30a
c
c 
c
c c 
GP202 Neo                       GP202 dTR                      GP202 3TR                        GP202 9TR                    GP202 42TR 
Figure 2  Adhesion of HP26695 and HPTx30a H pylori strains to GP202 transfectants GP202-Neo, GP202-dTR, GP202-3TR, GP202-9TR and GP202-42TR. aP < 0.05, 
compared to the control (GP202 Neo) and cP < 0.05.
a
a
a
a
a
a
a
a
Costa NR et al . MUC1 impact on H pylori  adhesion                                                                                            1413
www.wjgnet.com
 COMMENTS
Background
More than half of the world population is persistently infected by H pylori. Adhesion 
of the bacteria to the gastric mucosa is essential for attachment and infection. 
Therefore it is important to know host and bacterial factors that condition the 
adhesion.
Innovations and breakthroughs 
The study of host factors that influence the binding of H pylori to gastric cells may 
help to identify candidates more prone to bacterial colonization and patients more 
resilient to eradication strategies.
Applications
These findings may help to develop screening methods to identify candidates 
more prone to bacterial colonization and to develop more efficient eradication 
strategies, as well as to develop strategies to prevent or minimize H pylori binding 
to the gastric mucosa.
Peer review
This is a good study designed to elucidate that MUC1 VNTR polymorphism affects 
H pylori adhesion to gastric cells. The results are informative and potentially 
helpful for prevention of H pylori binding to the gastric mucosa.
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Abstract
Background: Gastric carcinoma is the second leading cause of cancer-associated death worldwide. The high mortality
associated with this disease is in part due to limited knowledge about gastric carcinogenesis and a lack of available
therapeutic and prevention strategies. MUC1 is a high molecular weight transmembrane mucin protein expressed at the
apical surface of most glandular epithelial cells and a major component of the mucus layer above gastric mucosa.
Overexpression of MUC1 is found in approximately 95% of human adenocarcinomas, where it is associated with oncogenic
activity. The role of MUC1 in gastric cancer progression remains to be clarified.
Methodology: We downregulated MUC1 expression in a gastric carcinoma cell line by RNA interference and studied the
effects on cellular proliferation (MTT assay), apoptosis (TUNEL assay), migration (migration assay), invasion (invasion assay)
and aggregation (aggregation assay). Global gene expression was evaluated by microarray analysis to identify alterations
that are regulated by MUC1 expression. In vivo assays were also performed in mice, in order to study the tumorigenicity of
cells with and without MUC1 downregulation in MKN45 gastric carcinoma cell line.
Results: Downregulation of MUC1 expression increased proliferation and apoptosis as compared to controls, whereas cell-
cell aggregation was decreased. No significant differences were found in terms of migration and invasion between the
downregulated clones and the controls. Expression of TCN1, KLK6, ADAM29, LGAL4, TSPAN8 and SHPS-1 was found to be
significantly different between MUC1 downregulated clones and the control cells. In vivo assays have shown that mice
injected with MUC1 downregulated cells develop smaller tumours when compared to mice injected with the control cells.
Conclusions: These results indicate that MUC1 downregulation alters the phenotype and tumorigenicity of MKN45 gastric
carcinoma cells and also the expression of several molecules that can be involved in tumorigenic events. Therefore, MUC1
should be further studied to better clarify its potential as a novel therapeutic target for gastric cancer.
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Introduction
Gastric cancer is one of the most common and life-threatening
cancers worldwide (for review see [1]).The poor prognosis of this
disease reflects our poor understanding of its etiological factors and
pathogenesis and the lack of effective treatments.
MUC1 is a high molecular weight transmembrane protein that
is expressed at the apical surface of most glandular epithelial cells
[2]. MUC1 is overexpressed in almost 95% of cancer cells [3], a
molecular pathological feature that is associated with carcinogen-
esis and poor prognosis [4,5,6,7,8]. Moreover, aberrant glycosyl-
ation and loss of apical expression of MUC1 have been reported
for gastric carcinomas [9,10,11].
MUC1 protein consists of a highly variable extracellular domain
composed of a variable number of tandem repeats (VNTR), and a
highly conserved cytoplasmic domain (CD), which are both
essential for MUC1-driven oncogenic activities [12,13]. The
MUC1 extracellular domain can be extensively glycosylated [14]
and was shown to interact with several extracellular ligands,
including ICAM-1[15] and galectin-3[16]. These interactions
influence cell adhesion [16], motility and migration [17,18],
metastasis [19] and cell-cell aggregation [20], which contribute to
the maintenance of a normal cell phenotype, and upon
disregulation contribute to tumor progression. The MUC1
cytoplasmic domain (MUC1-CD) engages in signal transduction
through several residues that can be phosphorylated by receptor
tyrosine kinases (and other kinases), which in turn regulate MUC1-
CD affinity to other mediators of signal transduction and
transcriptional regulation [for review see [21] and [22]. MUC1-
CD associates with molecules such as b-catenin, c-Src, Grb2/Sos,
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p53, GSK-3b, EGFR and PKC-d [for review see [22], Lyn [23] ,
Lck and Zap 70 [24] , ER-a [25], NFKb [26], c-Abl [27], ATM
[28] and CAML [29], that regulate processes of cell survival,
proliferation, apoptosis, adhesion, migration and cell-cell aggre-
gation. These functions of MUC1 are known to contribute to
tumor progression and poor survival of cancer patients [for review
see [6,30]. Nonetheless, the relevance of MUC1 in gastric cancer
progression has not been previously investigated.
In the report presented here we used retrovirus-mediated
transfection of short-hairpin RNAs (shRNA) to induce a stable
downregulation of MUC1 in the gastric carcinoma- derived cell
line MKN45. The effects of MUC1 downregulation were studied
in vitro with respect to cell proliferation, apoptosis, migration,
invasion and cell-cell aggregation. MUC1 downregulated cells
were more proliferative and apoptotic than the controls and
exhibited lower degrees of cell-cell aggregation. No significant
differences were found in terms of cell migration and invasion.
Global gene expression analysis, evaluated by oligonucleotide
microarrays, identified several genes influenced by MUC1
downregulation that may contribute to the observed phenotypic
alterations. In vivo studies have shown that MUC1 downregulation
impacts tumor development.
Materials and Methods
Cell culture
A human cell line derived from diffuse-type gastric carcinoma –
MKN45 (poorly differentiated adenocarcinoma, Japan Health
Sciences Foundation [31]) was grown in RPMI 1640 containing
GlutamaxTMI and 25mM HEPES, supplemented with 10% fetal
bovine serum (FBS) and 50 mg/ml gentamicin (Invitrogen). The
packaging cell line PhoenixGP [32] was maintained in Dulbecco’s
Modified Eagle Medium containing GlutamaxTMI, 4,500 mg/l D-
Glucose and Sodium Pyruvate, supplemented with 10% FBS and
1% (v/v) penicillin/streptomycin. Stable MUC1 downregulated
clones derived from MKN45 cells were grown in standard growth
medium supplemented with 5 mg/ml puromycin (Sigma). After
evaluation of MUC1 levels at different time points in culture, all
the assays were performed considering the time of cell culture in
which the downregulation was higher, at 96 hours of cell culture.
Cells were grown at 37uC with 5% CO2 in humidified
atmosphere.
MUC1 downregulation strategy
MUC1 downregulated cells were produced using a retroviral
expression system with short hairpin RNAs. Briefly, a 21-
nucleotide sequence of the MUC1 gene, with no homology to
other DNA sequences detected in a BLAST search, was chosen
according to standard RNAi rules [33]. The scramble control was
designed and tested for homology in a BLAST search as well.
Sense and antisense oligos (Proligo) were ligated and inserted in
the pSUPER.retro.puro vector (Oligoengine). The oligos used
were the following: MUC1 Exon 2 (sense: GATCCCCACCTC-
CAGTTTAATTCCTCTTCAAGAGAGAGGAATT AAACT-
GGAGGTTTTTTA; antisense: AGCTTAAAAAACCTCCAGT-
TTAATTCCTCTC TCTTGAAGAGGAATTAAACTGGAG-
GTGGG; the MUC1-cDNA target region is underlined) and
scramble control (sense: GATCCCCATCACCTTCGTACT-
CCTTA TTCAAGAGATAAGGAGTACGAAGGTGATTT-
TTTA, antisense: AGCTTAAAAAATC ACCTTCGTACTCCT-
TATCTCTTGAATAAGGAGTACGAAGGTGATGGG; the
‘‘unpaired’’-cDNA target region is underlined). The MUC1
specific target or the scrambled control constructs were transfected
into PhoenixGP packaging cell line by calcium-phosphate
mediated transfection and transfected cells were selected using
puromycin. Stable transfectants were seeded in a 6-well plate
(1x106cells/well) and incubated for 24 hours at 32uC. The media
containing the virus was collected, filtered through a 0.45 mm filter
to remove remnant cells, and used to infect MKN45 cells, during
24 hours at 37uC. The viral supernatant was then replaced by the
standard growth medium and cells were incubated 48 hours at
37uC. Efficiently transduced cells were selected and grown in
standard media supplemented with puromycin. Two independent
MUC1 downregulated clones (C1 and C2) were isolated and
expanded for three times using cloning rings.
Immunofluorescence
MKN45 cells at 96h in culture were harvested, seeded in 12-
well slides (Cell Line) and air-dried overnight at room tempera-
ture. Cells were then fixed in ice cold acetone for 5 minutes,
washed twice with PBS and blocked with normal rabbit serum
(DAKO) diluted 1:5 in 10% bovine serum albumin (BSA) for
30 minutes. Serum was then replaced by the MUC1 monoclonal
antibody HMFG1 (NovoCastra) diluted 1:50 in 5% BSA, and
incubated overnight at 4uC. After three washes with PBS, cells
were incubated with a rabbit anti-mouse FITC labeled antibody
(DAKO) diluted 1:70 in 5% BSA for 30 minutes in the dark at
room-temperature. Cells were washed 3 times with PBS and
mounted in vectashield (Vectorlabs). Images were acquired in a
Leica DMIRE2 fluorescent microscope. Results are representative
of three independent experiments.
Protein extraction and Western blot
MKN45 cells were cultured in 60-mm dishes to 80–90%-
confluence at 96h in culture. After washing twice with PBS, lysis
buffer (10mM Tris pH 7.4, 150mM NaCl, 0.1% (p/v) SDS, 1mM
PMSF, 1% (v/v) Triton X-100) was added and cells were scraped.
Lysates were incubated on ice for 1 hour and centrifuged for
2 minutes at 4uC to collect the supernatants. Protein content was
assessed by the bicinchoninic acid method (Pierce), as described in
the manufacturer’s instruction manual. Protein extracts were
analyzed by a 4–10% SDS-PAGE (Invitrogen), transferred to a
nitrocellulose membrane (Amersham Biosciences), and blotted
overnight at 4uC with anti MUC1-Ab5 monoclonal antibody
(1:300, ThermoScientific), anti-beta-actin polyclonal antibody
(1:8,000, Sigma), anti ERK1/2(1:1,000, Cell Signaling Technol-
ogy) and anti b-catenin (1:1,000, BD Transduction Laboratories)
in 5% non-fat milk in TBS-0.1%Tween20 (Sigma). Membranes
were washed 3 times with TBS-0.1%Tween20 and the primary
antibodies were revealed using goat anti-mouse peroxidase-
conjugated antibody (1:1,000, DAKO) in 5% non-fat milk in
TBS-0.1%Tween20, followed by ECL detection kit (BioRad).
Results are representative of three independent experiments.
RNA extraction and Real-Time PCR
Total RNA was isolated from MKN45 cells at 96h in culture
using TriReagentTM (Sigma), according to the manufacturer’s
instructions. 5 mg of RNA were primed with random hexamers
(Invitrogen) and reverse transcribed with Superscript II (Invitro-
gen) in a final volume of 20 ml. 2 ml of a 1:10 dilution of cDNA
were amplified with 300nM of each primer and SYBRGreen
(Applyed BioSystems) in a final volume of 20 ml, using the
fluorescence reader ABI Prism 7000. Each sample was run in
duplicate. The primers used were the following: MUC1 (sense:
CTCCTTTCTTCCTGCTGCTG, antisense: CTGGAGAGTA-
CGCTGCTGGT) and 18S (sense: CGCCGCTAGAGGTGA-
AATTC, antisense: CATTCTTGGCAAATGCTTTCG), and
their specificity was confirmed using the software BLASTn on-
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line and by melt curve analysis. For each sample, the level of 18S
RNA was measured and used for normalization of target genes
abundance. Relative mRNA levels were then calculated using the
comparative Ct method [34]. Data is expressed as a ratio of the
results obtained with each clone and the scramble control, from
three independent experiments. Statistical analysis was performed
using the Mann-Whitney test.
MTT proliferation assay
Cells were plated in triplicate in 96-well plates at 5,000 cells per
well and incubated at normal conditions for 96h for MKN45 cells.
At each time point, the medium was removed and cells incubated
with 20 ml of MTT solution (5mg/ml, Sigma) for 3 hours at
normal conditions. MTT was removed and 200 ml of DMSO were
added to each well to dissolve formazan. Finally, formazan optical
density was measured using a microplate reader at a wavelength of
540nm. The relative growth was defined as the following formula:
Relative Growth = (A540nm at Tn / A540nm at T024h). Data is
expressed as a ratio of the results obtained with each clone and the
scramble control, from three independent experiments. Statistical
analysis was performed using the Mann-Whitney test.
Terminal Transferase dUTP Nick End Labeling (TUNEL)
assay
Post-confluent cells at 96h in culture were harvested and fixed
with 4% paraformaldehyde in PBS for 15 minutes. Fixed cells
were seeded in 12-well slides (Cell Line) and air-dried overnight at
room temperature. Following washing with PBS, cells were
permeabilized with ice-cold freshly-made PBSTrCit solution
(PBS + 0.1%TritonX + 0.1% Sodium Citrate) for 2 minutes on
ice. Cells were washed again twice, and incubated with TUNEL
reaction mix (enzyme solution, label solution and dilution buffer,
Figure 1. MUC1 downregulation by shRNA. (A) MUC1 detection by immunofluorescence with HMFG-1 antibody in MKN45-C1 and MKN45-C2
and MKN45-SC control; (B) MUC1 protein detection by western-blot with MUC1-Ab5 antibody of total protein extracts from MKN45-C1 and MKN45-
C2 and MKN45-SC control; (C) Quantification of MUC1 RNA in MKN45-C1 and MKN45-C2 and MKN45-SC control by real-time PCR. MUC1 expression
was corrected to the house-keeping gene 18S and normalized to the data obtained with the scrambled control. *P,0.01.
doi:10.1371/journal.pone.0026970.g001
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1:9:10, In Situ Death Detection Kit, Fluorescein, Roche) for 1
hour at 37uC. Two additional washing steps were performed and
slides were mounted in Vectashield with DAPI (Vectorlabs).
Results were analyzed under a Leica DMIRE2 fluorescent
microscope and data is expressed as a ratio of the results obtained
with each clone and the scramble control, from three independent
experiments. Statistical analysis was performed using the Mann-
Whitney test.
Migration assay
MKN45 cells were cultured in 60-mm dishes for a full-
confluence at 96h in culture. The epithelial cells monolayer was
then washed with PBS and wounded with a 10 ml micropipette tip.
Non-adherent cells were removed by washing twice with PBS.
Images of cells at the edge of the wound were acquired
automatically at 20x magnification in a Leica DMIRE2
fluorescence microscope with a Leica DFC Twain camera for
144 frames at 10-minute intervals (corresponding to 24 hours)
controlled by Leica FW4000 software. Frames from 0, 6, 12, 18
and 24 hours were used to quantify the percentage of migration: a
grid of 50x30 squares was used to fulfill the wound space and the
percentage of migration was calculated by the number of squares
occupied by cells at each time point. Data is expressed as a ratio of
the results obtained with each clone and the scramble control,
from three independent experiments. Statistical analysis was
performed using the Mann-Whitney test.
Matrigel invasion assay
Cell invasion was studied by using BD BiocoatTM MatrigelTM
invasion chambers with 8-mm size pores (BD Biosciences),
according to the manufacturer’s instructions. MKN45 cells at
96h in culture were harvested and seeded in duplicate at 250,000
cells per insert (sized for 24-well plates) in 1% FBS containing
medium, and 20% FBS containing medium was added to the
bottom of the growth well, as an attractant. Cells were allowed to
invade for 22 hours (37uC, 5% CO2 atmosphere). The non-
invading cells were then swabbed from the top of the inserts and
the invading cells on the lower surface were fixed with 100%
methanol and stained with DAPI for 15 minutes in the dark. The
membranes were removed and cells were counted under a Leica
DMIRE2 fluorescence microscope. Data are expressed as a ratio
of the results obtained with each clone and the scramble control,
from three independent experiments. Statistical analysis was
performed using the Mann-Whitney test.
Cell-cell Aggregation assay
MKN45 cells at 96h in culture were harvested and seeded in
duplicate at 250,000 cells per well in 24-well plates. Plates were
placed at 37uC with constant stirring (150rpm) for 1 and 2 hours.
Cells were fixed with 100 ml of 25% glutaraldehyde at time zero
and at the end of the incubation. Aggregates were photographed
under a light microscope and isolated cells were counted (cells in
duplicates were counted as isolated cells). The aggregation index
was defined as the following formula: Aggregation index = 1-
(number of isolated cells at Tn / number of isolated cells at T0).
Data are expressed as a ratio of the results obtained with each
clone and the scramble control, from three independent
experiments. Statistical analysis was performed using the Mann-
Whitney test.
Gene expression analysis
The expression of 12,135 genes in MUC1 downregulated clones
and the respective scramble control were evaluated following the
same protocol as before [35]. Briefly, following RNA extraction (as
described previously), cDNA was obtained by reverse transcrip-
tion, during which labeled nucleotides were incorporated:
MKN45-C1 and MKN45-C2 cDNAs were labeled with Cy3
(green emission) and MKN45-SC control with Cy5 (red emission).
After hybridization, the mixture was hybridized with the array
overnight and then the array was digitalized with the ScanAr-
ray4000 (Perkin-Elmer) system and fluorescence analyzed by the
QuantArray software package (Perkin-Elmer).
Normalization and background subtraction were performed
and ratios for downregulated clones /Scrambled Control and
Scrambled Control/downregulated clones were calculated using
Microsoft Excel software. Gene expression with a ratio higher than
2 was considered statistically significant.
All data is MIAME compliant and that the raw from the
microarray experiments were uploaded onto the Gene Expression
Omnibus Database http://www.ncbi.nlm.nih.gov/geo (Geo ac-
cession numbers: GSM717858 and GSM717859).
In Vivo tumor growth Assays
Six-week-old female N:NIH(s)II:nu/nu nude mice were ob-
tained previously from the Medical School, University of Cape
Town in 1991 and maintained and housed at IPATIMUP Animal
House at the Medical Faculty of the University of Porto, in a
pathogen-free environment under controlled conditions of light
Figure 2. Quantification of cell proliferation by MTT assay.
Quantification of metabolically active cells by MTT assay in MKN45-C1
and MKN45-C2 clones and MKN45-SC control at 96h in culture. Data
from 24 hours was used to set time zero and results were normalized to
the data obtained with the scrambled control.*P,0.01.
doi:10.1371/journal.pone.0026970.g002
Figure 3. Quantification of apoptotic cells by TUNEL assay.
Apoptosis of MKN45-C1 and MKN45-C2 and scramble control (SC) were
evaluated at 96h in culture by the TUNEL assay. Results were
normalized to the data obtained with the scrambled control. *P,0.01.
doi:10.1371/journal.pone.0026970.g003
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and humidity. Males and females, aged 6–8 weeks, were used for in
vivo experiments. Animal experiments were carried out in
accordance with the Guidelines for the Care and Use of
Laboratory Animals, directive 86/609/EEC. Mice were subcuta-
neously injected in the dorsal flanks using a 25-gauge needle with
1x105 of MKN45-SC (2 male and 2 female mice) or MKN45-C2
cells (3 male and 3 female mice). Mice were weighed, and tumor
width and length were measured with calipers every week. Mice
were euthanized 21 days after cell injection, at the time when the
first tumor reached maximum allowable volume. For statistical
analysis, the Mann Whitney test-StatView Software version 5.0
(SAS Institute, Cary, NC) was used. A P value of less than 0.05 was
considered as statistically significant.
Results
MUC1 downregulation by shRNA
We established two independent MUC1 downregulated clones,
MKN45-C1 and MKN45-C2 and one scramble control, MKN45-
SC. MUC1 downregulation was verified by immunofluorescence
(Figure 1A), Western Blot (Figure 1B) and Real-Time PCR
(Figure 1C).
There was a significant downregulation of MUC1 expression in
MKN45-C1 and MKN45-C2 clones as compared to the MKN45-
SC control. The expression of MUC1 at the protein level was
detected with two different antibodies, one that binds the VNTR
extracellular domain (HMFG-1, Figure 1A) and other that
recognizes a 14–28 KDa sequence in MUC1 cytoplasmic domain
(MUC1-Ab5, Figure 1B). Both showed a significant reduction in
the amount of MUC1 protein in MKN45-C1 and MKN45-C2
clones when compared to the scramble control. Real-Time PCR
results indicate that the MUC1 downregulation was 48%
(MKN45-C1) and 38% (MKN45-C2) (Figure 1C). MUC1 RNA
levels were evaluated at 48, 72 and 96h of cell culture and the
highest downregulation occurred at 96h (results not shown).
Effects of MUC1 downregulation on MKN45 cells
Cell proliferation. MKN45-C1 and MKN45-C2 cells
showed significantly increased proliferation rates (P,0.01) when
Figure 4. Quantification of cell-cell aggregation. (A)Quantification of the cell-cell aggregation index in MKN45-C1 and MKN45-C2 and MKN45-
SC control. The cell-cell aggregation index was assessed by the observed decrease in the number of isolated cells over time, and normalized to the
data obtained with the scrambled control. *P,0.01; (B) Images of the aggregates formed after 1 and 2 hours of constant stirring. First column shows
isolated cells at time 0h (20x magnification) and second and third columns show aggregates formed after 1h and 2h of incubation (40x
magnification), in MKN45-C1 and MKN45-C2 and MKN45-SC control.
doi:10.1371/journal.pone.0026970.g004
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compared to the MKN45-SC control (2.29 and 2.48 vs 1), when
evaluated by MTT assay (Figure 2).
Cell apoptosis. MKN45-C1 and MKN45-C2 cells showed
significantly increased levels of apoptosis (P,0.01) when compared
to the MKN45-SC control (3.32 and 2.41 vs 1), when evaluated by
a TUNEL assay (Figure 3).
Cell-cell aggregation. MKN45-C1 and MKN45-C2 cells
showed significantly decreased cell-cell aggregation levels
(P,0.01), when compared to the MKN45-SC control (0.34 and
0.49 vs 1 at 1h; 0.52 and 0.64 vs 1 at 2h), when evaluated by a cell
aggregation assay (Figures 4A and 4B).
Cell migration and invasion. There were no significant
differences in cell migration and invasion of MKN45-C1 and
MKN45-C2 cells when compared to the MKN45-SC control,
when evaluated by motility and invasion assays (results not shown).
Effects of MUC1 downregulation in MKN45 cells gene
expression
The observed phenotypic modifications associated were likely
due in part to alterations in signal transduction pathways mediated
by MUC1-CD, since overexpression of MUC1 has been shown to
modulate gene expression through reprograming transcription of
multiple genes [36,37]. We evaluated the net effects of
downregulating MUC1 in the MKN45 gastric carcinoma cell
line by performing a global analysis of gene expression by
oligonucleotide microarrays (Table 1). The results revealed that a
number of genes that influence proliferation, migration, invasion
and motility were differentially expressed in MKN45-C1 and
MKN45-C2 and the MKN45-SC control. The most significant
differences were found for TCN1, KLK6 and ADAM29 (.10 fold
upregulated between the MKN45-C1 and MKN45-C2 clones and
the MKN45-SC control) and LGALS4, TSPAN8 and SHPS-1
(.3.5 fold downregulated between the MKN45-C1 and MKN45-
C2 clones and the MKN45-SC control).
In vivo tumor growth assays
In vivo tumorigenicity assays showed that mice injected with
MUC1-downregulated cells (MKN45-C2) developed smaller and
slower-growing tumors, when compared to mice injected with the
MKN45-SC control cells (Figure 5).
Discussion
In the work presented here, we evaluated the effects of MUC1
downregulation on cancer-related properties of MKN45 gastric
carcinoma cells. Stable downregulation of MUC1 expression was
achieved in MKN45 gastric carcinoma cell line by RNA
interference. MUC1 contributes to tumor progression of adenocar-
cinomas and therefore its downregulation was predicted to affect the
malignant properties of cancer cells, including proliferation,
apoptosis, migration, invasion and cell-cell aggregation.
We found that proliferation was significantly increased in MUC1
downregulated clones MKN45-C1 and MKN45-C2 when compared
to the control MKN45-SC. Similar studies with breast and pancreatic
carcinoma cell lines have shown similar [38] and opposite [35,38,39]
results. In different tumor models, MUC1 was shown to regulate cell
proliferation by interacting with several proteins such as ER-a, b-
catenin and EGFR [25,40,41]. However, for gastric carcinoma cells,
such interactions have not been investigated. Results obtained by an
oligonucleotide microarray analysis showed that expression of
molecules affecting cell proliferation such as KLK6 and LGAL-4
[42,43,44] were significantly altered in MKN45-C1 and MKN45-C2
clones when compared to the MKN45-SC control. KLK6 expression
was increased in MKN45-C1 and MKN45-C2 clones, whereas
LGAL4 expression was decreased and these differences may explain
the observed differences in proliferation. The mechanisms by which
KLK6 and LGAL4 expression is altered inMKN45-C1 andMKN45-
C2 when compared to MKN45-SC control remains to be elucidated.
Another important observation was that apoptosis was signif-
icantly increased in MKN45-C1 and MKN45-C2 clones when
compared to the MKN45-SC control. MUC1 was previously
shown to mediate a pro-apoptotic response in hamster ovary cells
[45] and it was also attributed with anti-apoptotic functions in
Table 1. Oligonucleotide microarray results by comparison
between MKN45-C1/MKN45-C2 and MKN45-SC control cells,
by order of magnitude.
Genes upregulated .2 fold in MUC1 downregulated clones
Transcobalamin 1 (TCN1)
Kallikrein-related peptidase 6 (KLK6)
Desintegrin and metalloproteinase 29 (ADAM29)
Keratoepithelin (TGFBI)
MRP family of ATP transport member 2 (ABCC2)
Amyloid beta precursor-like protein 2 (APLP2)
Mitochondrial ATP synthase (ATP5I)
Sulfide dehydrogenase like protein (SQRDL)
Sarcoglycan, epsilon (SGCE)
Hypothetical protein (FLJ20323)
Galectin 1 (LGALS1)
Proline-histidine rich protein (PHLDA1)
Trypsin 2 (PRSS2)
Mesotrypsin (PRSS3)
SP2 transcription factor (SP2)
Ubiquitin-conjugating enzyme (UBE2L6)
Vitellogenic-like carboxypeptidase (CPVL)
Genes downregulated .2 fold in MUC1 downregulated clones
Galectin 4 (LGALS4)
Tetraspanin 8 (TSPAN8)
Tyrosine phosphatase SHP substrate (SHPS-1)
Polymerase (DNA-directed), delta 4 (POLD4)
H2B histone family, member J (HIST1H2BH)
H2B histone family, member T (HIST1H2Bk)
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
Annexin IV (ANXA4)
Intercellular adhesion molecule 4 (ICAM4)
DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 (DDX39)
Apolypoprotein B (APOBEC2)
Clusterin (CLU)
GDP-mannose 4,6-dehydratase (GMDS)
Serine/threonine kinase 38 like (STK38L)
CD55 (CD55)
Apolipoprotein B-catalytic polypeptide-like 3C (APOBEC3C)
Cell adhesion related-molecule (CDON)
Villin-1 (VIL1)
MKN45-C1 and MKN45-C2 and the MKN45-SC control were analysed by
oligonucleotide microarrays. Listed are genes with expression increased or
decreased more than 2 fold in both MUC1 downregulated clones when
compared to the control.
doi:10.1371/journal.pone.0026970.t001
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myeloma, breast and colorectal carcinoma cell lines [46,47,48].
However, little is known about the influence of MUC1 on cell
apoptosis in gastric carcinoma cells.
No significant differences were found between MUC1-C1 and
C2 clones and MKN45-SC control with respect to cell migration
and invasion. This is in contrast to previous findings in which
MUC1 was shown to influence cell migration in breast, cervical,
renal and pancreatic carcinoma cell lines [18,49,50,51] and cell
invasion in breast, lung, gastrointestinal, hepatic and pancreatic
carcinoma cell lines [3,52,53].
Cell-cell aggregation was decreased in MKN45-C1 and
MKN45-C2 clones when compared to the MKN45-SC control.
Previous studies have shown that overexpression of different forms
of MUC1 can lead to an increase or a decrease in cell-cell
aggregation in a pancreatic carcinoma cell line [54], whereas
others have shown that MUC1 downregulation induces an
increase of cell-cell aggregation in an oral carcinoma cell line
[41]. MUC1 interactions with other adhesion molecules have been
shown to contribute to both adhesive [55,56] and anti-adhesive
[57,58,59] properties of cells. Our results showed that MUC1
plays a relevant role in MKN45 cell-cell aggregation, contributing
to gastric cells adhesive properties.
Another possibility is that signaling through the MUC1-CD
influences gene expression, which in turn affects the phenotypic
properties of the MKN45 cell line. By oligonucleotide microarray
analysis we found alterations in the transcriptional profile of cells
following MUC1 downregulation when compared to control cells.
These alterations are likely due to MUC1 downregulation, since
MUC1 has been shown to directly conduct signals that alter the
transcriptional program of tumor cells [36,37,60]. MUC1 cytoplas-
mic domain can be phosphorylated in several sites, modulating its
interaction with cell signalling partners and transcription factors [21].
The phosphorylation of MUC1-CD will be dependent on the
amount and availability of its signaling partners and therefore on the
cell type in question. We found significant alterations in the
expression levels of several genes, mainly TCN1, KLK6, ADAM29,
LGALS4, TSPAN8 and SHPS-1. Some of these molecules have
functions not yet fully clarified yet others are known to be associated
with cell proliferation and migration, including KLK6, LGAL4 and
SHPS-1 [42,43,59,61,62], invasion, including KLK6 [59] and
motility, including LGAL4 [43]. MUC1 may be facilitating the
transcription of these genes and therefore be contributing to the
observed phenotypic alterations observed.
In vivo assays confirmed that cells with decreased levels of
MUC1 form smaller and slower-growing tumors than the control
cells. This result emphasizes that MUC1 contributes to gastric
tumor progression in the context of the multicellular environment
of tumor growth in vivo.
MUC1 overexpression has been associated with the neoplastic
progression of several tumors, including the acquisition of invasive
and metastatic properties. Phenotypic studies in cell models other
than gastric cancer have suggested that MUC1 influences events
such as proliferation, apoptosis, migration, invasion, adhesion and
cell-cell aggregation. Previous studies of MUC1 in breast
carcinogenesis models show mixed results for different breast
cancer cell lines [38], which reinforces the relevance of the
molecular context on the MUC1-mediated cancer progression.
The effects of MUC1 in gastric carcinogenesis will thus be
dependent on MUC1 and the molecules interacting with MUC1,
which will significantly differ between cell lines. Evaluation of
different gastric cell lines will complement the data regarding the
impact of MUC1 gastric carcinogenesis.
The work presented here shows for the first time that MUC1
expression influences proliferation, apoptosis and cell-cell aggre-
gation of MKN45 gastric carcinoma cells. The results are
consistent with the view that MUC1 modulates different signaling
pathways in a manner that is dependent on the expression and
activity of other regulatory mechanisms and molecules, which are
influenced by the cellular and biological context of the cell type
that is overexpressing MUC1.
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Abstract 
Background:  Gastric cancer (GC) is one of the most common and life-
threatening cancers worldwide. The poor prognosis of this disease reflects the 
poor understanding of its etiological factors and pathogenesis and the lack of 
effective treatments.  
MUC1 is a high molecular weight glycoprotein that protects epithelial 
surfaces. MUC1 highly conserved cytoplasmic domain (MUC1-CD) is involved 
in cell signaling cascades in different tumor models, being phosphorylated by 
several kinases and interacting with several cell signaling oncogenic molecules. 
Overexpression, aberrant glycosylation and loss of apical expression of MUC1 
have been reported for gastric carcinomas. However, there is no information so 
far about MUC1-CD participation in cell signaling pathways in GC cells. The aim 
of this work was therefore to identify MUC1 oncogenic signaling partners in 
MKN45 gastric carcinoma cell line and to evaluate the impact of MUC1 
expression in its signaling partners expression and phosphorylation. 
Methodology: Identification of MUC1-CD signaling partners was performed by 
immunoprecipitation and proximity ligation assays. Evaluation of MUC1 
downregulation impact in MUC1-CD signaling partners expression and 
phosphorylation was performed using immunoblots, Real Time PCR and 
phospho-antibody screening (Kinexus). Results: Immunoprecipitation and 
proximity ligation assays have shown that MUC1-CD interacts with EGFR, 
Grb2, B-RAF, and ERK1/2 proteins, all important effectors of the MAPK 
signaling pathway in MKN45 GC cells and with ERK1/2 in AGS GC cells. 
 MUC1 downregulation conditions ERK1/2, EGFR and B-RAF protein 
levels, suggesting that MUC1 is also involved in the transcription and/or stability 
of these molecules. The evaluation of mRNA expression by Real-Time PCR has 
shown that ERK2 and B-RAF expression is likely regulated by MUC1 at a 
transcriptional level, whereas EGFR expression is most likely regulated by post-
transcriptional mechanisms. Furthermore, MUC1 downregulated clones have 
shown a general significant increase in the phosphorylation of ERK2 molecule 
and a decrease in the levels of ERK1, when compared to the control cells. 
Conclusions: MUC1-CD physically interacts and affects the expression and 
phosphorylation of MAPK-related oncogenic signaling proteins in gastric 
carcinoma cells.  
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fellowships SFRH/BD/36961/2007 and SFRH/BD/73410/2010). Fundação Luso-
Americana (FLAD). The funders had no role in the study design, data collection 
and analyzis, decision to publish or preparation of the manuscript.  
 
 
 
 
 
Introduction 
Gastric cancer (GC) is one of the most common and life-threatening 
cancers worldwide [1] and nowadays the third cause of cancer-related deaths 
all over the world and the fourth in Portugal ([2] GLOBOCAN 2008, IARC) . The 
poor prognosis of this disease with a 5-year survival rate of 20% [3] reflects the 
reduced understanding of its etiological factors and pathogenesis, the absence 
of specific symptoms and consequent late diagnosis and lack of effective 
treatments. Mucins that cover the gastric epithelium and that are the first 
contact barrier between cells and the external environment are thus elective 
targets to study gastric oncogenesis.   
MUC1 mucin is a high molecular weight transmembrane protein that is 
expressed at the apical surface of most glandular epithelial cells [4] and one of 
the major mucins expressed in the stomach. Immediately after translation, 
MUC1 protein undergoes proteolytic cleavage in the extracellular part of the 
protein, 71 to 53 amino acids upstream of the transmembrane domain. The two 
resulting proteins remain associated in a tight heterodimer complex that is 
expressed at the cell membrane [5, 6].  
The extracellular domain of this protein contains a region of variable 
number of tandem repeats (VNTR) rich in serine and threonine residues that 
constitute targets of O-glycosylation. In epithelial adenocarcinomas of several 
tissues, including lung, breast, ovary, prostate, pancreas, stomach and colon, 
immunohistochemical analysis of MUC1 expression with antibodies against 
epitopes of the VNTR region of the mucin shows overexpression of this 
molecule on the entire cell membrane and also its aberrant glycosylation [7]. 
Although the biological relevance of the VNTR domain of the mucin is still 
unknown, it was shown that the variability of the VNTR length is associated with 
the risk for cancer development [8, 9]. This association is related with the 
expression of tumor-associated carbohydrate antigens that are coupled to the 
VNTR region of MUC1 and other mucins [10, 11]. 
Contrasting to the variation observed in the extracellular domain, the 
cytoplasmic domain of MUC1 mucin (MUC1-CD) is highly conserved among 
species, suggesting its involvement in basic cellular processes [12]. In fact, 
most of the oncogenic features of MUC1-overexpressing tumor cells are 
thought to be driven by MUC1-CD interaction with proteins involved in signal 
transduction. Tyrosine residues present in MUC1-CD can be phosphorylated by 
several tyrosine kinases, including the epithermal growth factor receptor 
(EGFR) and members of the Src family, leading to the activation of the MAPK 
pathway through the RAS-MEK-ERK2 pathway in breast, COS-7 and mouse 
mammary gland [13-15]. Phosphorylation of the MUC1-CD by these kinases 
also protects β-catenin from the degradation mediated by GSK3-β, ultimately 
leading to the nuclear translocation of the complex  MUC1-CD/ β-catenin, and 
to the activation of transcription events in breast, colon and pancreatic 
carcinoma cell lines  [16-18]. However, in a recent report on MUC1-CD 
interaction with β -catenin it was shown that expression of this molecule in 
human embryonic kidney-derived cells decreases β-catenin translocation into 
the nucleus, reducing the activation of the LEF-1 transcription factor and 
blocking the expression of cyclin-D1, thus, inhibiting cell proliferation [19].  
MUC1-CD is also involved in the inhibition of oxidative stress-induced 
apoptosis. In the presence of high levels of reactive oxygen species, MUC1-CD 
expression is up-regulated, leading to an increase in the expression of anti-
oxidant enzymes and to the dephosphorylation-mediated activation of FOXO3a, 
a member of the forkhead family of transcription factors that induces oxidant 
scavenging and DNA repair in breast, colon and cervical carcinoma cell lines 
[20, 21]. The role of MUC1 in cell survival is also suggested by MUC1-CD 
interaction with p53 in response to genotoxic agents. MUC1-CD binds directly to 
p53 regulatory domain, suppressing p53-dependent apoptotic response to DNA 
damage [22]. Despite these reports, it was also shown, in a completely different 
model, that MUC1-overexpressing tumor cells are more sensitive to FasL-
induced apoptosis than  their negative counterparts, through an increase in the 
expression of Fas receptor [23]. 
The apparently contradictory data suggests that the complexity of the 
MUC1 mucin as a molecule involved in different signaling pathways may be 
dependent on the cell type and on the molecular context (e.g. amount and 
availability of signaling partners) where it is expressed. 
Data about MUC1-CD signaling partners or MUC1-CD participation in 
oncogenic cell signaling cascades in GC cells is very limited. There is one study 
that shows that interaction between MUC1-CD and β-catenin leads to 
upregulation of cyclin-D1 in H. pylori derived gastric cancer [24]. 
In the present study we aimed to identify MUC1-CD signaling partners by 
immunoprecipitation and proximity ligation assays (PLAs) and to evaluate the 
impact of MUC1 expression levels in possible MUC1-CD-signaling partners 
expression (by immunoblots and real Time PCR) and phosphorylation (by 
Kinexus phospho-antibody screening, using MKN45 clones with stable 
downregulation of MUC1 previously established [25]. 
We have found that MUC1-CD binds EGFR, Grb2, B-RAF and ERK1/2 
proteins. Furthermore, ERK1/2, EGFR and B-RAF mRNA and protein levels are 
altered upon MUC1 downregulation, suggesting that this mucin is involved in 
the transcription and/or stability/recycling of these signaling partners. Moreover, 
MUC1 downregulated clones have shown a significantly increased 
phosphorylation of ERK2 and decreased phosphorylation of ERK1 proteins. 
Our work allowed us to identify MUC1-CD signaling partners in GC cells 
and to show the impact of MUC1 downregulation in the expression and 
phosphorylation of some of these MUC1-CD signaling partners.  
 
Material and methods 
 
Cell culture 
Human cell line derived from diffuse-type gastric carcinoma – MKN45 
(poorly differentiated adenocarcinoma, Japan Health Sciences Foundation [26]) 
was grown in RPMI 1640 containing GlutamaxTMI and 25mM HEPES, 
supplemented with 10% fetal bovine serum (FBS) and 50μg/ml gentamicin 
(Invitrogen). MUC1 downregulated stable clones derived from MKN45 cells 
were grown in standard growth medium supplemented with 5µg/ml puromycin 
(Sigma). Cells were grown at 37ºC with 5% CO2 in humidified atmosphere. 
 
Clinical Samples 
Normal gastric tissues were obtained from the University of Nebraska 
Medical Center’s Tissue Bank through the Rapid Autopsy Pancreatic program in 
compliance with IRB 091-01. To ensure minimal degradation of tissue, organs 
are harvested within three hours post mortem and the specimens flash frozen in 
liquid nitrogen or placed in formalin for immediate fixation. After processing the 
sections were cut from paraffin blocks of formalin fixed tissue into 4µm thick 
sections and mounted on charged slides. For gastric carcinoma samples, we 
have used paraffin embebbed slides from the antrum part of the stomach 
treated in a similar way as the normal samples and obtained from the Medical 
Faculty of Porto University from gastric biopsies.  
 
Confocal Microscopy 
MKN45-SC and MKN45-C2 cells were grown until confluency in round 
slides, washed with PBS and fixed with 4% paraformaldehyde/120mM sucrose 
for 15 min. 0.1M glycine was added after paraformaldehyde removal for 15 min. 
Cells were washed with PBS 1% BSA twice and permeabilized with 0.15% 
Triton-X100/1% BSA in PBS for 15 min. After washing with PBS 1% BSA, the 
primary antibodies were added in PBS 1% BSA: MUC1-Ab5 monoclonal 
antibody (1:300, ThermoScientific), and calreticulin 1:50 (Cell Signaling) and 
incubated overnight at 4ºC. After washing with PBS, the secondary antibodies 
were added (Alexa Dylight-488 anti-hamster 1:500 and donkey anti-rabbit-649 
1:500) for 1h at RT. After PBS washing, nuclei were stained with DAPI 
(1:10,000 in PBS for 2min) cells were washed again with PBS and mounted in 
Vectashield (Vectorlabs). 
    
Phospho-antibody screening (Kinexus) 
Cells  were  lysed   by  the  addition  of   lysis buffer (20 mM Mops, pH 
7.0, 2 mM  EGTA, 5mM  EDTA, 30 mM sodium fluoride, 60 mM  β-
glycerophosphate, 10 mM  sodium  pyrophosphate, 2 mM  sodium 
orthovanadate, 1 mM PMSF, 3 mM benzamidine, 5 μM pepstatin,10 μM 
leupeptin, and 0.5% Triton X-100; final pH 7.0). Cells sonication was performed 
twice for 15 s and the homogenate was subjected to ultracentrifugation for 30 
min at 50,000 rpm. 
    Protein concentration was measured by the Bio-Rad assay and phospho-
kinase screening was performed by Kinexus (Vancouver, BC; KPSS-10.1). 
 
Immunoprecipitations and immunoblots 
        Subconfluent cells were lysed in appropriate ice-cold lysis buffer. Lysates 
were cleared by centrifugation at 4,000 rpm for 30 min. Lysates were incubated 
for 3 h at 4ºC with anti MUC1-Ab5 monoclonal antibody (1:300, 
ThermoScientific), and normal armenian hamster IgG (EBioscience) previously 
precipitated with Protein G Sepharose (Sigma) for 1 h at 4ºC. After washing 
with non-denaturing lysis buffer, the immunoprecipitates and lysates were 
separated in 12% Tris-Glycine Gels (Invitrogen). Proteins were transferred to 
PVDF membranes and were blocked with 5% nonfat dry milk in phosphate-
buffered saline (PBS) containing 0.01% Tween 20. Membranes were then 
incubated with anti-ERK1/2 (1:1,000, Cell Signaling), anti-EGFR (1:200, 
Santacruz Biotec.), anti B-RAF (1:200, Santacruz Biotec.), anti-Grb2 (1:200, 
Santacruz Biotec.) and anti-β-actin (1:8,000, Sigma) in 5% non-fat milk in PBS-
0.1%Tween20 (Sigma). Membranes were washed 3 times with PBS-
0.1%Tween20 and the primary antibodies were revealed using goat anti-
mouse/rabbit peroxidase-conjugated antibody (1:1,000, DAKO) in 5% non-fat 
milk in PBS-0.1%Tween20, followed by ECL detection kit (BioRad). Results are 
representative of three independent experiments. 
 
RNA extraction and Real Time PCR 
Total RNA was isolated from MKN45 cells using TriReagentTM (Sigma) 
according to the manufacturer’s instructions. 5μg of RNA were primed with 
random hexamers (Invitrogen) and reverse transcribed with Superscript II 
(Invitrogen) in a final volume of 20μl. 2μl of a 1:20 dilution of cDNA were 
amplified with 300nM of each primer and SYBRGreen (Applyed BioSystems) in 
a final volume of 20μl, using the fluorescence reader ABI Prism 7000. Each 
sample was run in triplicate. The primers used were the following: MUC1 
(sense: CTCCTTTCTTCCTGCTGCTG, antisense: 
CTGGAGAGTACGCTGCTGGT); TBP  (sense:   
GCACAGGAGCCAAGAGTGAA, antisense: TCACAGCTCCCCACCATATT ) , 
EGFR (sense: GAGCGACTGCCTGGTCTGCC, antisense: 
CACGCAGGTGGCACCAAAGC) , ERK2 (sense: 
GACACAACACCTCAGCAATGACCA, antisense:  
GGCTTGAGGTCACGGTGCAGA) and B-RAF (sense: 
TTAGTGAGCCAGGTAATGAGGCA; antisense: 
ATCAATTTGGGCAACGAGACCGA)   and their specificity was confirmed using 
the software BLASTn on-line and by melt curve analysis. For each sample, the 
level of TBP RNA was measured and used for normalization of target genes 
abundance. Relative mRNA levels were then calculated using the comparative 
Ct method [27]. Data is expressed as a ratio of the results obtained with each 
clone and the scrambled control, from three independent experiments. 
Statistical analysis was performed using the Mann Whitney test -StatView 
Software version 5.0 (SAS Institute, Cary, NC). 
 
Conjugation of MUC1-CT2 antibody with DuolinkII Probemarker 
MUC1-Ab5 monoclonal antibody (1:300, ThermoScientific), is produced 
in hamster. Since there are no probes against hamster antibodies 
commercialized by O-link Bioscience, we have first labelled it with a kit, the 
Duolink II Probemarker Plus (OLink Bioscience), according to the 
manufacturer’s instructions. 
 
Relative Quantification of interaction between MUC1-CD and cell signaling 
molecules by Proximity Ligation Assays (PLAs) 
MKN45-SC clones were grown until subconfluency in round slides, fixed 
with paraformaldehyde 4% 120mM sucrose and permeabilized with Triton-X  at 
RT and washed with PBS. We have followed the instructions of the kit DII anti-
rabbit minus (OLink Bioscience) or the DII anti-mouse minus (OLink Bioscience) 
(depending on the origin of the secondary antibodies used), followed by the 
detection kit DII Det. Reag.Orange (OLink Bioscience). Assays were made in 
duplicate and for each one, MUC1-Ab5 antibody was incubated with ERK1/2 
(1:100, Cell Signaling), EGFR (1:50, SantaCruz Biotec.), B-RAF (1:50, 
SantaCruz Biotec.) and Grb2 (1:50, SantaCruz Biotec.). Fluorescence spots 
were observed under a fluorescence microscope. The negative controls are 
cells incubated with no MUC1-CD antibody. 
 
 
 
Results  
 
Interactions between MUC1-CD and oncogenic signaling effectors in 
gastric carcinoma cells 
Immunoprecipitation and PLA assays have shown that MUC1-CD 
interacts with ERK1/2 molecules in the diffuse type MKN45 GC cells (Figures 1 
and 2). We have also studied the possible interaction between MUC1-CD and 
ERK1/2 in AGS intestinal gastric carcinoma cells and it was clearly positive 
(results not shown). PLA assays have also shown an interaction between 
MUC1-CD and EGFR, B-RAF and Grb2 (Figure 3, 4 and 5), other members of 
the MAPK signaling pathway. We have performed the same PLA assays in 
gastric carcinoma and also normal gastric tissues and the results were 
negative. 
 
Impact of MUC1 downregulation in MAPK oncogenic signaling partners 
expression and phosphorylation 
MUC1 expression in MKN45 gastric carcinoma cells has been previously 
obtained, with the isolation of one scrambled control (MKN45-SC) and two 
MUC1 downregulated clones (MKN45-C1 and MKN45-C2) [25]. MUC1 silencing 
is shown in MKN45-SC and MKN45-C2 cells by confocal microscopy (Figure 
6). 
The relative levels of ERK1/2, EGFR and B-RAF vary between the 
silenced clones and the scrambled control, suggesting that MUC1 may regulate 
their transcription and/or stability (Figure 7).  
ERK2, EGFR and B-RAF mRNA levels were studied by Real-Time PCR 
(Figure 8) in MKN45 GC cells. mRNA levels of ERK2 and EGFR increased, 
whereas mRNA levels of B-RAF decrease between MUC1 dowregulated clones 
and the control.  
Phosphorylation profiling of MKN45-SC, MKN45-C1 and MKN45-C2 by 
Kinexus antibody screening have shown that phosphorylation of MKN45-C1 and 
MKN45-C2 clones is significantly altered when compared to the MKN45-SC 
control in ERK1/2 proteins. There is an increase in the phosphorylation levels of 
active sites of ERK2 while ERK1 shows decreased phosphorylation levels 
(Figure 9). 
 
Discussion 
 
Interactions between MUC1-CD and oncogenic signaling effectors in 
gastric carcinoma cells 
The MAPK signaling pathway has been one of the signaling pathways 
more often shown to be deregulated in several carcinomas, including GC [28]. 
Our aim was to study the impact of MUC1-CD in this signaling cascade in 
MKN45 gastric carcinoma cells.  
The MAPK signaling pathway is composed of several cell signaling 
molecules. The initiator molecule is the epidermal growth factor receptor 
(EGFR), a member of the growth factor family HER that works as a cell surface 
receptor of extracellular ligands. Ligand binding to EGFR extracellular domain 
leads to its activation, with subsequent homodimerization, leading to the 
phosphorylation of its intracellular tyrosine kinase domain. This will initiate a 
series of phosphorylations and intracellular signals that will ultimately activate 
the central Ras/RAF/MEK/ERK mitogen activated protein kinase (MAPK) 
signaling pathway. 
EGFR molecule modulates processes of cell proliferation, migration, 
adhesion and proliferation and it is known to provide tumor cells with growth 
and survival advantages [29]. EGFR expression was found to be deregulated in 
several types of cancers, including GC. High EGFR levels in GC were found 
have been associated with the diseases’ prognosis [30] and presence of lymph 
node metastasis [31]. 
Grb2 is an important molecule that integrates the stimulatory signals of 
the MAPK signaling pathway [32]. This molecule has been previously shown to 
interact with MUC1 in breast carcinoma [33]. 
B-RAF is another member of the MAPK signaling pathway often 
overexpressed in GCs, promoting tumorigenesis and angiogenesis [34]. MUC1 
was previously shown to activate the RAS-mediated signaling pathway in non-
tumorigenic and tumorigenic mammary cell lines [35]. 
ERK1/2 molecules are the final effectors of the MAPK signaling cascade 
and have been shown to be activated by MUC1 mucin in some cancer models 
[15, 36, 37]. These molecules were also shown to be overexpressed and 
activated in the majority of GC cases and correlate with tumor progression and 
invasion [38]. These molecules were also found to be activated in H.pylori 
related cancers [39, 40]. These events were found for gastric carcinoma cell 
lines, but when examining human gastric carcinoma specimens, a decrease in 
the activation of ERK1/2 was found [41]. One possible explanation for this fact 
is that gastric cells start expressing molecules that attenuate ERK-mediated 
signaling upon its activation, or on the other hand, the cells act by activating 
negative feedback mechanisms.  
MUC1 was shown to interact with ERK1/2 in MKN45 control and 
downregulated cells, as shown by immunoprecipitation assays.  The interaction 
between MUC1-CD and ERK1/2 was later confirmed by a proximity ligation 
assay. This technique also allowed us to show interactions between MUC1-CD 
and other MAPK signaling effectors such as EGFR, Grb2 and B-RAF. 
Although further studies need to be performed to better clarify the 
relevance of these interactions, this finding suggest that MUC1-CD is directly 
associated with an oncogenic signalling pathway and that might be valuable to 
develop new strategies to limit and control the development of GC. 
In order to see if these interactions were restricted to MKN45 cell line, 
derived from a diffuse gastric carcinoma, we have tested the possible 
interaction between MUC1-CD and ERK1/2 in AGS gastric carcinoma cells, 
derived from an intestinal-type gastric carcinoma and the result was also 
positive (results not shown). Therefore, this interaction is not restricted to cells 
from diffuse gastric carcinomas.  
We checked if the interactions found to exist between MUC1-CD and 
ERK1/2, EGFR, B-RAF and Grb2 were also occurring in gastric normal cells. In 
order to do so, we used normal gastric tissue samples in PLA assays. However, 
no interactions seem to exist between all the mentioned molecules and MUC1-
CD in the samples studied. A similar result was obtained when testing the same 
interactions in gastric carcinoma tissue samples.  
Tissue samples and cancer cell lines have several important differences. 
One of these differences is that gastric carcinoma cell lines grow with high 
proliferation rates, while in normal and carcinoma tissue samples, the 
proliferative pool is restricted to a few set of cells. This reason can explain the 
fact that the results obtained by PLA assays regarding MUC1-CD interaction 
with cell signaling molecules are different between MKN45-SC cells and normal 
and gastric carcinoma tissue samples. 
This is the first report that shows MUC1-CD interaction with ERK1/2, 
EGFR, B-RAF and Grb2 in MKN45 gastric carcinoma cell line, and with ERK1/2 
in AGS gastric carcinoma cell line (results not shown). 
 
Impact of MUC1 downregulation in MAPK oncogenic signaling partners 
expression and phosphorylation 
The relative levels of ERK1/2, EGFR and B-RAF vary between the 
silenced clones and the scrambled control, suggesting that MUC1 may regulate 
not only their phosphorylation but also their transcription and/or stability.  
We have observed that ERK2 upregulation and B-RAF downregulation at 
a protein level, considering Real Time PCR results, are likely due to MUC1-
mediated transcriptional mechanisms, whereas EGFR protein levels difference 
is most likely due to post-transcriptional regulation mechanisms.  
Kinexus antibody screening has shown that phosphorylation profiling of 
MKN45-C1 and MKN45-C2 clones is significantly altered when compared to the 
MKN45-SC control in ERK1/2 proteins important activation sites (T202/Y204; 
T185/Y187). Phosphorylation of the specific phosphorylation sites analyzed by 
Kinexus is known to lead to an activation of the proteins [42, 43]. 
The differences in phosphorylation observed are rather due to physical 
interactions between MUC1-CD and ERK1/2, since MUC1 is not known to 
possess any kinase activity. It’s also possible that MUC1-CD is interacting with 
kinases that phosphorylate ERK1/2 and that this interaction is altering the 
phosphorylation of these proteins. 
 
Conclusions 
Gastric cancer is a worldwide major health problem, mostly due to the 
reduced knowledge of its etiological factors and pathogenesis model. This 
cancer is also resistant to most cancer therapies with no significant progress 
made during the last decades. Therefore it is critical to find new therapeutic 
targets to overcome resistance mechanisms. The main objective of this work as 
to better understand the biology of MUC1 mucin, previously described as 
frequently altered in gastric cancer, in this disease pathogenesis model. 
This research work allowed us to identify molecules that directly interact 
with MUC1-CD in MKN45 GC cells and that may therefore be MUC1 oncogenic 
signaling partners, contributing for GC development (EGFR, B-RAF, Grb2 and 
ERK1/2). We were also able to identify signaling molecules (ERK1/2, EGFR, B-
RAF) whose expression is significantly altered by MUC1 downregulation in 
MKN45 GC cells. Furthermore, we have shown that ERK1/2 phosphorylation 
and consequent activation is significantly altered by MUC1 downregulation in 
MKN45 GC cells. 
The results found in this research work reinforce the participation  of 
MUC1 in the MAPK signaling pathway of gastric carcinoma cells  and therefore 
its importance as a new elective target for innovative therapeutic approaches.   
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Figures 
 
 
 
 
 
Figure 1: Immunoprecipitation assays. MKN45-SC, C1 and C2 lysates were 
immunoprecipitated with anti-MUC1-CT2 and with normal hamster IgGs as a control 
and blotted with anti-ERK1/2 antibody. 
 
 
 
 
 
 
 
 
 
Figure 2: In situ PLA assay. PLA assay was performed using MKN45-SC cells and 
the antibodies MUC1-CT2 and ERK1/2. MKN45-SC(-) – negative control. 
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Figure 3: In situ PLA assay. PLA assay was performed using MKN45-SC cells and 
the antibodies MUC1-CT2 and EGFR. MKN45-SC(-) – negative control. 
 
 
 
Figure 4: In situ PLA assay. PLA assay was performed using MKN45-SC cells and 
the antibodies MUC1-CT2 and B-RAF. MKN45-SC(-) – negative control. 
 
 
 
Figure 5: In situ PLA assay. PLA assay was performed using MKN45-SC cells and 
the antibodies MUC1-CT2 and Grb2. MKN45-SC(-) – negative control. 
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Figure 6: MUC1 downregulation by siRNA. Effect of siRNA on MUC1-CD expression 
in MKN45 gastric carcinoma cell line assessed by confocal microscopy. A) MKN45-SC 
control cells and B) MKN45-C2 downregulated clone. Nuclei are stained with DAPI, 
MUC1-CD is shown in green and the endoplasmic reticulum in red. 
 
 
 
 
Figure 7: Immunoblots assays. MKN45-SC, C1 and C2 lysates were blotted with 
anti-ERK1/2, anti-EGFR, anti-B-RAF, anti-Grb2 and anti-β-actin.  WL-Whole Lysates.  
 
 
 
 
 
 
Figure 8: Relative quantification of ERK2, EGFR and B-RAF by Real-Time 
PCR in MKN45-SC, C1 and C2 clones. Values were adjusted to the expression of 
TBP gene. * P < 0.05, when compared to the MKN45-SC control. 
 
 
 
Figure 9: Phospho-site kinexus assay. Relative phosphorylation levels of important 
phosphorylation sites of the proteins ERK1/2 in MKN45-SC, MKN45-C1 and MKN45-
C2 cells.  
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1. Introduction 
Gastric cancer is one of the most common and life-threatening cancers worldwide (for 
review see Power et al., 2010). The late diagnosis and high mortality of this disease reflects 
the reduced understanding of its etiological factors and pathogenesis model and the lack of 
effective treatments. This disease results from the complex interplay between genetic and 
environmental factors at the gastric mucosa level that deregulates cell potentially oncogenic 
signaling pathways, leading to gastric cancer development. It is known that more than 80% 
of gastric cancer cases can be attributed to deregulation of signaling pathways caused by 
Helicobacter pylori infection (Houghton & Wang, 2005). Some of these signaling pathways are 
important during gastric embryogenesis and during the normal lifetime of a gastric cell, but 
can be tumorigenic if deregulated and therefore their better understanding is crucial for the 
development of new therapeutic drugs. In this review we will summarize the most 
important intracellular signaling pathways that have been found to be deregulated in gastric 
carcinoma and we will include new data recently obtained in our laboratory, focused on 
MUC1 mucin-mediated signaling pathways.This new information is a relevant contribution 
for the understanding of the gastric oncogenic signaling scenario and opens new 
perspectives for the development of innovative therapeutic strategies against the disease.  
2. Signaling pathways involved in gastric carcinogenesis 
2.1 EGFR and the extracellular signal-regulated MAPK pathway 
The mitogen-activated protein kinases (MAPKs) pathway is activated either by extracellular 
ligand binding or intracellular stimuli, and regulates a series of cell activities such as 
proliferation, differentiation and cell death. The extracellular signal-regulated kinase (ERK) 
MAPK pathway has been often found to be deregulated in cancers and consists of several 
kinases (Ras, Raf, MEK) that are activated by phosphorylation upon ligand binding to a 
membrane receptor, ending up in the activation of several proteins involved in processes of 
cell invasion, apoptosis, transcription, survival and drug resistance (for review see Kim EK 
& Choi E, 2010). Members of this cascade have been found to be deregulated in gastric 
cancers, such as RAS family members (Adjei, 2001; Velho et al., 2010). Ras/MAPK activation 
was found  to be associated with cell proliferation in gastric carcinomas (Regalo et al., 2010). 
ERK1/2, the final effectors of this pathway, were also found to be  activated in gastric 
cancers (Liang et al., 2005) and in Helicobacter pylori related gastric cancers (Hatakeyama , 
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2006; Chen et al., 2006). In contrast, ERK2 activity was found to be reduced by nonsteroidal 
anti-inflammatory drugs NSAIDS, therefore inhibiting the proliferation of gastric carcinoma 
cells (Husain et al., 2001). All of these events were found in cell lines, but when examining 
human gastric carcinoma specimens, a decrease in the activation of ERK1/2  was found (Wu 
et al., 2008). One possible explanation for this fact is that gastric cells start expressing 
molecules that attenuate ERK-mediated signaling upon its activation, or on the other hand, 
the cells act by activating negative feedback mechanisms. 
The epidermal growth factor receptor (EGFR) is a member of the growth factor family HER 
and works as a cell surface receptor of extracellular ligands. Ligand binding to EGFR 
extracellular domain leads to its activation, with subsequent homodimerization, leading to 
the phosphorylation of its intracellular tyrosine kinase domain. This will initiate a series of 
intracellular signals, including activation of the central Ras/Raf/mitogen activated protein 
kinase (MAPK) signaling pathway (Figure 1). This molecule modulates processes of cell , 
migration, adhesion and proliferation and it is known to provide tumor cells with growth 
and survival advantages (for review see Nicholson et al., 2001). EGFR expression was found 
to be deregulated in several types of cancers, including gastric cancer. High EGFR levels in 
gastric carcinoma have been associated with the disease prognosis (Kim et al., 2008) and 
presence of lymph node metastasis (Choi et al., 2009). Therapies against EGFR have been 
developed and are active in gastric cancer treatments (Pinto et al., 2007; Liu et al., 2011), 
although not completely effective. The EGFR/MAPK pathway has also been  shown to be 
activated in gastric carcinomas with microsatellite instability (Corso et al., 2011). 
 
 
Fig. 1. EGFR/MAPK signaling pathway. 
2.2 E-cadherin and Wnt/beta-catenin pathway 
E-cadherin is a calcium-dependent cell-cell adhesion molecule that is essential for the 
maintenance of the normal epithelium architecture (for review see Van Roy & Berx , 2008). 
Loss of expression of this molecule has been found in gastric cancers, relating with tumor 
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dedifferentiation, invasiveness, metastasis and prognosis (Shino et al.,1995; Gabbert et al., 
1996). Mutations of this molecule have been often found in familial gastric cancers (for 
review see Oliveira et al., 2006). The cytoplasmic domain of this molecule interacts with the 
molecule beta-catenin, forming strong cohesive nets between the actin cytoskeleton 
(Leckband & Sivasankar, 2000), essential for processes of cell-cell adhesion and cell shape, 
polarity, migration and invasion.  
EGFR and E-cadherin were found to interact through the respectives extracellular domains 
and signaling mediated by EGFR was found to be inhibited by E-cadherin (Qian et al., 2004). 
EGFR was found to be hyper-activated in cells where the extracellular domain of E-cadherin 
is not present (Bremm et al., 2008). Therefore, it may be of therapeutic value to use EGFR 
inhibitors in the treatment of gastric cancers in which there is a deregulation of E-cadherin. 
Beta-catenin is important in mediating the E-cadherin related cell adhesion and also by 
participating in Wnt signaling pathways. The Wnt signaling pathway regulates several 
processes during development, such as determination of cell fate, morphology, polarity, 
adhesion and growth. Wnt signaling can be divided into canonical and non-canonical 
pathways. In the canonical one, wnt signals (extracellular ligands, such as wnt-1) stabilize 
beta catenin, therefore activating gene transcription by interaction of beta-catenin with 
transcriptional factors (Figure 2). 
 
 
Fig. 2. Wnt signaling pathway (canonical). 
This pathway was found to be deregulated in several cancers (for review see Polakis, 2007), 
including gastric carcinoma (Katoh et al., 2001; Clements et al., 2002; Nabais et al., 2003). The 
non canonical pathway is not related to beta-catenin and is involved in embryonic 
development and cell polarity and has also been linked to the development of gastric 
cancers (Kurayoshi et al., 2006;  Gencer et al., 2010).  This pathway seems to be repressed by 
Notch1 receptor in keratinocytes (Nicolas et al., 2003). Beta catenin was found to be 
activated by the bacterium Helicobacter pylori in gastric cancers (Franco et al., 2005). 
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In gastric cancer tissues, the expression of Wnt-1, beta-catenin and E-cadherin was found to 
be increased when compared to normal gastric tissue, as well as tumor size, tumor invasive 
depth, lymph node metastasis, pTNM stage, differentiation and five-year survival rate 
(Zhang & Xue , 2008). Therefore, these molecules are promising therapeutic targets for 
gastric carcinoma. 
2.3 Hedgehog pathway 
Hedgehog (Hh) signaling plays an important role during embryonic development and 
differentiation, proliferation and maintenance of adult tissues through the maintenance of 
stem cells population. Until now, three different members of the Hh family have been 
identified: Sonic Hedgehog (Shh), Indian Hedgehog (Ihh) and Desert Hedgehog (Dhh). All 
of them are secreted-type glycoproteins with a N-terminal signal peptide, a Hedgehog 
signaling domain and a Hint domain that signals through ligation to the hedgehog receptor 
Patched (Ptch), which usually acts by inhibiting the seven-span transmembrane receptor 
Smoothened (Smo) (Katoh and Katoh, 2005).  
Of all Hh members, Shh is the most studied signaling pathway in vertebrates and plays a 
crucial role in stomach development. Shh protein expression is increased in parietal cells of 
the normal adult, gastric corpus and antrum (Saqui-Salces and Merchant, 2010). It is 
believed that Shh is important for regulation of gastric epithelial differentiation and its 
silencing causes gastric atrophy and subsequent disruption of glandular differentiation (Van 
den Brink, 2007). Recently, with the development of a mouse model expressing a parietal 
cell-specific Shh deletion, the function of this protein in adult stomach has been better 
clarified (Xiao et al., 2010). 
  
 
Fig. 3. Human Hedgehog signaling pathway. 
Shh ligand is expressed as a 45-kDa precursor that is cleaved autocatalytically to yield a 
19kDa amino terminal fragment, that contains all the signaling functions and a 26-kDa 
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carboxy-terminal fragment (ShhC), that acts as a cholesterol transferase (Goetz et al., 2006; 
Zavros et al., 2007). This activation process depends on the acid-activated protease pepsin A. 
Gastrin increases acid secretion in parietal cells leading to conversion of pepsinogen A to 
pepsin A, mediating Shh processing (Zavros et al., 2007). In the stomach, Shh binds directly 
to Ptch receptor but not to Smo being the activity of Smo controlled indirectly by Ptch 
(Figure 3). In Shh absence Ptch supresses Smo activity. The binding of Shh to Ptch results in 
loss of Ptc activity and consequently Smo activation. Smo activation triggers Hh signal into 
the cytoplasm by triggering activation of Glioblastoma family transcription factors (Gli1, 
Gli2 and Gli3) that induce transcription of signaling targets like Wnt and the zinc finger 
transcription factor, Snail (Martin et al., 2010). Gli 1 induces the transcription of Snail that 
inhibits E-cadherin transcription. The inhibition of E-cadherin, a protein that plays an 
important role in cell adhesion, is associated with an increase in nuclear beta-catenin, 
triggering the activation of Wnt pathway targets like CD44, c-Myc and cyclin D1 (Li et al., 
2006; Medici et al., 2008; Tanaka et al., 2002).  
Alterations in Hh signaling pathway activation are related to different types of cancer such 
as gastric cancer, breast cancer, small-cell lung cancer, skin and pancreatic cancer (Kubo et 
al., 2004; Thayer et al., 2003; Watkins et al., 2003; Yang et al., 2010). The expression of Hh 
ligands, Ptch1, Smo and the three Gli transcription factors (Gli1, Gli2 and Gli3) has been 
related with more than two-thirds of primary gastric cancers and correlated with poorly 
differentiated and more aggressive tumors (Fukaya et al., 2006; Lee et al., 2007). Hh 
signaling activation is triggered by expression of hedgehog ligands like Shh and Ihh or an 
increased Ptch receptor expression (Wu et al., 2010; Zavros, 2008). Inhibition of Shh 
signaling pathway using Smo or antagonists like cyclopamine or Hedgehog neutralizing 
antibody 5E1 causes growth inhibition and regression of xenograft tumors in vivo (Berman 
et al., 2003). However, in the presence of precancerous lesions such as gastric atrophy (loss 
of parietal cells) or intestinal metaplasia, Shh protein expression is reduced or totally lost 
(Shiotani et al., 2005; Suzuki et al., 2005; van den Brink et al., 2001). This observation is 
associated with Helicobacter pylori infection, which is directly linked to the development of 
gastric cancer (Correa et al., 1975; Uemura et al., 2001). Taken together, these evidences may 
indicate that the inactivation of Hh signaling mediates in part the precancerous tissue 
alterations induced by Helicobacter pylori infection while its re-activation confers survival 
advantages in later stages of gastric carcinogenesis.  
2.4 Notch pathway 
Notch signaling pathway is evolutionary conserved and plays a role in many important and 
fundamental processes in cell and tissues such as proliferation, differentiation, apoptosis, 
cell fate determination, and maintenance of stem cells (Koch and Radtke, 2007; Leong and 
Karsan, 2006; Radtke and Raj, 2003). Notch signaling is activated during cell-to-cell contact 
through four receptors (Notch1-4) that can interact with ligands of the Delta (Dll-1, Dll-3, 
Dll-4) and Jagged (Jagged-1 and Jagged-2) family (Bray, 2006). Notch-ligand binding 
induces the cleavage of Notch receptor through a cascade of proteolytic cleavages by the 
metalloprotease tumor necrosis factor-α-converting enzyme (TACE) and γ-secretase, 
releasing the intracellular domain of Notch (NICD) (Katoh, 2007a; Wang et al., 2009). The 
NICD is translocated into the nucleus to associate with CSL transcription factor triggering 
the activation of Notch target genes (Androutsellis-Theotokis et al., 2006; Miele, 2006). Until 
now, few Notch target genes have been identified in different cellular and developmental 
contexts (Borggrefe and Oswald, 2009), such as Hes-1 (Hairy enhance of split-1), Cyclin D1, 
Nuclear factor-κB (NF-κB) and c-myc (Miele, 2006) (Figure 4). 
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Fig. 4. Notch signaling pathway. 
Recently, it has been described an association between Notch signaling and progression of 
gastric cancer. Three Notch receptors (Notch1-Notch3) and Notch ligand Jagged1 are 
expressed in human gastric cancer (Katoh, 2006; Sander and Powell, 2004; Sekine et al., 2006) 
and Notch signaling pathway is activated after infection with Helicobacter pylori in gastric 
cancer (Katoh, 2007b). Gastric cancer patients with Jagged1 expression in tumor tissues have 
more aggressive tumors and poor survival, suggesting an important role of this pathway in 
gastric cancer progression (Yeh et al., 2009).  This aggressiveness seems to be correlated with 
the interaction between Notch signaling pathway and COX-2, an independent prognostic 
factor of gastric cancer (Shi et al., 2003). Notch signaling induces Cox-2 expression by 
directly binding to it through the intracellular domain of Notch1 receptor producing a 
stimulatory effect on cancer growth and invasion (Yeh et al., 2009). Nuclear factor-κB is also 
involved in Notch signaling and mediates COX-2 expression to regulate cell proliferation of 
human gastric cancer cells (Espinosa et al., 2003). Therefore, COX-2 inhibitors may be a new 
strategy to be used for treatment of gastric cancer in the future. 
Twist, another transcription factor regulated by Notch signaling, was also shown to regulate 
cell motility and invasion in gastric cancer cell lines, probably through N-cadherin and 
fibronectin (Yang et al., 2007). Possibly, these EMT mediators induced by NICD could lead 
to an increased expression of COX-2. Whether N1ICD induces expression of COX-2 to 
modulate metastasis in gastric cancer through EMT mediators remains unknown.  
Furthermore, activation of Notch signal pathway is involved in epithelial-mesenchymal 
transition (EMT), during development and tumorigenesis. Notch signaling increases Snail-1 
expression and elevates EMT in cardiac development, kidney tubular cell differentiation, 
and hypoxia (Sahlgren et al., 2008; Timmerman et al., 2004; Zavadil et al., 2004). The 
Jagged1-activated Notch signaling also promotes EMT through E-cadherin repression by 
Slug (Leong et al., 2007). Jagged1 and Hey1, a target gene of Notch signal pathway, are also 
involved in mediating transforming growth factor-β–induced EMT (Zavadil et al., 2004). All 
these findings together indicate that Notch signaling plays a multitude of important roles in 
gastric carcinogenesis. 
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2.5 COX-2/PGE2 pathway 
The regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a 
reduced risk of cancer development in the gastrointestinal tract (Thun et al., 1993; Farrow et 
al., 1998; Oshima et al., 2009). The major target of NSAIDs is cyclooxygenases (COXs), such 
as COX-2, which is a rate-limiting enzyme responsible for the conversion of arachidonic acid 
to prostaglandins (PGs) (Chan et al., 2007; Williams et al., 1999). The anticancer effect of 
these agents is thought to be caused by the inhibition of COX-2 and, consequently the 
reduction of PG synthesis (Wu et al., 2010). Regular use of NSAIDs is associated with a 
decreased incidence of gastric cancer (Oshima et al., 2009, as cited in Thun et al, 1993; 
Zaridze et al., 1999). 
The over-expression of COX-2 was reported in several common human malignancies, such 
as in lung, colon, pancreas, bladder, head and neck cancers, being its main expression in 
gastrointestinal tract (Pereira et al., 2009, as cited by Fujimura et al., 2006 and van Rees & 
Ristimaki, 2001; Schuller et al., 2006). Several studies have shown that the treatment with 
NSAIDs or COX-2 selective inhibitors (COXIBs)  suppressed chemically induced tumor 
formation and xenografted tumor growth, so these results show that the COX-2 pathway 
plays an essential role in cancer development (Oshima & Taketo, 2002; Oshima et al., 2009). 
The inducible enzyme, COX-2 is responsible for catalyzing the biosynthesis of prostaglandin 
(PG) H2, which is further converted to PGE2 by microsomal PGE synthase-1 (mPGES-1), a 
PGE2 converting enzyme that is functionally coupled with COX-2 (Murakami et al., 2000; 
Seno et al, 2002). Cox-2-derived PGE2, a stable prostanoid synthesized by prostaglandin E 
synthase (PGES) can modulate inflammation (Huang & Chen, 2011, as cited in Harizi et al., 
2000), relax vascular smooth muscles (Huang & Chen, 2011, as cited in Smyth et al., 2009) 
and act as a promoter of cancer progression (Huang & Chen, 2011, as cited in Iniguez, 2008). 
This molecule also has the ability to stimulate tumor-associated angiogenesis (formation of 
new blood vessels that supply oxygen and nutrients), promote cellular proliferation, inhibit 
apoptosis and enhance cellular invasiveness, facilitating the progression of cancers (Gross et 
al, 2005). Among the COX-2 downstream prostanoids, PGE2 is the one that is better studied, 
concerning its potential role in tumor progression (Huang & Chen, 2011) and mediates most, 
if not all, of the oncogenic effect of COX-2 in gastric cancer (Muller-Decker & Furstenberger, 
2007). Such as for COX-2, an up-regulation of PGE2 in most of the gastrointestinal cancers 
also occurs (Huang & Chen, 2011).  Therefore, it is crucial for gastric carcinogenesis an 
increased level of PGE2 through the induction of COX-2 and mPGES-1. Simultaneous 
induction of COX-2 and mPGES-1 is observed in gastric cancer tissues, which suggests the 
induction of PGE2 pathway in gastric tumors (Oshima et al., 2006).  Several studies using 
mouse models have elucidated the roles of the PGE2 pathway in gastric tumorigenesis in the 
Wnt-activated and BMP-suppressed gastric mucosa (Oshima et al., 2009).  
It is known that Helicobacter pylori infection causes chronic gastritis, as well as an over-
expression of COX-2 and mPGES-1(Oshima et al., 2009). Concordantly, after eradication of 
H. pylori, COX-2 expression is suppressed (McCarthy et al., 1999), with correlation with 
decreased levels of mPGES-1, indicating that H. pylori infection induces the PGE2 pathway 
through induction of both COX-2 and mPGES-1. Several studies have found over-expression 
of COX-2 in gastric precancerous lesions and in gastric cancer (Tatsuguchi et al., 2000; 
Wambura et al., 2002). The molecular mechanism for COX-2 induction in tumors has not 
been totally elucidated, however there is a possibility that H. pylori can stimulate Toll-like 
receptors (TLRs) leading to the activation of the nuclear factor-κB (NF-κB) pathway that in 
turn induces the expression of COX-2. Another possibility is that the cytokine network can 
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be activated by infection and, as a result, an induction of COX-2 expression occurs (Chang et 
al., 2004; Smith et al., 2003). Transgenic mice over-expressing COX-2 and mPGES-1 
simultaneously develop intestinal metaplasia and hyperplastic tumors in the glandular 
stomach, which is associated with macrophage infiltration, so these results suggest that 
increased levels of PGE2 enhance infiltration of macrophages, whose activation by H. pylori 
may enhance gastric carcinogenesis (Oshima et al., 2004; Wu et al., 2010). 
2.6 NF-KB pathway 
NF-κB (Nuclear Factor kappa B) is a critical regulator of genes involved in cell survival and 
proliferation, cellular stress response, innate immunity and inflammation (Baeuerle & 
Baltimore, 1996; Barnes & Karin, 1997). The NF-κB family is composed by five closely 
related DNA binding proteins: RelA (p65), RelB, c-Rel, NF-κB1/p50 and NF-κB2/p52, which 
function as various homodimers and heterodimers. All share a highly conserved domain 
called the Rel homology domain (RHD), responsible for their dimerization, nuclear 
translocation, DNA binding and also interaction with the inhibitors of NF-κB (IκBs) 
(Gilmore, 2006). This family can be subdivided according to differences in synthesis and C-
terminal sequences. While members of the “Rel subfamily” (RelA, RelB and c-Rel) have a 
transactivation domain (TAD) at their C-termini and are synthesized directly as mature 
forms, p50 and p52 from “NF-κB subfamily” are generated from large precursor proteins, 
p105 and p100, respectively, by limited proteolysis or arrested translation. Although lacking 
a TAD, the precursors of the second subfamily contain a C-terminal with multiple copies of 
ankyrin repeats - ankyrin repeat domain (ARD) - the typical domain of IκBs. Characteristic 
NF-κB dimmers usually involve one member from each subfamily, although all NF-κB 
members may form various homo- or heterodimers. p50 or p52 homodimers inhibit NF-κB 
target gene expression due to lack of a TAD, therefore, members of the NF-κB subfamily are 
generally not activators of transcription but function as IκB-like inhibitors of NF-κB, except 
when they form heterodimers with members of the Rel subfamily, participating in target 
gene transactivation (Li & Verma, 2002). 
NF-κB is essencial in cellular response regulation being an example of transcription factors 
that are present in cells in an inactive state and do not require new protein synthesis to be 
activated. The activation of NF-κB requires phosphorylation of IκBs, resulting in their 
ubiquitin-dependent degradation. Therefore, NF-κB can enter the nucleus and activate the 
genes in response to certain stimuli, including reactive oxygen species (ROS), tumor necrosis 
factor alpha (TNFα), interleukin 1-beta (IL-1β) and bacterial lipopolysaccharides (LPS) - a 
component of the outer membrane of Gram-negative bacteria including H. pylori (Thanos & 
Maniatis, 1995). In unstimulated cells, the NF-κB dimers are sequestered in the cytoplasm by 
IκBs. There are two pathways leading to NF-κB activation: the canonical/classical and non-
canonical/alternative. The canonical pathway can be activated by several stimuli including 
inflammation cytokines and antigens that induce the phosphorylation and activation of an 
IκB kinase (IKK) complex, consisting of catalytic kinase subunits (IKKα and/or IKKβ) and a 
scaffold, sensing protein termed NF-κB essential modulator (NEMO). The activated IKK 
promotes phosphorylation of IκBα and its ubiquitin-dependent degradation by the 
proteasome. The released NF-κB is able to enter the nucleus and regulate the expression of a 
wide range of genes including activation of its own repressor, IκBα (Nelson et al., 2004) 
(Figure 5).  
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Fig. 5. NF-kB signaling pathway (canonical activation). 
The non-canonical pathway is induced by certain receptor signals like B-cell activating 
factor (BAFF), Lymphotoxin β (LTβ), CD40 ligand, TNF-like weak inducer of apoptosis 
(TWEAK) and receptor activator of NF-κB ligand (RANKL) (Xiao et al., 2006). It is a slow 
process that depends on NF-κB-inducing kinase (NIK) protein synthesis. Despite the fact 
that its mRNA expression is abundant, protein levels are usually low due to its constitutive 
degradation by a TRAF3-dependent mechanism (Qing et al., 2005). When non-canonical NF-
κB stimuli occur, the key components of this mechanism are degraded by the proteasome 
and NIK is activated and then able to activate an IKKα complex (an homodimer lacking 
NEMO), that consequentially phosphorylates p100, leading to its partial proteolysis (in the 
proteasome) and formation of p52. The p52/RelB complex then translocates into the nucleus 
to modulate gene expression (Zarnegar et al., 2008) (Figure 6). 
There is evidence that NF-κB is constitutively activated in gastric cancer tissues, with 
higher levels in gastric carcinoma cells in comparison to normal adjacent epithelial cells 
(Sasaki et al., 2001) although it is RelA and not NF-κB that is used as a prognostic 
indicator of gastric carcinoma. It has also been reported that patients with highly 
activated NF-κB levels in cancer cells would have a lower survival potential when 
compared to those with low NF-κB activation (Yamanaka et al., 2004). In gastric cancer, 
abnormal NF-κB activation has been shown to lead to enhanced proliferation, evasion of 
apoptosis, genomic instability, increased rate of glycolysis and drug resistance (Cho et al., 
2008; Kang et al., 2008; X. Liu et al., 2010). 
Regarding drug resistance, a study has been performed in order to evaluate the effect of 5-
Fluorouracil (5-FU) and irinotecan (CPT-11) in NF-κB activation. It led to the conclusion that 
these components are inducing two different pathways: apoptosis through direct effect on 
nucleic acids, and inhibition of apoptosis through activation of NF-κB. Moreover, the same 
authors used an inhibitor of NF-κB and predicted that its combination with 5-FU and CPT-
11 may be a more effective treatment option instead of chemotherapy alone for gastric 
cancer (Camp et al., 2004). 
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Fig. 6. NF-kB signaling pathway (non-canonical activation). 
Since the discovery that blocking NF-κB can cause tumor cells to stop proliferating, to die, or 
enhance their sensitivity to the action of anti-tumor agents NF-κB has been widely used as a 
target for anti-cancer therapy (Escarcega et al., 2007). HIF-1α, one of the components of 
hypoxia-inducible factor 1 (HIF-1), has been directly implicated in tumorigenesis including 
angiogenesis, tumor cell proliferation, metastasis, as well as chemo- and radiotherapy 
response, particularly in gastric cancer ( Liu et al., 2008; Weidemann & Johnson, 2008). 
Interestingly, a recent study showed that NF-κB inhibition in gastric cancer suppressed 
hypoxia-induced HIF-1α protein expression (but not at the mRNA level), suggesting that 
this protein is a downstream molecule of NF-κB in the angiogenesis pathway in gastric 
cancer. Also, NF-κB seems to be activated by hypoxia leading to HIF-1α protein 
accumulation at the translational level, but not at the transcriptional or post-translational 
levels. Thus, NF-κB/HIF-1α pathway may be a fitter candidate target for inhibition in 
gastric carcinoma therapy (Nam et al., 2011).  
Using a different approach, other investigators described a new mechanism in gastric tumor 
cells associated with NF-κB inhibition responsible for impairment of cell proliferation and 
induction of apoptosis of cancer cells. By blocking NF-κB (with a RelA inhibitor, SN50) they 
achieved an increase in p53 expression, which led to the induction of pro-apoptotic and 
autophagic proteins. Thus, p53 contributes to NF-κB inhibitor-induced apoptosis of cancer 
cells by activation of autophagic mechanisms (Zhu et al., 2011). 
2.7 Transforming growth factor- β, bone morphogenic protein pathway 
Transforming growth factor (TGF)-β is a multifunctional cytokine that controls 
differentiation, apoptosis, cell growth and immune reactions (Roberts, 2002; Shi & 
Massagué, 2003). TGF-β1, -β2, and -β3 are three isoforms of TGF-β that are present in 
mammals. In most types of cells, TGF-β is a potent growth inhibitor, so alterations on TGF-β 
signaling lead to tumor progression by the induction of angiogenesis, extracellular matrix 
accumulation and immunosuppression (Blobe et al., 2000; Derynck et al., 2001; Wakefield & 
Roberts, 2002). 
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This pathway is considered to be a tumor suppressor pathway that negatively regulates cell 
growth and promotes apoptosis of epithelial cells (Siegel & Massagué, 2003). In early stages 
of cancer, TGF- β signaling acts as a tumor-suppressor and in later stages promotes invasion 
and metastasis (Wu et al., 2010). TGF-β signaling pathway is composed of two distinct 
receptors with intrinsic serine/threonine kinase activity, TGF-β type I and type II receptors 
(TbRI and TbRII) and Smad proteins. The binding of TGF-β to TbRII leads to recruitment 
and transphosphorylation of TbRI (heteromeric complex). Cytoplasmatic Smad2 and Smad3 
are then phosphorylated by activated TbRI kinase, allowing them to form a heteromeric 
complex with Smad4, that is translocated into the nucleus acting as transcription factors.  
(Massagué, 1998; Miyazono et al., 2000; Miyazono et al., 2003) (Figure 7).  
 
 
Fig. 7. Wnt signaling pathway (canonical). 
Several studies demonstrated that the over-expression of TGF-β, in gastric cancer, is 
correlated with lymph node metastasis and poor prognosis (Maehara et al., 1999; Saito et al., 
2000), as well as promotion of invasion and metastasis (via Smad3-, ERK- and JNK-
dependent signal pathways) (Fu et al., 2009; Wang et al., 2006; Yoo et al., 2008). TGF-β 
induces RUNX3, a transcription factor that is involved in the formation of a variety of 
cancers (Ito, 2004). RUNX3 is expressed in glandular stomach epithelial cells, however, the 
loss of expression of this gene is associated with the progression, differentiation, metastasis 
and poor prognosis of gastric cancer (Li et al., 2002; Sugiura et al., 2008; Wei et al., 2005). 
Vogiatzi and colleagues (2006) demonstrated that RUNX3 interacts with FoxO3a /FKHRL1 
to activate Bim and induce apoptosis in gastric cancer cells. H. pylori causes methylation of 
RUNX3 gene and its loss of expression in gastric epithelial cells (Katayama et al., 2009). 
Moreover, RUNX3, Smad4 inactivation has been documented in gastric cancer (Wu et al., 
2010 as cited in Powell et al., 1997). Another study carried out by Shinto and colleagues 
(2011) demonstrated that the expression of p-Smad2 is associated with malignant phenotype 
and poor prognosis in patients with advanced gastric carcinoma.  
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Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily (von Bubnoff 
& Cho, 2001). They were originally identified as osteoinductive cytokines that regulate bone 
and cartilage formation  (Balemans & Van Hul, 2002; Chen et al., 2004; Hogan, 1996). The 
BMPs mediate their effects by binding to type I and II serine–threonine kinase receptors 
(BMPR), leading to the phosphorylation of Smad1, Smad5 and Smad8. These 
phosphorylated Smads heterodimerize with Smad4 and this complex is translocated to the 
nucleus to activate the transcription of downstreams targets  (Derynck et al., 1998; 
Kretzschmar et al., 1997; Heldin et al., 1997). Several studies have demonstrated that BMPs 
play important roles in the regulation of cell motility, proliferation, apoptosis, 
differentiation, self-renewal of embryonic stem cells and remodeling of the extracellular 
matrix (Hardwick et al., 2004; Hogan, 1996; Li et al., 1996; Massagué, 1996; Nissinen et al., 
1997; Von Bubnoff, 2001). BMP proteins are expressed in adult stomach (Peek & Blaser, 2002; 
van den Brink et al., 2001).  
BMP signaling in the stomach is down-regulated in cancer and upregulated during 
inflammation (Wu et al., 2010). H. pylori infection leads to an increase in BMP expression, 
mainly caused by an influx of BMP2-producing cells. The influx correlates with an increase 
in the activity of the BMP pathway (Bleumeing et al., 2006). A study carried out by Wen and 
colleagues (2004) demonstrated that BMP-2, a BMPR ligand, caused cell cycle arrest in the 
G1-phase in MKN74 and OUMS37 cells, and that this growth inhibitory action may be 
mediated by p21Waf1/Cip1 (BMP-2 suppresses gastric cancer cells proliferation). Moreover, 
this BMP is suppressed by tumor methylation in gastric cancer cells (Wen et al., 2006). Taken 
together, these results suggest that the inhibition of BMP signaling contributes to gastric 
tumorigenesis through the suppression of differentiation. (Oshima et al., 2009). However, 
recent studies have discovered that BMP-2 can accelerate the migration and invasiveness of 
gastric cancer cells and may correlate with disease progression (Kang et al., 2010; Park et al., 
2010).  
3. MUC1 mucin-mediated signaling pathways in gastric cancer  
The stomach is continuously subjected to a harsh acidic environment and several external 
aggressions. The mucus layer produced by the gastric epithelium has a crucial protective 
role against these adverse conditions. Three major heavily glycosylated proteins (mucins) 
line the stomach epithelium under normal conditions: one membrane associated mucin, 
MUC1, and two secreted mucins, MUC5AC and MUC6. They all contribute to the formation 
and maintenance of a cohesive “mucin net” that covers the entire epithelium, working as an 
efficient barrier. Abnormal expression and glycosylation have been described for these 
highly polymorphic mucins in gastric carcinoma and pre-neoplastic lesions (Reis et al., 1999; 
Teixeira et al., 2002). MUC1 polymorphism defines different susceptibility backgrounds 
associated with the development of conditions that precede gastric carcinoma: chronic 
atrophic gastritis and intestinal metaplasia (Silva et al., 2001). 
MUC1 and MUC4 have been recently identified as participating in intracellular signaling 
pathways, by their cytoplasmic domains (Carraway et al., 2003; Hollingsworth and 
Swanson, 2004). The phosphorylation of MUC1 cytoplasmic domain (MUC1-CD) has been 
found to modulate its interaction with several molecules, such as EGFR, β-catenin, p53, ER- 
α, ICAM-1, among other molecules (for review see Singh & Hollingsworth , 2006). These 
interactions have been mainly found for breast, pancreatic and lung cancer cells and so far 
the data about MUC1-mediated signaling pathways or MUC1 signaling partners in gastric 
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carcinoma cells is limited. MUC1-CD is known to interact with beta-catenin and upregulate 
the Wnt signaling pathway in CagA Helicobacter pylori-infected gastric carcinoma 
(Udhayakumar et al., 2007). 
Our group has been studying the MUC1-dependent signaling pathways in gastric cancer 
cells. We have stably down-regulated MUC1 expression in MKN45 gastric carcinoma cell 
line by shRNA and we evaluated MUC1 down-regulation impact in potential MUC1-
mediated signaling pathways. We observed that MUC1-downregulation leads to abnormal 
expression levels of ERK1/2 proteins and an increased phosphorylation of these kinases. We 
further characterized the association between MUC1 and ERK1/2 and we showed by 
proximity ligation assays that MUC1-CD directly interacts with ERK1/2 kinases in these 
cells. The impact of MUC1 in the transcription and stability of these kinases and the 
interaction with other signaling partners (e.g. EGFR) are being currently evaluated, 
nonethless this clearly suggests that MUC1-CD is involved at different levels in the 
regulation of the MAPK signaling pathway in gastric carcinoma cells (Figure 8). 
 
 
Fig. 8. MUC1 and EGFR/MAPK signaling pathway. 
The kinases of EGFR/MAPK signaling pathway are crucial effectors responsible for cell 
proliferation and oncogenic transformation. Recent data from other tumor models further 
reinforce the relevance of MUC1 as a key player in cell-cell (microenvironment) signaling 
contexts (Behrens et al., 2010). Therefore, it assumes critical relevance an extensive 
characterization of MUC1-mediated signaling events in this pathway and their impact in 
gastric carcinoma phenotype. These results suggest MUC1 as a new and promising 
candidate to be targeted by therapies against gastric cancer.  
4. Conclusions 
Gastric cancer is a leading cause of cancer-related death worldwide. Given the limited 
options currently available for gastric cancer therapy and prevention, it becomes urgent to 
better understand the oncogenic signaling pathways beyond the emergence of the disease. 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
16
There is an increased knowledge about the alterations occurring in multiple signaling 
pathways and the acquisition of gastric cancer phenotype. The complex interplay between 
environmental factors and oncogenic signaling pathways involving cell proliferation, 
differentiation, apoptosis and invasion, remains however elusive. Emerging evidence in 
other models has brought new evidences on the complex interaction among different 
oncogenic signaling pathways. Whether such phenomena occur in gastric cancer, remains 
unclear.  
The elucidation of individual interactions is thus required to develop a more consistent 
understanding of the gastric oncogenic signaling networks and will help to identify novel 
targets for anticancer drug development. The reviewed signaling pathways are relevant 
contributors for gastric carcinogenesis and encompass a multitude of potential therapeutic 
targets. In addition to these signaling-related targets we included new data on MUC1 
mucin, previously described as being involved in gastric cancer susceptibility phenotype. 
The characterization of the complete spectrum of MUC1-dependent oncogenic signaling 
interactions in gastric cancer cells, will offer the molecular basis for the development of 
innovative therapies using MUC1 as an elective target. Furthermore an integrative 
perspective, of these MUC1-mediated signaling pathways, will be critical to design 
therapeutic strategies that inhibit multiple signaling pathways enhancing the efficacy of 
gastric cancer therapies and probably prevent the development of drug resistance 
phenotype. 
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